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Background/aims   
The macula is a specialised part of the retina responsible for detailed central and colour 
vision. The carotenoids lutein, zeaxanthin and meso-zeaxanthin are uniquely 
concentrated in the inner and central layers of the primate macula, where they are 
collectively known as macular pigment (MP). Macular pigment confers potent 
antioxidant and anti-inflammatory effects in the eye. Many studies have suggested that 
these carotenoids are lower in age-related macular degeneration (AMD) and that 
increased levels of MP may confer protection against AMD, especially the late form 
of the disease. Research is now beginning to focus on MP optical density (MPOD) and 
carotenoid intake in diabetes mellitus, a condition which similar to AMD, is known to 
cause oxidative damage and inflammation in the retina. 
Methods   
The optical density of MP was measured in a group of participants with diabetes (Type 
1 and Type 2) and findings compared with normal healthy controls. A comprehensive 
review was performed to investigate the putative causal mechanisms and metabolic 
perturbations associated with lower MP in diabetes. Surrogate biomarkers for the 
prediction of low MP in participants with Type 2 diabetes and older adults free of 
ocular pathology, including clinical [blood pressure], plasma [lipoproteins, 
inflammatory markers] and anthropometric [waist (cm), hip (cm), height (cm), weight 
(kg)] parameters, were investigated and identified as part of a large randomly selected 
sample from the Republic of Ireland (as part of The Irish Longitudinal Study on 





The optical density of MP was lower among Type 2 diabetes subjects (0.33 ± 0.21) 
compared with Type 1 subjects (0.49 ± 0.23) and normal controls (0.48 ± 0.35) (p= 
0.01). A comprehensive review of MP and diabetes, Type 2 diabetes, in particular, 
revealed that MP may become depleted through at least four possible causal 
mechanisms in this condition including overweight/obesity, dyslipidaemia, oxidative 
stress and inflammation. Research performed on the TILDA cohort confirmed that 
participants with Type 2 diabetes had significantly lower MPOD compared with non-
diabetic controls (p=0.047). In-depth analysis on this Type 2 diabetes cohort revealed 
that MP was significantly lower in diabetes participants who were deficient in plasma 
vitamin D (<50 nmol/L) (p=0.006); who had a raised triglyceride (TG) over high-
density lipoprotein (HDL) ratio (TG/HDL) [>1.74 mmol/L; p=0.039]; who had 
hypertension (p=0.043); who were current smokers (p=0.022); or who had cataracts 
(p=0.049). Among older adults who were free of ocular pathology (i.e. AMD, 
glaucoma, diabetes, pre-diabetes), MPOD was significantly lower among participants 
with an elevated waist circumference (WC) (p=0.034), those who had low plasma 
HDL (p=0.038), those with a raised plasma TG/HDL ratio (p=0.003) and those with a 
raised total cholesterol (TC) over HDL ratio (TC/HDL) (p=0.030). 
Conclusion 
Overall, our findings suggest that individuals with Type 2 diabetes have lower MP 
relative to healthy controls. The metabolic correlates associated with Type 2 diabetes, 
in particular, i.e. oxidative stress, inflammation, overweight/obesity and 
dyslipidaemia, may have important implications for MPOD in the retina. Surrogate 
biomarkers associated with lower MP in Type 2 diabetes include low plasma levels of 
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vitamin D (25(OH) D), dyslipidaemia (i.e. raised TG/HDL ratio), hypertension, 
cataracts and smoking. While an altered lipoprotein profile (i.e. low HDL, raised 
TG/HDL ratio, raised TC/HDL ratio), may affect the transport, uptake, and 
stabilisation of carotenoids in the retina of older adults free of ocular pathology, it 
appears that WC is a more robust predictor of lower MPOD in this patient cohort. 
However, its effect size appears to be small and therefore its clinical applicability is 
questionable. 
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The hydroxyl-carotenoids lutein, zeaxanthin and the retinal metabolite of lutein, meso-
zeaxanthin, concentrate at the macula where they are collectively known as macular 
pigment (MP).1 The selective accumulation of only three specific dietary carotenoids, 
to the exclusion of all other carotenoids in nature, suggests an exquisite biological 
function at the site of best vision and indicates a role that is uniquely suited to this 
anatomic location. It has been shown that MP can influence the quality of visual 
performance through the selective absorption of short-wavelength light before 
photoreceptor light capture.2 Macular pigment also protects the retina from photo-
oxidative damage by means of its optical filtration and/or antioxidant properties.2, 3 
Evidence is now emerging that these carotenoids exhibit a neuroprotective and anti-
inflammatory function in the retina.4 While there is a growing body of evidence to 
suggest that MP is lower in patients with age-related macular degeneration (AMD), 
and that increased levels of MP may confer protection against this disorder,3, 5 only a 
small number of studies have focused on carotenoid intake and MP optical density 
(MPOD) in diabetes mellitus.6, 7 Diabetic retinopathy is one of the primary 
microvascular complications of diabetes and the leading cause of blindness in the 
working-age population.8 There is strong evidence to suggest that oxidative stress 9 
and its associated inflammation 10 play an important role in the development of 
diabetic retinopathy. Macular pigment may, therefore, through its antioxidant, anti-
inflammatory and/or pre-receptoral filtration properties; 2-4 confer protection against 




The condition diabetes mellitus is explored in detail. Whilst diabetes is characterised 
by having higher than normal blood glucose levels, the pathogenesis and development 
of the two main forms of the disease, Type 1 and Type 2 diabetes, differ, and may, 
therefore, have unique and independent relationships with MP. While there is no cure 
for diabetic retinopathy, new approaches are now being taken to understand the 
pathophysiology of the disease to help improve its detection, prevention, and 
treatment. Current treatment paradigms for diabetic retinopathy include laser 
photocoagulation,11 intravitreal injections,12 and vitreoretinal surgery,13 all of which 
focus on the advanced form of the disease, often after permanent damage has occurred. 
Newer treatments which are preventative in nature or which address early pathological 
changes are therefore highly desirable. Research is now beginning to examine the 
possible beneficial effects of dietary supplemental lutein, zeaxanthin, and meso-
zeaxanthin in protecting ocular tissues and cells, including retinal neurons, in the hope 
that these phytochemicals may retard disease progression, a concept explored in 
section one.14, 15 
 
An initial evaluation of the available evidence suggested that MP appears to be 
generally lower in populations with diabetes compared with healthy controls,6 in 
particular amongst patients with Type 2 diabetes.7 A comprehensive review of the 
available evidence pertaining to the relationship between diabetes mellitus and MPOD 
was undertaken, therefore, with the primary focus to explore the putative causal 
mechanisms and metabolic perturbations which might explain any associations 
between diabetes, (Type 2 diabetes in particular) and MP status. Metabolic correlates 
associated with Type 2 diabetes include overweight/obesity,16, 17 dyslipidaemia,18, 19 
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oxidative stress,9 and inflammation;10 mechanisms which may have both independent 
and synergistic relationships with MP, a concept which is explored in detail in the 
review. 
 
In addition to the review evidence, a body of experimental work was also designed 
and executed to; a) explore MP levels in a group of participants with diabetes mellitus 
(Type 1 & Type 2) relative to normal healthy controls; b) explore this concept further 
in Type 2 diabetes participants derived from a large representative population of older 
adults as part of the Irish Longitudinal Study of Aging (TILDA), with specific focus 
on the identification of surrogate biomarkers for the prediction of low MP in these 
Type 2 diabetes subjects; and c) identify proxy biomarkers associated with lower MP 
in a group of older Irish adults in TILDA who are free of ocular pathology (i.e. AMD, 
glaucoma, diabetes, pre-diabetes). 
1.3 Research benefits 
Macular pigment has several important functions in the eye including blue light 
filtration and potent antioxidant activities.2, 3 More recently, research has suggested 
that MP also has neuroprotective and anti-inflammatory effects in the eye.4 Diabetic 
retinopathy is the leading cause of blindness in the working-age population,8 and 
chronic disease progression is believed to be linked to the interaction between 
inflammation 10 and oxidative stress.9 There is a growing body of evidence to suggest 
that increased levels of MP may confer protection in AMD,3, 5 and there is also 
preliminary evidence from animal studies to suggest a similar protective effect in 
diabetes.14, 20 In humans, a recent randomised control trial (RCT) in this area has also 
yielded promising data which suggests that higher MP levels may prevent or retard 
the progression of diabetic retinopathy.21  
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Optometrists and eye care practitioners can play an important role in preventative eye 
care. At a community level, screening for lutein, zeaxanthin and MP levels in the 
macula would help identify patients at risk of low MPOD and stratify those patients 
requiring appropriate dietary intervention and/or additional supplementation. The 
density of MP can be augmented by eating foods rich in these carotenoids (i.e. green 
leafy vegetables, fruits, and legumes).22 Supplements rich in these phytonutrients are 
also widely available. The MPOD can be measured in vivo 23 and represents a long-
term measure of dietary carotenoid accumulation over months to years. However, 
MPOD is not routinely measured in clinical practice. Consequently, there may be 
value in exploring commonly measured surrogate biomarkers for the prediction of 
patients at risk of low MP, given that higher levels of MP may be beneficial to the 
retina. Clinical benefits may be realised by using these proxies to identify patients at 
increased risk of MPOD depletion (i.e. patients with Type 2 diabetes, older adults free 
of ocular pathology), and the use of early intervention protocols to address these 
MPOD deficits.  
 
Given the myriad of mechanisms which may contribute to MPOD depletion in Type 
2 diabetes, and the ocular risks putatively associated with lower MPOD in diabetes, 
lifestyle modification which involves a comprehensive dietary approach is a logical 
first step to optimise MPOD status and ocular health outcomes. De novo synthesis of 
MP is not possible in humans, therefore, the importance of diet cannot be 
overemphasised in the management of diabetic eye disease risk. Nutritional advice on 
the inclusion of foods rich in the carotenoids lutein and zeaxanthin (i.e. fruit, 
vegetables, legumes), and other dietary strategies to optimise lipoprotein status (i.e. 
triglycerides (TGs), high-density-lipoprotein (HDL), low-density-lipoprotein (LDL)) 
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may, therefore, have long-term clinical impacts on disease prevention and progression. 
Dietary advice and lifestyle modifications which are also applicable to older adults 
identified with MP deficits. 
 
Although the long-term benefits of maintaining high MP density during life are not 
yet known, there is the possibility that a more robust MP status over the full life course 
may retard disease progression in later years. Research has shown that neuroretinal 
changes can occur long before retinal signs of pathology become visible (i.e. micro-
aneurysms, dot and blot haemorrhages in diabetic retinopathy). Therefore, increased 
awareness of the ocular risks associated with certain metabolic disturbances, (i.e. 
increased visceral fat, dyslipidaemia) and lifestyle choices (i.e. tobacco use) may yield 
behavioural changes which ultimately confer long-term visual health benefits, not only 












2. THE RETINA 
2.1 Introduction 
Diabetes mellitus is a group of metabolic disorders characterised by hyperglycaemia, 
arising from defects in either insulin secretion, insulin action or both.24 Diabetic 
retinopathy is the most frequent microvascular complication of the disease and the 
most common cause of blindness in the working-age population.25 The main reasons 
for vision loss are diabetic macular oedema and proliferative diabetic retinopathy. The 
likelihood of developing retinopathy is related to the duration of disease, 
hyperglycaemia, hypertension and possibly dyslipidaemia.26 Type 1 and Type 2 
diabetes are the two main forms of the disease.27 Type 2 diabetes has an insidious 
onset and can go unnoticed for many years. As a result, patients may already have 
diabetic retinopathy at the time of diagnosis.25 Conversely, Type 1 diabetes patients 
are diagnosed promptly and typically do not develop retinopathy until years after the 
diagnosis is made. Approximately 60% of Type 2 diabetes patients and nearly all Type 
1 patients, however, will show some signs of retinopathy 20 years after disease 
diagnosis.25 Although the incidence and progression of the potentially blinding 
complications of retinopathy can be reduced with tighter glucose control,28 the 
fundamental causes of diabetic retinopathy remain uncertain. The unique anatomy and 
physiology of the retina may even make it uniquely susceptible to the metabolic 
stresses of diabetes.29 In this regard, an understanding of the anatomy and physiology 
of the normal retina may give us better insight into what can go wrong in diabetes, and 
how these pathological mechanisms can be averted. The pathological sequelae of 
diabetes which are relevant to ocular health will be explored in this chapter. 
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2.2 The retina  
The retina is the light-sensitive layer that extends over the inner surface of the back of 
the eyeball, lying in contact with the vitreous matter internally and with the vascular 
layer, the choroid, externally. The retina is a transparent layer of neural tissue. The 
gross anatomy of the retina is divided into the outer pigmented epithelial layer and the 
inner neural sensory layers. These layers form a functional unit essential for vision.  
 
Figure 2.1: Schematic drawing of the human eye (Adapted from Morello 30). 
 
Normal vision depends on cell to cell communication between the neuronal, glial, 
microglial, vascular, and pigmented epithelial cells of the retina.29 The major functions 
of the retina are to capture photons of light, convert this photochemical energy into 
electrical energy, integrate the resulting action potentials and transmit them to higher 
brain centres where they are interpreted into recognisable images.29 The neural 
components of the eye are an extension of the forebrain and thus form part of the 
central nervous system.  
 
The structure of the retina consists of ten distinct layers, of which there are two 
synaptic layers. The lamellar cellular architecture of the retina (Figure 2.2), has 
alternating layers of neurons (outer and inner nuclear layers and ganglion cell layer) 
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interposed with two plexiform layers where neurons communicate and where visual 




Figure 2.2: Light micrograph of a vertical section through central human retina 
(Adapted from Kolb et al, 31).  
 
Abbreviations: OLM-outer limiting membrane; ONL-outer nuclear layer; OPL-outer 
plexiform layer; INL-inner nuclear layer; IPL-inner plexiform layer; GCL-ganglion 
cell layer; ILM-inner limiting membrane. 
 
The anatomy of the retina in Figure 2.3 is described in relation to optical coherence 
tomography (OCT), a technique currently used in the diagnosis and follow-up of 
diabetic retinopathy. It allows the multiple layers of the retina and choroid to be seen 





Figure 2.3: Nomenclature for normal anatomic landmarks seen on spectral-domain 
OCT images proposed and adopted by the International Nomenclature for OCT Panel. 
Healthy retina imaged using Zeiss Cirrus.32 
Abbreviation: RPE = retinal pigment epithelium. 
2.3 The macula 
The macula represents the central part of the retina which is specialised for high spatial 
resolution and colour vision. The term macula derives from the presence of 
xanthophyll pigments, lutein, zeaxanthin, and meso-zeaxanthin, appearing as a yellow 
spot (macula lutea) when viewed in red-free light.33 The macula is approximately 5.85 
mm in diameter and is centered about 4 mm temporal and 0.8 mm inferior to the centre 
of the optic disc.34 Based on microscopic anatomy, the macular area can be subdivided 
into several zones: the macula lutea (~5.85 mm diameter), fovea centralis (~1.85 mm 





Figure 2.4: Schematic drawing of human foveolar (Adapted from Kanski et al,36). 
 
The macular area can also be described and divided in terms of its different areas: the 
fovea containing the foveola; the parafovea and the perifovea 37 (Figure. 2.5). The 
foveola is surrounded by a wide ring zone where the ganglion cell layer, inner nuclear 
layer and outer plexiform layer of Henle are thickest. This is called the parafoveal 
area.38 This area has a relatively low density of retinal vessels and below-average 
spatial density of rods.39 The perifovea circumscribes the parafovea. The high rod: 





Figure 2.5: An anatomical view of the macula region as viewed through cross-section 
(Adapted from Thibos et al,37 ). 
2.3.1 Specialisation of the macula 
The central retina has evolved to enable us to see better i.e. to resolve fine spatial detail 
and allow colour perception. This is possible because of the unique structure of the 
macula which includes close packing and elongation of photoreceptors (especially 
cones), ‘midget’ circuitry which dominates the macular region, and refinement and 
specialisation of the central retinal vasculature.40 The fovea accounts for almost all of 
our useful photopic vision, even though it comprises less than 4% of the total retinal 
area. The fovea has the highest cone density and the central 100 µm of the foveola 
contains only red and green cones.39 Blue cone density is highest in a zone between 




 1.85mm     
foveola diameter 0.35 mm     
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An important factor contributing to foveal morphology is the predominance of a 
‘midget’ circuitry, in which the majority of bipolar cells are ‘midget bipolar cells’ 
which each connects to a single cone in the outer nuclear layer and a single ganglion 
cell in the ganglion cell layer.40 These ‘midget’ pathways are distinctive in the absence 
of convergence of photoreceptor signals onto bipolar and ganglion cells.41 Conversely, 
‘parasol’ cell circuits in the periphery are converging, and a single parasol ganglion 
cell receives input from multiple ‘diffuse’ bipolar cells and numerous receptors in the 
outer nuclear layer.40 The foveola coincides with an area which is devoid of retinal 
blood vessels, called the ‘foveal avascular zone’ (FAZ). Most layers of the sensory 
retina are displaced sideways at the foveola to create the foveal pit, thus, 
photoreceptors have unimpeded stimulation from light forming the retinal image 
(Figure 2.6). This anatomic specialisation serves to maximise visual function by 
removing angioscotomas from the visual image at fixation.42 Outside the fovea, rod 
photoreceptors dominate and second (horizontal, bipolar and amacrine cells) and third 






Figure 2.6: A comparison of histological and OCT images of the cross-sectional 
appearance of the human retina, at the fovea centralis (Adapted from Provis et al,40). 
 
Abbreviations: NFL-nerve fibre layer; GCL-ganglion cell layer; IPL-inner plexiform 
layer; INL-inner nuclear layer; OPL-outer plexiform layer; ONL-outer nuclear layer; 
ELM-external limiting membrane; IS-inner segment; OS-outer segment; RPE-retinal 
pigment epithelium. 
2.4 Macular pigment   
Although MP is found throughout the tissue of the eye, it is concentrated in the macula 
lutea region of the retina. The primary localisation of human MP is in the inner retinal 
layers, in the fibres of Henle of the fovea, and parafoveally MP is located in the inner 
and outer plexiform layers.43 The unique distribution of MP within the retina implies 
that these carotenoids play an important role in vision and macular health, and are 
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biologically relevant to the eye.44, 45 Carotenoids lutein, zeaxanthin and meso-
zeaxanthin are collectively referred to as MP.46 De novo synthesis of MP is not 
possible in humans, therefore, must be obtained from dietary sources. Current studies 
indicate an ability to influence concentrations of carotenoids in MP by increasing 
concentrations ingested from foods 17, 47 and/or supplements.48 Individual responses to 
dietary intake and/or supplementation, however, is quite variable and may change with 
time. Investigators have examined and identified possible predictors of MPOD, and 
found associations with age, 49, 50 sex,51  overweight/obesity status,52-54 and smoking,52 
among others, and will be discussed herein. 
Age 
Several lines of evidence suggest that MP may play a protective role against AMD, 
however, the association between age and MPOD remains unclear. Some studies have 
demonstrated a decline in MPOD with age, 49, 55, 56 while others have shown an 
increase 57, 58 and yet other studies have shown no such relationship.59, 60 Research 
reporting on the association between age and MP is variable possibly due to differing 
methodologies being used to measure MPOD, differences in sample sizes and/or 
inconsistencies in age ranges. One recent study demonstrated that MPOD appeared to 
increase during adulthood (peak at 45-50 years) followed by a gradual reduction after 
60 years.61 This study postulated that if these findings can be confirmed in larger 
studies then it would be important to recommend supplementation, using lutein and 
zeaxanthin, in older populations as prophylaxis against age-related maculopathy.61 
Longitudinal data in larger cohorts, however, is required to satisfactorily investigate 






Gender differences in MPOD have also been reported.16, 17 Hammond et al.51 found 
that males had an average of 38% more MP than females and suggested that lutein 
might accumulate in the retina more readily in men than in women. While there was a 
positive correlation between plasma carotenoids and the density of MP for both sexes 
the relationship was stronger for men (males r=0.62, females r=0.3).51 Another study 
found a significant negative correlation between adipose tissue lutein concentrations 
and MP for women and a significant positive correlation was found for men.17 These 
researchers suggested that sex differences in lutein metabolism may be an important 
factor in tissue interactions and in determining MP density,17 and that adipose tissue 
may compete for carotenoids more effectively in women than men. Not all research, 
however, supports these findings. A relative lack of MP was associated with adiposity 
in men, and these researchers suggested that this link might underlie the association 
between body fat and risk for AMD progression in males.16 
Smoking 
Several investigations have reported an association between cigarette smoking and 
MP.49, 62 55, 63 Hammond et al.64 compared MP measurements in participants who were 
current smokers compared with non-smokers, matched for age, sex, dietary patterns 
and overall pigmentation. Tobacco users had significantly lower MP (MPOD 0.16) 
compared with the controls (MPOD 0.34). Nolan et al.52 reported not only a significant 
difference in MP between current and non-smokers but also an inverse dose-response 
relationship between MP and the number of cigarettes smoked per day. Research 
suggests that current smoking may lead to lower MP levels in the eye as smoking is 
associated with increased oxidative stress, not only through the increased systemic 
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production of free radicals but also though the weakening of the antioxidant system 
and/or poor diet.65  Of interest, cigarette smoking is an established and important 
modifiable risk factor for AMD.66 It is possible that the lack of macular carotenoids 
among smokers may shift the oxidant/antioxidant balance in favour of AMD. 
Overweight/obesity 
Studies have reported an inverse relationship between overweight/obesity and MPOD 
16, 54 with the observed relationships largely attributable to participants with a BMI > 
29 kg/m2.54 Although BMI measures do not provide a precise measure of adiposity it 
is likely that higher BMI levels are reflective of excess adipose tissue. Lutein, 
zeaxanthin and meso-zeaxanthin, the major components of MP, are fat-soluble 
pigments and adipose tissue is a major storage site of the macular carotenoids.67 As 
body weight increases, it is suggested that more dietary xanthophyll carotenoids will 
be absorbed into adipocyte, thereby, making these carotenoids less available to the 
macula.68 Also, increased adipose tissue, visceral fat, in particular, is associated with 
a state of chronic low-grade inflammation, which in turn leads to increased oxidative 
stress,69 factors which may exert an even greater demand on antioxidant defences 
within the body, including MPOD. 
 
Concentrations of carotenoids in the macular are highly variable. Apart from dietary 
intake, age, gender, current smoking and overweight/obesity, MP levels may also be 
influenced by other factors including the effective absorption of these 
phytonutrients,70 competition among carotenoids for absorption, 17 dyslipidaemia, 18, 
71 metabolic status, 6 and genetic variation.72 Macular pigment will be discussed in 




2.5 Cell types in the retina 
The retinal tissue contains both neuronal and non-neuronal elements which work 
together to enable vision and maintain retinal homeostasis. The five major cell types 
in the retina perform sensory, nutritional, regulatory and immunomodulatory 
functions. 
2.5.1 The neurons 
The neurons (photoreceptors, bipolar, horizontal, amacrine and ganglion cells) 
perform sensory functions and define colour perception, spatial resolution and contrast 
discrimination.73 The laminated organisation of the retina generates two streams of 
visual information: a main or vertical pathway, from the photoreceptors to bipolar cells 
and from bipolar cells to ganglion cells; and a secondary lateral pathway, comprising 
local feedback circuits from horizontal cells back to photoreceptors,74 and from 
amacrine cells back to bipolar cells.75 Neurons mediate phototransduction and 
modulate and convey nerve impulses which are ultimately transmitted to the brain 
through the axons of the ganglion cells which comprise the nerve fibre layer and the 
optic nerve.76 The distribution and variable density of photoreceptors and ganglion 
cells across the retina, the differential light sensitivity of photoreceptors and the 
convergence of information from the extra-foveal retina mean that a hierarchy exists 
in the architecture of retinal processing and that foveal information is given higher 
priority.2 This hierarchy continues back to the striate cortex, where a high percentage 
of cortical cells are dedicated to foveal information 2 (i.e. cortical magnification).The 
fovea is particularly important for functional vision and blindness results when this 
area is lost to disease. The concept of neurodegeneration as an early component of 
diabetic retinopathy and the potential neuroprotective effects of MP in preserving the 
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integrity of the neural retina will be explored in more detail in chapters three and four.   
2.5.2 Retinal glial cells 
Three main types of glial cells are found in the mammalian retina which serves to 
maintain retinal homeostasis. These include macroglial retinal cells (Muller cells and 
astrocytes) and microglial cells. Glial cells exhibit distinct morphological and 
antigenic characteristics which not only provide structural support for the retina but 
which are also involved in metabolism, phagocytosis of neuronal debris and the release 
of certain trophic factors and neurotransmitters (reviewed by Vecino et al,77). Glial 
cells have intrinsic signalling systems which can spread in the form of calcium ion 
(Ca2+) waves, and these are correlated with glutamate release.77 This signalling process 
plays an important role in immunity, angiogenesis, and neuroprotection.77 Neuroglia 
respond to injury as part of the defence to restore homeostasis; however, when they 
malfunction, these cells can become a primary pathogenic element.77  
2.5.2.1 Müller cells 
Müller cells are the predominant macroglial element, representing 90% of retinal 
glia.77 These cells span from the pigment epithelium to the internal limiting membrane, 
and their cell bodies sit in the inner nuclear layer. Müller cells have intimate contact 
with both the retinal blood vessels and the retinal neurons and serve a variety of 
important functions. Müller cells are involved in; 1) the control of metabolism and 
supply of nutrients to the retina; 2) the uptake and recycling of neurotransmitters, 
retinoic acid compounds and ions (such as potassium (K+)); and 3) the regulation of 





Müller cells play an essential role in the normal function of a healthy retina. These 
cells maintain glucose and neurotransmitter homeostasis by removing glucose and the 
main retinal neurotransmitters glutamate and gamma-aminobutyric acid (GABA) from 
the extracellular space.79 Müller cells synthesise, store and degrade glycogen, 
therefore, when nutrient supplies are low Müller cells utilise glycogen to provide 
metabolites for other cell types in the retina 80 including photoreceptors which 
preferentially take up lactate (partially-metabolised glucose produced by Müller cells) 
as fuel for their oxidative metabolism.81 Müller cells transform GABA and glutamate 
into glutamine, which is then returned to the extracellular space and re-utilised by 
neurons.81 Additionally, Müller cells induce blood-barrier properties in retinal 
endothelial cells.82 While Müller cells play a critical role in maintaining a healthy and 
functioning retina, abnormalities in any of these functions can result in neuronal 
dysfunction, cell death, retinal swelling (i.e. macular oedema) and break-down of the 
blood-retinal barrier.78  
2.5.2.2 Astrocytes 
Astrocytes are the second type of macroglial cell and are almost exclusively confined 
to the innermost retinal layers. A difference between astrocytes and Müller cells is that 
while Müller cells are distributed throughout the retina independently of 
vascularisation,83 astrocytes are present only in vascularised regions.77 Astrocytes 
wrap around blood vessels and contact both ganglion and amacrine cells.77 Like Müller 
cells, they are key regulators of neuronal nutrition as they store glycogen and provide 
glucose to neurons. They also serve a role in ionic homeostasis in regulating 
extracellular K+ levels and in metabolising neurotransmitters like GABA. Astrocytes 
also contribute to the integrity of the blood-retinal barrier (reviewed by Wang & 
Bordey84). Of key importance, astrocytes are the main producers of vascular 
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endothelial growth factor (VEGF) during both normal and pathological vessel 
formation (reviewed by Penn et al,85). Astroglial cells are therefore strongly implicated 
in vascularisation. While these cells perform essential tasks for the normal physiology 
of the retina, in response to injury or disease these same astrocytes express several 
proteins which compromise the integrity of the blood-retinal barrier, upregulate the 
expression of various genes encoding cytokines, chemokines and elements of the 
complement cascade, and promote retinal degeneration.86  
2.5.3 Microglial cells 
Microglial cells are found in every layer of the human retina and provide an 
immunomodulatory function. These cells migrate through the extracellular space 
between retinal layers and contribute to the healing of degenerating neurons, thereby 
protecting the functional and structural integrity of the retina.87 Microglial cells share 
some of the same properties as circulating and resident macrophages, such as 
phagocytic activity and the release of various cytokines.87 Microglial cells are 
extremely sensitive to changes in their microenvironment and become activated by 
extracellular signals such as neuronal damage, chronic neurodegeneration, cell death 
and ischaemia.87 Once activated, microglia undergo morphological and functional 
changes, developing into one of two possible phenotypes: an activated pro-
inflammatory M1 phenotype which releases inflammatory molecules including 
cytokines (tumour necrosis alpha (TNF-α), interleukin 1 beta (IL-1β) and interleukin 
6 (IL-6)) and toxic metabolites like glutamate. Alternatively, activated microglia can 
develop an M2 phenotype. These cells are primarily involved in neuroprotection by 
releasing anti-inflammatory cytokines (IL-4 and IL-10).88, 89 In summary, microglial 
activity initially contributes to neuronal protection and tissue regeneration; however, 
continuous stimulation from exogenous and endogenous stressors can lead to chronic 
48 
 
over activation and loss of these auto-regulatory mechanisms, changes which are 
detrimental to local neurons.87, 90 Figure 2.7 is a schematic of the various types of 




Figure 2.7: Schematic of the major types of retinal cells: vascular; macro glial cells 
(Müller cells and astrocytes); neurons (photoreceptors, bipolar cells, amacrine, and 
ganglion cells); and microglia (Adapted from Gardner et al,91). 
2.5.4 The retinal pigment epithelium 
Morphologically the RPE forms a highly polarised epithelial sheet that separates the 
choroid from the retina. This layer of cells is divided into a basal half which faces the 
choroid, and an apical half which faces the retina. The basal end of each cell is much 
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in folded and rests on the basement membrane which forms part of Bruch’s membrane. 
The apical ends of the cells have multiple microvilli and these project between and 
surround the outer segments of the rods and cones 92 (Figure 2.8). The epithelial cells 
are joined together by tight junctions which prevent diffusion of large toxic molecules 
from the choroid capillaries to the photoreceptors; therefore, the RPE acts as a barrier 
(the outer blood-retinal barrier).93 The RPE also provides the principal route for the 
transfer of nutrients to the retina. It takes up nutrients such as glucose, retinol and fatty 
acids from the blood and delivers these nutrients to the photoreceptors.94 
 
 
Figure 2.8: Diagram showing the relationship between the photoreceptor cells and 
the RPE (Adapted from Katz & Robison 95).         
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The RPE performs several highly specialised functions essential for homeostasis of 
the neural retina. The RPE plays an integral part in the visual cycle, as it is the principal 
storage depot for vitamin A.93 In this regard, it supplies the essential visual cycle 
intermediate, 11-cis-retinal, to photoreceptors for the regeneration of rhodopsin.96 The 
RPE is also involved in the phagocytosis of shed photoreceptor outer segments.97 
These segments are digested and essential substances, such as retinal, are recycled and 
returned to the photoreceptors.98 Additionally, the RPE is known to produce and 
secrete a variety of growth factors as well as factors which are essential for 
maintaining the structural integrity of the retina and choriocapillaris, including 
pigment epithelium-derived factor (PEDF), insulin-like growth factor-1 (IGF-1) and 
VEGF among others (reviewed by Strauss 93). The RPE allows oxygen diffusion from 
the choroidal circulation to the outer retina, a process critical in maintaining normal 
photoreceptor cell function and survival.94 Furthermore, as a layer of pigmented cells, 
the RPE protects the retina from light damage by the absorption of excessive 
photons.99 The many complex and unique functions of the RPE play a critical role in 
vision. A failure of any one of these functions can lead to degeneration and loss of 
visual function; however, to date, the role of the RPE in diabetic retinopathy remains 
elusive.  
2.5.5 Endothelial cells and pericytes 
The fifth class of cells includes vascular endothelial cells and pericytes. Retinal 
capillaries are comprised of a single layer of endothelial cells bound by pericytes, and 
both cell types are covered by a common basement membrane100 (Figure 2.9). 
Interaction between pericytes and vascular endothelial cells is important in the 
regulation of vascular function and the maintenance of the retinal homeostatic 
environment. Endothelial cells line the vasculature and serve as a physical barrier 
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between blood and the surrounding tissue and constitute the inner blood-retinal 
barrier.91 The presence of tight junctions prevents the outward flow of macromolecules 
and maintains the local microenvironment.101 The endothelium also efficiently 
supplies oxygen and nutrients to the neural retina. Under certain conditions such as 




Figure 2.9: Endothelial–pericyte interactions in micro vessels. Pericytes surrounding 
endothelial cells share the basement membrane with endothelial cells (Modified from 
Simo et al,100). 
 
Pericytes are modified smooth muscle cells that line the outer walls of capillaries and 
play a critical role in vessel patency by regulating vascular tone and providing 
structural support.102 In this way, pericytes regulate retinal vascular flow by dilating 
and contracting,91 and provide nutritional support and waste product removal for the 








Endothelial cells’ and pericytes’ wide-ranging functions include mediating repair of 
the vasculature, promoting the blood-retinal barrier and functioning as hypoxic 
sensors.104  
 
Retinal microvascular dysfunction is a major component of diabetic retinopathy and 
is characterised clinically by dot and blot haemorrhages and micro aneurysms on the 
retina in the earlier stages of diabetes. Visible retinal changes have led to the general 
assumption that diabetic retinopathy is predominantly a microvascular abnormality, 
however, it is now evident that diabetic retinopathy affects all of the major retinal cell 
types (including neuronal and non-neuronal cells). Both retinal neurodegeneration and 
microvascular complications are therefore implicated in diabetic retinopathy.91 The 
interaction and functional integration of all of these cell types is required for normal 
vision, however, disruption to any of them may impair vision.  
2.5.5.1 The blood-retinal barrier  
Metabolic support for the inner retina comes from a vascular network that traverses 
the ganglion cell layer and extends down to the outer plexiform layer. Support for the 
outer retina is achieved by diffusion from the vascularised choroid across the RPE. 
Together, these retinal vessels along with the RPE form the inner and outer blood-
retinal barrier.105, 106 The blood-retinal barrier partitions the neural elements of the 
retina from the circulation to protect it from circulating inflammatory cells and their 
cytotoxic products, and allows the retina to regulate its extracellular composition.105 
This functional barrier resides at the level of tight junctions between adjacent 
endothelial cells.91 Several unique proteins constitute the vascular endothelial tight 
junctions including occludin and claudins.107 These proteins span the plasma 




Figure 2.10: Schematic presentation of the inner and outer blood-retinal 
barriers and their relative location (Adapted from Cuhna-Vaz et al, 106). 
Abbreviation: ECF = extracellular fluid. 
 
The cytokine, VEGF, can induce changes in the expression of these proteins and 
therefore influence vascular permeability.105 Because all retinal cells (macroglial, 
microglial, and neurons) are capable of releasing pro-inflammatory cytokines such as 





Figure 2.11: Pathways for solute movements across the inner blood-retinal barrier 
(retinal endothelial cells). (A) Normal. (B) Mechanisms of the breakdown of the inner 
blood-retinal barrier (Adapted from Cunha-Vaz et al,106). 
2.6 Blood supply to the retina 
The retina receives vascular supply from two sources: the central retinal artery 
supplies the inner retina and the choriocapillaris supplies the RPE and outer retina 
(both of which originate from the ophthalmic artery). The retina is one of the most 
metabolically active tissues in the body, therefore, the retina must have an extensive 
vascular network to maintain proper functioning and to cope with such a high oxygen 
demand. The central retinal artery enters the optic nerve some 10 to 15 mm behind the 
globe. On entering the eye, the vessels branch into inferior and superior divisions 
which continue to subdivide into arterioles (superior, inferior, nasal and temporal), 






Figure 2.12: A fundus photograph showing the retinal blood supply to the superior 
temporal (ST), superior nasal (SN), inferior temporal (IT) and inferior nasal (IN) 
arcades. 
 
The arterial intra-retinal branches supply three layers of capillary networks: the radial 
peri-papillary capillaries and the inner and outer layer of capillaries 108 (Figure 2.13). 
The retinal vascular vessels provide blood to the inner retinal neurons which receive 









Figure 2.13: Schematic cross-section showing the retinal blood vessels lining the 
inner surface of the retina (Adapted from Santiago et al, 101). 
 
Three capillary plexuses are embedded among retinal neurons: the superficial layer 
lies within the inner nerve fibre layer (NFL) with branches extending into the ganglion 
cell layer (GCL), while the intermediate and deep capillary plexuses align along each 
side of the inner nuclear layer (INL). ONL, outer nuclear layer; IPL, inner plexiform 
layer; OPL, outer plexiform layer.  
 
The choroidal network supplies the choroid and the outer third of the retina with 
oxygen and other necessary nutrients. The choroid receives 65-85% of ocular blood 
flow,31 and is vital for the maintenance of the avascular outer retinal layers, 
particularly the photoreceptors. The choroid is supplied primarily by the long and short 
posterior ciliary arteries (branches of the ophthalmic artery), with a minor contribution 
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from the anterior ciliary arteries.31 The choriocapillaris supplies the RPE and the outer 
retinal layers. Retinal vessels are absent centrally at the fovea, (i.e. the FAZ) and the 
choroid is responsible for blood supply to this region (Figure 2.14). The foveola has 
the highest perfusion rate of any vascular bed within the human body reflecting the 
high metabolic activity of the photoreceptors.109  
 
 
Figure 2.14: Image of the FAZ. The calliper measurement of both horizontal and 
vertical diameters of superficial (a) and deep (b) capillary plexus of the FAZ (Adapted 
from Hussain & Hussain 110). 
 
The retinal venous system exits the eye via the central retinal vein. The corresponding 
retinal venous branches have much the same distribution as the retinal arteries. 
Choroidal blood is thought to be drained exclusively through the vortex veins, with 
one or two vortex veins draining each of the four quadrants of the eye.111 The vortex 
veins penetrate the sclera to merge with the ophthalmic vein. 
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2.6.1 Retinal oxygen consumption 
Retinal oxygen distribution varies across the retina according to retinal cell type and 
their associated level of metabolic activity. The highest oxygen tension is found in the 
choroid and the lowest at the level of the photoreceptor inner segments.112 While the 
choroid has a high oxygen tension, the extraordinarily high oxygen demand of the 
photoreceptors, combined with the avascular nature of the foveola, results in a 
substantially increased risk of these cells experiencing hypoxic episodes.112   
2.7 Vulnerability of the retina to diabetic retinopathy  
The physiology of the retina, and the unique structure of the macula, in particular, may 
contribute to the eye’s susceptibility and vulnerability to diabetic retinopathy.29 The 
central retina is adapted for high acuity vision. To maximise vision, there is a 
requirement for transparency at the macula, and this transparency imparts several 
anatomical and physiological constraints in this region including; 1) the central retina 
is devoid of blood vessels (i.e. the FAZ), an anatomic specialisation that serves to 
enhance visual acuity (VA) by removing angioscotomas; 42 2) the retinal axons are not 
ensheathed by myelin, as myelin is opaque and would, therefore, block light 
transmission; 29 and 3) there is a reduced number of mitochondria in the inner retina, 
as mitochondria contain light-absorbing haem-based cytochrome proteins which 
would impede vision.29 These structural arrangements and adaptations are necessary 
to ensure undisturbed light transmission at the point of highest VA, at the foveola. 
Retinal and neural adaptations, such as these may, however, increase the eye’s 
vulnerability to oxidative stress and inflammation.29 The partial oxygen pressure 
declines from the outer retina to the inner retina.113 The oxygen tension of the inner 
retina is relatively hypoxic because of the reduced density of blood vessels at the 
59 
 
foveola. Furthermore, the inner retina possesses relatively few mitochondria. 
Consequently, the inner retina relies heavily on anaerobic respiration (i.e. glycolysis) 
which is a less efficient means of generating energy, compared with aerobic respiration 
(i.e. oxidative phosphorylation) which predominates in the outer retina.29 Furthermore, 
demyelinated retinal nerves require more energy to maintain membrane potentials 
compared with myelinated axons.114  
 
Despite the sparse vascularity and low oxygen tension, the retina has one of the highest 
metabolic demands of any tissue in the body.112 Energy is required for 
phototransduction, for neurotransmission at synapses, to replenish photoreceptor outer 
segment membranes (daily), and to transport proteins and neurotransmitters via axons 
to the optic nerve and lateral geniculate body of the thalamus.29 A healthy, visually-
functioning retina requires intact cell-cell communication, a specialisation that may, 
however, be vulnerable to the hyperglycaemia-induced metabolic perturbations 
typical of diabetes, which may result in neurotoxic or pro-inflammatory responses. 
Interestingly, the outer retina is relatively protected from the early insults of diabetes 
as it receives its oxygen and nutrients by diffusion from the choroid through the 
pigmented epithelium. The combination, however, of high metabolic demand of the 
retinal neurons, low vascular supply, and the presence of few mitochondria may limit 
the inner retina’s ability to adapt to chronic hyperglycaemia in diabetes and its 





3. DIABETES MELLITUS 
3.1 Introduction to diabetes mellitus 
Diabetes mellitus (diabetes) is a complex metabolic disorder, characterised by the 
elevation and dysregulation of blood glucose levels as a result of a lack or 
insufficiency of insulin.24 The condition is broadly classified into Type 1 and Type 2 
diabetes.27 Type 1 diabetes is less common accounting for approximately 10 % of all 
diabetes cases. It results from the autoimmune destruction of pancreatic beta (β)-
cells,115 leading to complete dependence on exogenous insulin to regulate blood 
glucose levels.116 Type 1 diabetes typically presents in childhood or young adulthood. 
Type 2 diabetes mellitus is the more common form of the disease accounting for 
approximately 90% of patients.117 It normally affects individuals in later life, however, 
due to increasing prosperity, lifestyle changes, and obesity, Type 2 diabetes is now 
affecting a much younger age group.118 Type 2 diabetes is characterised by insufficient 
secretion of insulin from the β-cells of the pancreatic islets, coupled with impaired 
insulin sensitivity in target tissues such as muscle, liver and adipose tissue (a condition 
termed insulin resistance).119 Therapy for Type 2 diabetes consists initially of dietary 
control and lifestyle modification, followed by oral hypoglycaemic agents, which may 
reduce insulin resistance, increase insulin secretion or reduce hepatic glucose 
output.120 If these treatments fail to control hyperglycaemia, then insulin is given. Both 
forms of diabetes (Type 1 and Type 2) are caused by a combination of genetic and 
environmental risk factors.  
 
The pathogenesis of Type 1 and Type 2 diabetes is different. Type 1 diabetes is a 
chronic disease that destroys the body’s ability to make insulin. Young patients with 
suspect Type 1 diabetes require prompt referral and diagnosis or else they risk diabetic 
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ketoacidosis, a potentially life-threatening condition. Diabetic ketoacidosis 
can develop when the body fails to store blood glucose as glycogen in the fed state 
due to a lack of insulin; in this scenario, the body metabolises fat in a non-
physiological manner producing ketones to fuel the brain and other tissues which 
normally use glucose. Unabated, this adaptive process results in a build-up of ketones 
in the body with toxic effects,121 giving rise to diabetic coma or even death in extreme 
circumstances. Once diagnosed, patients with Type 1 diabetes require a lifetime of 
treatment with insulin.122  
 
Type 2 diabetes usually develops insidiously in adulthood, although it is now affecting 
a much younger age group. In Type 2 diabetes the pancreas usually produces some 
insulin, however, the amount produced is not enough to overcome the resistance of 
target tissues to its effects. In an insulin resistance state, normal or elevated insulin 
levels consequently produce an attenuated biological response.123 The relative timing 
of β-cell dysfunction and insulin resistance can, however, vary and it has been shown 
that ‘abnormal’ insulin sensitivity can precede the clinical diagnosis of diabetes by up 
to 15 years.124 The failure of compensatory hyperinsulinaemia by the pancreas is the 
‘hallmark’ of frank hyperglycaemia 125 and Type 2 diabetes ensues. At the time of 
diagnosis patients with Type 2 diabetes generally present with a series of metabolic 
comorbidities, including, insulin resistance, hyperinsulinaemia, hyperlipidaemia, 
hypertension and overweight/obesity, features which are less common in Type 1 
diabetes at diagnosis.126 Abnormal glucose metabolism can exist for many years in 
Type 2 before overt diabetes is diagnosed and there may be no initial symptoms.24 
Lifestyle modification early on, however, may not only address the existing 





With life expectancy and obesity on the rise worldwide, diabetes mellitus is becoming 
a major public health problem, approaching epidemic proportions. Globally, an 
estimated 422 million adults were living with diabetes in 2014, compared to 108 
million in 1980.127 The prevalence (age-standardised) of diabetes worldwide has 
nearly doubled since 1980, rising from 4.7% to 8.5% in the adult population.128 The 
number of patients with diabetes is predicted to rise to 642 million (uncertainty 
interval: 521–829 million) by 2040.127 The International Diabetes Federation Diabetes 
Atlas estimated that 207,490 people in the 20 – 79 year age group were living with 
diabetes in Ireland in 2013 (prevalence 6.5%).129 A study carried out by TILDA in 
2015, estimated that the prevalence of Type 2 diabetes and pre-diabetes was 9.5% and 
5.5% respectively, with approximately 10% of cases undiagnosed.130 According to the 
Healthy Ireland survey, 854,165 adults over 40 in the Republic of Ireland have Type 
2 diabetes or are at increased risk of developing it.131 Furthermore, there are 304,383 
people in the 30-39 year age group who are overweight and not taking the 
recommended quantum of weekly physical activity, leaving them at an increased risk 
of developing Type 2 diabetes.131 Therefore, there are over a million adults in Ireland 
who need to make changes to their habitual dietary and physical activity patterns in 
order to address their elevated risk of diabetes.131 
 
Diabetic retinopathy, a common and specific microvascular complication of diabetes, 
remains the leading cause of blindness in working-aged people.25 Up to 21% of 
patients with Type 2 diabetes have retinopathy at the time of diagnosis.25 After 20 
years with diabetes, nearly all patients with Type 1 and more than 60% of Type 2 
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patients have developed retinopathy,25 and this prevalence increases with advancing 
age.132 Early detection of retinopathy in individuals with diabetes is critical in 
preventing vision loss.133 Irish statistics show that on average one person with diabetes 
goes blind in Ireland each week.134 The National Diabetic Retinal Screening 
Programme was developed in Ireland in 2013 and offers free regular diabetic 
retinopathy screening to all people with diabetes aged 12 and over. Optometrists play 
an important role in ensuring that patients participate. While there is no cure for 
diabetic retinopathy, prompt treatment may be effective in preventing, delaying or 
reducing vision loss in patients with this diabetes complication.  
3.3 Diabetic retinopathy 
Diabetic retinopathy is a major complication of diabetes mellitus and remains a 
leading cause of preventable blindness.135 Traditionally it has been viewed as a 
microvascular disease where microvascular lesions have been used as the major 
criterion for evaluating and classifying diabetic retinopathy. Clinically, diabetic 
retinopathy can be divided into two stages: non-proliferative and proliferative diabetic 
retinopathy.136 Non-proliferative retinopathy is characterised by damage to the retinal 
vasculature, increased vascular permeability, thickening of the basement membrane 
and loss of pericytes.137 It can be classified into mild (micro-aneurysms), moderate 
(micro-aneurysms, retinal haemorrhages or hard exudates) and severe (20 
haemorrhages in each of the four quadrants, venous beading in two quadrants or the 






Figure 3.1: Non-proliferative diabetic retinopathy; retinal micro-aneurysms, 
haemorrhages and hard exudates (A and B); intra-retinal microvascular 
abnormalities (C arrow); venous beading (D arrow) and venous loop formation (E 
arrow) (Modified from Cheung et al,138). 
 
Proliferative diabetic retinopathy is marked by the growth of new vessels on the retina 
and posterior surface of the vitreous (angiogenesis), vitreous haemorrhage, retinal 
scars and detachment.136 The ischaemic retina contains high levels of VEGF, the 
driving force for neovascularisation.139 This stage of the disease can result in profound 









Figure 3.2: Proliferative diabetic retinopathy; neovascularisation is a hallmark of 
proliferative diabetic retinopathy (A, arrows). It can also be identified on fluorescein 
retinal angiogram (B, arrows). Resolution of retinopathy with pan-retinal 
photocoagulation (C). Progression of retinopathy without treatment (D) (Modified 
from Cheung et al,138). 
 
Diabetic macular oedema, a side effect of both non-proliferative and proliferative 
diabetic retinopathy, can occur at any stage of the disease.137 It is caused by increased 
vascular permeability and leakage of proteins and lipids into the extravascular space 
due to functional damage of the retinal vascular epithelium and a breakdown of the 









Figure 3.3: Diabetic macular oedema; clinical diagnosis of diabetic macular oedema 
based on stereoscopic examination of the macula (A, arrow). Diagnosis can also be 
supplemented by OCT; three-dimensional topographic maps of the macula from OCT 
allow visualisation of macular oedema in relation to internal limiting membrane or 
RPE; B; overall topographic image (C), and horizontal (upper image, D) and vertical 
(lower image, D). Cross-sectional images of the macula from OCT allow quantitative 
and qualitative assessment of macular oedema (Modified from Cheung et al,138). 
 
Improving technology has enabled the detection of more subtle pathologies and neural 
layer abnormalities in patients with diabetes. Optical coherence tomography 
angiography (OCTA) is a new vascular imaging technique which allows practitioners 





indices and FAZ parameters have been found to correlate with glycated haemoglobin 
(HbA1c) (a measure of the patient’s average glucose level over the previous 2 to 3 
months), in those with non-proliferative diabetic retinopathy.140 Early detection of 
diabetic retinopathy can prevent severe loss of vision and even blindness. 
3.4 Pathophysiology of diabetic retinopathy 
Diabetic retinopathy has long been recognised as a microvascular disease. Chronic 
exposure to hyperglycaemia and other causal factors (e.g. hypertension, 
dyslipidaemia) are believed to initiate a cascade of biochemical and 
pathophysiological events which ultimately lead to microvascular changes and retinal 
dysfunction. An understanding of the pathological processes leading to the onset of 
diabetic retinopathy may provide the means to better manage and treat the disease. A 
summary of these processes are presented here.  
3.4.1 Hyperglycaemia  
The initial stages of retinopathy collectively relate to endothelial dysfunction (i.e. 
leukocyte adhesion, blood flow alterations, capillary closure and formation of leaky 
vessels) and are most probably caused by the effects of elevated blood glucose 
concentration on microvascular tissues.141 Adverse effects of persistently elevated 
glucose levels vary according to cell type. Cells expressing high levels of the glucose 
transporter 1 (GLUT 1), such as vascular endothelial cells, are unable to regulate 
intracellular glucose concentrations and are, therefore, more susceptible to 
hyperglycaemia-induced damage.142 The presence of hyperglycaemia affects various 
molecular pathways, ultimately resulting in a breakdown of the blood-retinal barrier, 
and damage to cells that make up these structures, including endothelial cells and 
pericytes.143 Multiple metabolic pathways have been implicated in hyperglycaemia-
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induced microvascular damage and these include the polyol pathway, activation of 
advanced glycation end products (AGEs), and the hexosamine and protein kinase C 
(PKC) pathways (Figure 3.4).144 
 
Figure 3.4: The four major mechanisms involved in diabetic retinopathy are increased 
polyol pathway flux, increased AGE formation, activation of PKC, and hexosamine 
pathways (Adapted from Safi et al,144). 
 
These pathways in one way or another result in increased oxidative stress, 
inflammation and vascular occlusion, factors which contribute to the pathogenesis of 
diabetic retinopathy. Several significant studies have provided strong evidence that 
tight control of blood glucose, as assessed by HbA1c, can delay diabetic retinopathy 
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onset and progression in patients with Type 1 28 and Type 2 145 diabetes. The Diabetes 
Control and Complications Trial (DCCT) showed that intensive glycaemic control 
reduced the incidence of retinopathy by 76%, and progression from early to advanced 
retinopathy by 54% 28 highlighting that strict glycaemic control is much more effective 
in preventing and delaying the onset of diabetic retinopathy in patients with diabetes 
without retinopathy, compared with limiting the severity of retinopathy once it occurs.  
 
Notwithstanding these findings, research has also shown that if blood glucose is 
rapidly controlled in patients with previously poor control, it can worsen diabetic 
retinopathy.146 Furthermore, there are a group of diabetes patients who are unable to 
prevent the onset or progression of diabetic retinopathy despite achieving good 
metabolic control of the disease.146 These findings highlight that hyperglycaemia does 
not fully explain the wide range of functional and cellular changes which appear over 
the course of diabetic retinopathy, and that other pathogenic components of diabetes 
may also contribute to its progression. 
3.4.2 Hypertension 
Hypertension and diabetes are common, intertwined, conditions that share a 
significant overlap in their underlying risk factors (including familial predisposition, 
advancing age, dyslipidaemia and obesity, among others); and in their complications 
(microvascular and macrovascular disorders).147, 148 Up to 75% of adults with diabetes 
also have hypertension, and patients with hypertension alone often show evidence of 
insulin resistance.147 Moreover, as hypertension and diabetes are both components of 
the metabolic syndrome, these conditions commonly co-occur.147, 149  
 
Oxidative stress plays an important pathophysiological role in hypertension. Normally 
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reactive oxygen species (ROS) are produced in the vessel wall in a controlled and 
tightly regulated manner; however, under pathological conditions (i.e. hypertension), 
increased production of ROS leads to endothelial dysfunction, impaired vascular 
relaxation, increased smooth muscle growth, and hypertrophy.150 Blood flow and 
blood pressure can cause internal stresses in vessels (such as endothelial shear stress 





Figure 3.5: Fluid flow within a tube creates two types of forces: shear stress, which is 
a force tangential to the vessel wall, and pressure, which creates a circumferential 




Hypertension exacerbates diabetic retinopathy through increased blood flow (shear 
stress) and pressure (circumferential wall stretch) of vascular endothelial cells.151,153, 
154 Collectively, oxidative balance regulates the degree of tone or vasodilation, and this 
balance is upset in hypertension. Treatment with antioxidants or agents to inhibit 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase has been shown to 
decrease ROS production, prevent target-organ cellular damage and decrease blood 
pressure in animal models and human hypertension (reviewed by Touyz & Shiffrin 
155). Effective treatment of hypertension (goal blood pressure less than 140/85 mmHg) 
has been shown to reduce the rate of worsening of diabetic retinopathy by 34 % over 
9 years follow-up,156 and to reduce the risk of vision loss by three lines or more by 
47%.156 The recommended guidelines, according to the American Diabetes 
Association, for systolic blood pressure and diastolic blood pressure levels are <130 
mmHg and <85 mmHg respectively.157 The role of hypertension in diabetes will be 
explored in more detail in chapter seven. 
3.4.3 Dyslipidaemia 
Hyperglycaemia and defects in insulin action may also lead to changes in plasma 
lipoproteins in patients with diabetes.158 Additionally, the obesity/insulin-resistant 
metabolic disarray commonly associated with Type 2 diabetes, may itself, lead to lipid 
abnormalities exclusive of hyperglycaemia.158, 159 Dyslipidaemia is characterised by a 
moderate elevation in TGs, low HDL cholesterol and the presence of small, dense, 
atherogenic LDL particles,160 (reviewed in chapter six). In brief, dyslipidaemia often 
arises in untreated or uncontrolled diabetes, or in people who become overweight and 
develop insulin resistance.161 Impairment of the biological action of insulin at a 
cellular level (insulin resistance) is thought to primarily underlie the metabolic defects 
which contribute to the development of dyslipidaemia.161 Insulin plays a central role 
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in how the body utilises and stores glucose and fat. Insulin suppresses lipolysis in 
adipocytes via its effect on hormone-sensitive lipase (HSL), and it also stimulates the 
action of lipoprotein lipase (LpL), an important enzyme in the hydrolysis of plasma 
TGs and free fatty acid (FFA) delivery to adipocytes.158 In an insulin-resistant state, 
(i.e. Type 2 diabetes, overweight/obesity), there is an increase in intracellular 
hydrolysis of TGs and the release of FFAs into circulation from adipose tissue. 
Furthermore, insulin activation of LpL is delayed.162 Overall, this culminates in an 
increased concentration of FFAs in circulation returning to the liver, where they are 
reassembled into TGs. The presence of excess TGs in the liver promotes TG-rich very-
low-density lipoprotein (VLDL) production,163, 164 and the accompanying hepatic 
insulin resistance fails to effectively suppress the release of TG rich VLDL in 
circulation.165  
 
Heterogeneity exists in the size and composition of all classes of lipoproteins. The 
core of lipoproteins contain hydrophobic cholesterol ester and TGs, and their 
proportions are determined by the enzyme cholesteryl ester transfer protein (CETP). 
In the presence of increased concentrations of VLDL in circulation, CETP will 
exchange VLDL TGs for cholesteryl ester in the core of LDL and HDL, resulting in 
smaller, denser LDL and HDL particles.158 This CETP-mediated exchange is 
accelerated in the presence of excess TGs,166 and explains the hypertriglyceridaemia, 
reduced HDL and small dense LDL particles commonly observed in diabetes, and 





Figure 3.6: Plasma lipid exchange. CETP will exchange VLDL triglyceride for 
cholesteryl ester in the core of LDL and HDL. The net effect is a decrease in size and 
an increase in density of both LDL and HDL (Adapted from Goldberg 158). 
 
Triglyceride levels also correlate with the degree of glycaemic control in patients with 
Type 1 diabetes.167 The absolute insulin deficiency in Type 1 diabetes patients 
presenting with ketoacidosis leads to hypertriglyceridaemia.168 Additionally, treated 
Type 1 diabetes patients with poor or suboptimal control also present with elevated 
TGs, similar to their Type 2 diabetic counterparts, due to relative insulin deficiency.169 
Metabolic control after insulin administration, however, rapidly improves TG levels 
in Type 1 diabetes by normalising LpL activity. In fact, intensely treated Type 1 
diabetes patients often have no observed lipid abnormalities, and plasma TGs may 





Dyslipidaemia often precedes the overt appearance of Type 2 diabetes by several 
years, which suggests that dysregulation of lipoprotein metabolism is an early event 
accompanying insulin resistance and precedes β-cell failure in Type 2 diabetes.171 It is 
worth noting that centrally-deposited adipose tissue (visceral fat or intra-abdominal 
fat) differs considerably in its metabolic activities and clinical consequences compared 
with other body fat. Excess subcutaneous fat does not appear to contribute 
significantly to elevated TG levels 172 compared with visceral adiposity.173 Visceral 
adipose tissue is also highly vascular and drains directly into the portal vein. 
Furthermore, the ability of insulin to suppress lipolysis and to re-esterify FFAs is 
significantly reduced in visceral adipocytes.174 In summary, patients with diabetes 
and/or individuals who are overweight/obese have an increased risk of suffering from 
dyslipidaemia.  
3.4.4 Oxidative stress 
While the exact mechanisms by which oxidative stress contributes to diabetic 
retinopathy remain elusive, it is thought that chronic hyperglycaemia leads to the 
overproduction of free radicals and that hyperglycaemia also impairs the endogenous 
antioxidant defence system,175 rendering the affected cells and tissues (i.e. lipids, 
protein and de-oxy ribonucleic acid (DNA) constituents) more susceptible to oxidative 
damage.176 Under normal physiological conditions, ROS are detoxified by their 
interaction with various reducing and sequestering agents. However, when the body 
becomes overwhelmed (e.g. by hyperglycaemia), oxidative stress ensues. 
 
Reactive oxygen species can be defined as intermediate oxygen-carrying metabolites 
with or without an unpaired electron, (i.e. oxygen-centered free radicals such as 
superoxide anions, hydroxyl radicals); and non-radicals (such as hydrogen peroxide, 
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and singlet oxygen).177 Free radicals can either donate an electron to or accept an 
electron from, therefore, behave as oxidants or reductants.178 Radicals and non-
radicals are both capable of oxidising other components, turning them into free 
radicals, thereby, causing a chain reaction that can lead to the formation of numerous 
new radicals.179, 180  
3.4.4.1 Overproduction of reactive oxygen species 
Sustained hyperglycaemia and increased chronic local oxidative stress disrupts retinal 
metabolism and accelerates premature endothelial cell apoptosis in both Type 1 and 
Type 2 diabetic retinopathy.181-183 There is also evidence to suggest that oxidative 
damage occurs in non-vascular retinal cells (Muller, bipolar, amacrine, ganglion, and 
photoreceptor cells) in the early stages of diabetic retinopathy.184-186 Glial cells 
normally produce large amounts of glutathione (GSH), whereas, hyperglycaemia 
induces depletion of GSH within these cells, resulting in impaired glutamate 
metabolism.187 This culminates in the release of inflammatory substances by glial cells 
which damage their close structural relationship with blood vessels.188 These 
pathogenic changes are linked to increased vascular permeability and resultant 
diabetic macular oedema.  
 
Additionally, Muller cells stimulated by hyperglycaemia increase ROS production 
which amplifies AGE formation, contributing directly to neuronal cell apoptosis.189, 
Capillary occlusion and retinal ischaemia increase expression and release of growth 
factors (i.e. VEGF) and cytokines (discussed in more detail in section 3.4.5). Vascular 
endothelial growth factor increases vascular permeability and also favours the growth 
of abnormal vessels.190 Pathological angiogenesis driven by VEGF originating from 
pericytes, retinal ganglion and glial cells has been implicated in irreversible vision 
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loss.190    
3.4.4.2 Role of antioxidant defence system 
The balance between oxidation and anti-oxidation is believed to be critical in 
maintaining healthy biological systems. The endogenous antioxidant defence 
mechanisms include enzymatic and non-enzymatic antioxidants. The primary 
endogenous antioxidant enzymes are catalase (CAT), glutathione peroxide (GPx) and 
superoxide dismutase (SOD).177 Non-enzymatic antioxidants include vitamin E (α-
tocopherol), β-carotene, GSH compound and lipoic acid.177 The endogenous 
antioxidant system is supported by smaller exogenous antioxidant molecules derived 
principally from a diet rich in fruit, vegetables and grains, a diet which includes 
vitamins C and E, carotenoids (β-carotene, lutein, zeaxanthin, meso-zeaxanthin) and 
polyphenols.177 The synergistic action of several ocular antioxidants is what protects 
the eye most effectively from oxidative damage.180 While ROS has been linked to 
diabetic complications, antioxidants have shown promise as a possible therapy for the 
prevention and treatment of the disease (reviewed in more detail in chapters four and 
six). 
3.4.5 Inflammation  
Inflammation is common in many chronic diseases, including diabetes.191 In Type 1 
diabetes islet inflammation is thought to be a local phenomenon driven by a focal 
autoimmune attack on islet antigens, whereas, in Type 2 diabetes activation of 
inflammation results from systemic features such as obesity and insulin resistance.192 
The comorbidities of hypertension, dyslipidaemia, insulin resistance, obesity, 
(metabolic correlates commonly associated with Type 2 diabetes), have been 
incriminated in the maintenance and exacerbation of these inflammatory reactions.192 
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Ultimately, inflammatory mediators activate a series of receptors and transcription 
factors, such as nuclear factor Kappa B (NF-kB), which leads to impaired insulin 
signalling in insulin-sensitive tissues, systemic endothelial dysfunction, and altered 
vascular flow.193 Figure 3.7 outlines the association between inflammatory mediators 
and anatomical changes to retinal tissue in diabetic retinopathy.194 The role of 
inflammation in diabetes mellitus will be reviewed in chapter six. 
 
 
Figure 3.7: Role of vitreous mediators in diabetic retinopathy progression. In diabetic 
retinopathy, several inflammatory vitreous mediators are upregulated and induce 
anatomical changes in the retinal tissue. The structural changes enhance retinal tissue 
degeneration and mediate pathogenesis of diabetic retinopathy (Adapted from 
Semeraro et al,194). 
3.4.5.1 Adipose tissue and inflammation 
Adipose tissue also contributes importantly to the inflammatory process in 
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overweight/obese subjects.195 Pro-inflammatory and pro-coagulant mediators released 
by stressed adipose tissue have both local and systemic effects on metabolism and 
vascular function.192 Adipose tissue from obese individuals contains activated 
macrophages that together with adipocytes produce inflammatory adipokines such as 
TNF-α, IL-6, and molecules that may contribute to insulin resistance such as FFAs, 
TNF-α, and resistin.196 Overweight/obesity-induced inflammation in association with 
diabetes mellitus and MP will be discussed in chapters six, seven and .eight 
3.4.6 Retinal neurodegeneration 
Diabetic retinopathy has traditionally been described as a microvascular disease of the 
retina, however, more recent research suggests that retinal neurodegeneration is an 
early event in its pathogenesis. Biochemical and histopathological changes, 
characteristic of retinal neurodegeneration have been observed in diabetic patients 
before any visible changes in the retina.197-199 It is now widely accepted that structural 
and functional damage to nonvascular cells (ganglion cells, glial and microglial cells) 
contribute to the pathogenesis of diabetic retinopathy.135, 200, 201Important 
neuroprotective factors include somatostatin (SST) and PEDF. Neurotoxic factors 
involve elevated levels of extracellular glutamate, oxidative stress and overexpression 
of the renin angiotensin system (RAS).202, 203 The balance between neurotoxic and 
neuroprotective factors is what determines the presence of retinal neurodegeneration 
in the diabetic retina. 
 
Retinal neurodegeneration has been identified in experimental models on rodent rats 
at the very early phase of diabetic retinopathy. Rats with streptozotocin (STZ) induced 
diabetes exhibited a high rate of apoptosis in the neuroretina within one month after 
inducing diabetes, without any significant apoptosis in endothelial cells.204 Apoptosis 
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and glial activation have also been shown to occur in the retina of diabetic patients, 
before microvascular abnormalities.197 Retinal ganglion cells appear to be the earliest 
cells affected and have the highest rate of apoptosis,205 however, cell death has also 
been observed in the outer nuclear layer (photoreceptors),200 and the RPE.206 
Neuroretinal damage produces functional abnormalities early in the course of the 
disease, as demonstrated by abnormal responses of oscillatory potentials in 
electroretinograms (ERGs), findings which reflect malfunctioning of inner retinal 
layers.201  
 
It is now believed that carotenoids, lutein, zeaxanthin, and meso-zeaxanthin may 
prevent and protect against the development of diabetic retinopathy via 
neuroprotective properties, however, the molecular basis for these effects remain 
unknown. The neuroprotective properties of these carotenoids will be explored in 
more detail in chapter four. 
3.5 Current treatment options for diabetic retinopathy 
Diabetic retinopathy remains one of the most debilitating complications of diabetes. 
Both neuronal and vascular retinal damage occurs as a result of chronic 
hyperglycaemia, and this damage is progressive, however, most patients remain 
asymptomatic until very late stages of the disease. Regular screening is, therefore, 
essential. While there is no cure for diabetic retinopathy, timely treatment may be 
effective in delaying or reducing vision loss and remains the gold standard for 
ameliorating blindness due to diabetic retinopathy. Clinically significant macular 
oedema is the most common cause of moderate vision loss (< 6/12 vision) in all types 
of diabetic retinopathy. The majority of severe vision loss (< 6/60 vision) in diabetic 
retinopathy is the result of complications from proliferative diabetic retinopathy, either 
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from a vitreous haemorrhage, retinal detachment, or neovascular glaucoma. It is 
recommended that patients with Type 1 and Type 2 diabetes have an initial dilated and 
comprehensive eye examination by an ophthalmologist or optometrist within 3–5 
years after onset of diabetes for Type 1 diabetes and yearly after diagnosis for Type 2 
diabetes.136 Clinical judgment should, however, be used when applying these 
recommendations to individual patients.25 
 
Primary prevention of diabetic retinopathy involves strict control of blood sugars,145 
blood pressure,156 and lipids.207 Secondary interventions for diabetic retinopathy 
include pan-retinal photocoagulation,208 focal laser photocoagulation,209 and surgical 
vitrectomy.13 More recently, intravitreal anti-VEGF injections have demonstrated 
their superiority to laser therapy in reducing vision loss and improving rates of vision 
gain in eyes with diabetic macular oedema.210 Anti-VEGF therapy has also been 
shown to be highly effective in regressing retinal neovascularisation in eyes with 
proliferative diabetic retinopathy.211 This form of treatment may, however, not be 
optimal for patients who cannot comply with monthly follow-ups and the repeated 
intravitreal injections necessary for adequate treatment and prevention of proliferative 
diabetic retinopathy. Furthermore, intravitreal injections are invasive, increasing the 
likelihood of local complications including uveitis, cataract, retinal detachment, and 
endophthalmitis.212 While intravitreal injections are very effective at preventing vision 
loss and often result in a visual gain for patients with both diabetic macular oedema 
and proliferative diabetic retinopathy, there is a substantial proportion of eyes 





Improvements in understanding the pathogenesis of diabetic retinopathy and an 
increase in diagnostic techniques, including imaging, opens up the possibility of 
earlier diagnosis of diabetic retinopathy and will, therefore, optimise efforts toward 
more precise management of the disease. While Type 1 diabetes patients tend to be 
diagnosed promptly, patients with Type 2 diabetes can be insulin resistant for many 
years prior to diagnosis, and can often present with signs of diabetic retinopathy at the 
time of diagnosis.25 Lifestyle modifications including an increase in physical activity 
and a healthy diet (i.e. diet of fruit, vegetables, legumes), offer potential to manage 
diabetes after onset and can even prevent Type 2 diabetes development.214 Early 
detection and education on lifestyle behaviours broaden therapeutic objectives beyond 
direct suppression of pathological vascular changes.  
3.6.2 The role of macular pigment in diabetes 
While the Age-Related Eye Disease Study 2 (AREDS2) has established a clear clinical 
benefit for dietary carotenoids (lutein and zeaxanthin) supplementation in patients 
with AMD,5 their role in another retinal disease putatively associated with oxidative 
stress and inflammation (i.e. diabetes) remains comparatively unexplored. Current 
treatment paradigms for diabetic retinopathy (laser photocoagulation, intravitreal 
injections and vitreoretinal surgery) focus on the treatment of advanced disease, often 
after permanent damage has ensued. These treatments are also invasive, expensive and 
need to be repeated at frequent intervals. An important conceptual advance in recent 
research has been the recognition that diabetic retinopathy is a disease of the 
neurovascular unit, with multiple interdependent cell types contributing to the 
dysfunction of the retina. Therefore, new therapeutic approaches should adopt a more 
holistic view of how diabetes affects the retina. Newer treatments that are preventative 
or address early pathology are more appealing. Researchers are now beginning to look 
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at the beneficial effects of lutein, zeaxanthin, and meso-zeaxanthin in protecting ocular 
tissues and cells, including retinal neurons, and on the prevention of diabetic 
retinopathy which has been studied in a variety of experimental animal models 14, 186, 
215 and human studies.15, 21 There is increasing evidence that MP levels can be 
augmented through increased intake of dietary lutein and zeaxanthin in both healthy 
and diseased retinas,5, 216-218 suggesting the possibility that therapeutic intervention in 
the form of dietary modification or nutritional supplementation may modulate the risk 
of diseases with a relative lack of MP.5, 47 The putative protective role of lutein, 
zeaxanthin and meso-zeaxanthin in the pathogenesis of diabetic retinopathy will now 

















4. MACULAR PIGMENT AND DIABETES MELLITUS 
4.1 Background 
The human macula uniquely concentrates three hydroxyl-carotenoids: lutein, 
zeaxanthin, and meso-zeaxanthin, collectively known as MP.46 Lutein and zeaxanthin 
cannot be produced endogenously in humans, therefore, these carotenoids must be 
obtained from dietary sources such as green leafy vegetables and bright coloured 
fruits,22 while meso-zeaxanthin is believed to be mainly formed at the macula through 
a poorly understood process of bioconversion.219 Although, meso-zeaxanthin has been 
found in specific dietary sources such as turtle, shrimp and fish skin.220 While there 
are many hundreds of carotenoids present in the plant world, the primate macula 
contains only these three.  
 
The anatomical location of MP has generated a lot of interest in this pigment’s role in 
vision and macular health. Macular pigment is highly concentrated in the central retina 
(the macula) and concentrations decrease nearly 100-fold with increasing retinal 
eccentricity.44 While not considered to be essential micronutrients, MP’s constituent 
carotenoids have powerful antioxidant, anti-inflammatory and neuroprotective 
properties 2, 4, 221, 222 and these phytonutrients have been studied extensively. 
Epidemiological studies and large-scale clinical trials, such as AREDS2, have brought 
attention to the functional benefits of these carotenoids in the prevention of retinal 
diseases such as AMD.5, 218 The fact that MP is modifiable, through diet and/or 
supplementation, means that ongoing research into their role in the prevention or 
progression of AMD is important. Researchers are now beginning to focus on the 
relationship between MP and diabetes mellitus, a condition similarly known to cause 
oxidative damage and inflammation in the retina.9, 10 Studies have shown that MP is 
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lower in diabetes, 6, 9 however, the causal mechanisms and metabolic perturbations 
associated with lower MP in diabetes have yet to be elucidated. While all humans 
appear to have some quantity of MP within their retina, foveal concentrations tend to 
vary quite dramatically.223,224 The basic science and clinical research underlying the 
assessment of MP and recommendations for nutritional interventions against diabetic 
eye disease are under-acknowledged by practitioners and vision researchers alike. This 
chapter will explore the structural and functional benefits of MP in the eye, with a 
particular focus on MP and diabetic retinopathy. 
4.2 Location of macular pigment 
The yellow colouration of the macula is attributable to the presence of lutein, 
zeaxanthin and meso-zeaxanthin.44 The ratio of lutein to zeaxanthin to meso-
zeaxanthin is 1:1:1 in the centre of the fovea.1 Near the fovea, there is twice as much 
zeaxanthin and meso-zeaxanthin as lutein, and in the peripheral retina, this relationship 
is reversed.46, 60 Xanthophylls are highly concentrated within the photoreceptor axons 
of the Henle nerve fibre layer centrally, where the inner retinal layers are displaced.43, 
44 In the parafoveal region they are located in the inner and outer plexiform layers of 
the photoreceptors.43, 44 At 7 degrees retinal eccentricity, it is believed that these 




Figure 4.1: Histology of human MP illustrating the spatial profile and pre-receptoral 
location of MP. The main location of MP is in the layer of the fibres of Henle in the 
fovea (A) and in the inner nuclear layer at the parafoveal site (B) (Modified from 
Trieschmann et al,43).  
4.3 Carotenoid chemistry 
The MP of primates can be traced to its dietary origins. Around 700 carotenoids exist 
in nature, however, only 40 to 50 carotenoids are present in a typical Western diet,45, 
225 of which 15 to 30 enter the human bloodstream.45, 225 The most prominent plasma 
carotenoids include lycopene, α-carotene, β-carotene, lutein and zeaxanthin.45 The 
carotenoid group include phytochemicals with the basic structure C40 H56. These 
compounds act as antioxidants as they contain several double bonds and react with 
ROS to scavenge free radicals. Carotenoids are classified as carotenes if they are 
exclusively hydrocarbons, composed of only carbon and hydrogen, and are classified 
as oxo-carotenoids (xanthophylls) when they carry at least one oxygen atom.226-228 
Xanthophylls and their hydroxyl (-OH) functional groups permit lutein, zeaxanthin 
and meso-zeaxanthin to cross both the blood-ocular and blood-brain barriers. 




not cross these barriers.229 Lutein, zeaxanthin and meso-zeaxanthin are the only 
carotenoids to ultimately reach the human retina.45, 46 Figure 4.2 shows the chemical 





Figure 4.2: Chemical structure of lutein (C40H56 O2); lutein contains double bonds 
that scavenge ROS.230 
 
Xanthophylls are a large group of plant pigments responsible for the colour of brightly 
coloured fruit and vegetables. Lutein is found in the highest concentrations in dark 
green leafy vegetables (spinach, kale, collard greens and others).22 Zeaxanthin is the 
major carotenoid found in corn, orange peppers, oranges and tangerines.22 The highest 
molar percentage of lutein and zeaxanthin are found in egg yolk and maize.22 Meso-
zeaxanthin, was previously thought to be undetectable in the human liver or plasma 
and thought to be generated solely at the macula following a biochemical 
transformation of lutein.1, 219 The 3:1 ratio of lutein to zeaxanthin in plasma and the 
2:1 ratio in the fovea support this theory of conversion.1 Meso-zeaxanthin, however, 
has more recently been found in trace amounts in blood plasma,231 and has been 
identified in some less commonly consumed foods including fish (e.g. salmon and 
trout), shrimp, and turtle.220, 232 Supplementation trials have also demonstrated a 
significant increase in MP’s levels after oral supplementation with meso-zeaxanthin, 
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suggesting that it can be absorbed after oral administration and transported to the 
macula.233 Meso-zeaxanthin accounts for about one-third of total MP at the fovea.  
4.3.1 Stereochemistry of macular carotenoids 
Macular pigment was shown in 1985 by Bone et al,234 and later by Handleman et al,235 
using high-performance liquid chromatography (HPLC) to be composed of two 
chromatographically separable components, namely lutein and zeaxanthin. The lutein 
component of MP consists of a single stereoisomer of lutein [(3R, 3′R, 6′R)- β, ε-
carotene-3,3′-diol], whereas, the zeaxanthin component consists of three possible 
stereoisomers which include dietary zeaxanthin itself or RR-zeaxanthin [(3R,3′R)- 
β,β- carotene-3,3′- diol], SS-zeaxanthin [(3S,3′S)- β, β- carotene-3,3′-diol] (found only 
in trace amounts), and meso- zeaxanthin [(3R,3′S)- β, β- carotene-3,3′-diol].46, 60, 234 
Macular pigment refers to the accumulation at the macula of a single isomer of lutein 
and 3 stereoisomers of zeaxanthin (RRZ, meso-zeaxanthin, and SSZ).44, 46 The 
hydroxyl group at the C-3′ position in lutein (3R, 3′R, 6′R- β, ε- carotene-3,3′-diol) is 
configured exactly opposite to that of zeaxanthin (3R, 3′R-β, β -carotene-3,3′-diol), 
while the C-3 and C-3′ hydroxyl groups in meso-zeaxanthin (3R, 3′S-β, β, -carotene-
3,3′-diol) are positioned identically to lutein.226 These hydroxyl groups, one at each 
side of the molecule, appear to control the biological function of xanthophylls.219 The 
double-bond in lutein at the 4′, 5′ position is shifted to the 5′, 6′ position in zeaxanthin 
and meso-zeaxanthin.226 Additionally, there is an extra conjugated double bond in 
zeaxanthin and meso-zeaxanthin which makes them more stable and better 
antioxidants than lutein.236,237,1 Zeaxanthin is superior in preventing lipid peroxidation 
induced by ultraviolet (UV) light,238 while meso-zeaxanthin has a greater capability of 
quenching oxygen radicals than lutein, although, lutein has a better filtering 
efficacy.239 The functional differences of these carotenoids appear to correlate with 
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their spatial distribution in the retina. Zeaxanthin and meso-zeaxanthin predominate in 
the centre of the retina where cone density is highest and risk of oxidative damage is 
greatest.235, 237 The combination of all three carotenoids and their essential functions, 
however, is what reduces oxidative stress in both normal and diseased retinas. Figure 
4.3 shows the stereochemistry of all three macular carotenoids.226  
 
 
Figure 4.3: Chemical structure of macular pigment carotenoids. (a),(b) lutein; (c) 
zeaxanthin; (d) meso-zeaxanthin (Adapted from Bernstein et al,226). 
4.4 Functional properties of macular pigment 
The retina is an ideal environment for the generation of ROS for several reasons; 1) 
the retina is subject to high levels of cumulative irradiation; 2) the membranes of the 
outer segments of photoreceptors have high concentrations of polyunsaturated fatty 
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acids (PUFAs) which are susceptible to photo-oxidation; 240 3) oxygen consumption 
by the retina is much greater than by any other tissue and the outer retina has a high 
oxygen tension (70 mmHg), almost that of arterial blood; 4) furthermore, the process 
of phagocytosis by the RPE itself creates oxidative stress.241 Therefore, a rich oxygen 
supply, combined with high-energy short-wavelength light stimulation, and a 
vulnerable substrate creates ideal conditions for oxidative damage.242 Some of the 
major proposed functions of these ocular carotenoids include blue light filtration 
effects, antioxidant, anti-inflammatory and neuroprotective properties, and are 
discussed in more detail herein.2, 221, 222, 243, 244  
4.4.1 Macular pigment as a blue light filter   
Macular pigment reduces sensitivity of the macular region to short-wavelength light 
by acting as a broadband filter.245 Most UVC (100-200 nm) radiation is absorbed by 
the atmosphere; while UVB (290-320nm) and UVA (320-400nm) radiation are 
absorbed by the cornea and crystalline lens. Slightly longer-wavelength light (400-500 
nm) is for the most part absorbed by MP, which has a peak absorbance of 460nm.44, 
246 Absorption by MP occurs before light reaches the photoreceptors,44 therefore, 
penetration of damaging short-wavelength light is minimised. While macular 
xanthophylls reach their highest concentrations in the centre of the fovea, these 
carotenoids are also highly distributed throughout the photoreceptor cell. Therefore, 
each photoreceptor screens other photoreceptors as well as itself because of the lateral 
course of the axons.44  
 
Blue light being a shorter wavelength has more energy and is, therefore, potentially 
more damaging to the eye. Chronic exposure to radiation (400-520 nm) can cause 
damage to both the intraocular lens and the retina through photo-oxidative reactions.247 
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Beyond the first three years of life yellow chromophores develop in the crystalline 
lens which are capable of absorbing UV and short-wavelength light.248 Because of 
these chromophores the absorbed energy is safely dissipated and the lens and retina 
are protected against photo-oxidative damage.249 With advancing age, however, these 
chromophores become modified and phototoxic. Absorption of UV and short-
wavelength visible light by a phototoxic chromophore causes the chromophore to 
become excited, firstly to a singlet state, then a triplet state, and from a triplet state 
free radicals and ROS are produced (e.g. singlet oxygen and superoxide), free radicals 
which can damage ocular tissue (reviewed by Roberts & Dennison 250), (Figure 4.4).  
 
Figure 4.4: Photo-oxidation (Adapted from Roberts & Dennison 250). 
 
Exposure to UV and short-wavelength blue light is particularly hazardous after the age 
of 40 because there is an increase in light-absorbing endogenous phototoxic 
chromophores, that efficiently produce singlet oxygen and other ROS. Chromophores 
which produce free radicals and singlet oxygen upon photoexcitation are known as 
photosensitisers. A single molecule of a photosensitiser is capable of producing 
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numerous free radicals and singlet oxygen molecules as long as it is recycled and 
photoexcited by subsequent photons. It is thought that increased levels of ROS and the 
concomitant decrease in the production of antioxidants and antioxidant enzymes in the 
lens leads to DNA damage and cross-linking of proteins, resulting in cataract 
formation.251  
 
The continual exposure of the retina to incident light, in addition to the high 
concentrations of oxygen, and the presence of photosensitisers, such as vitamin A 
derivatives, rhodopsin, cone opsins, lipofuscin and melanin, make the outer retina 
inherently susceptible to photo-oxidative damage. Damage induced by chronic 
phototoxic reactions over many years has been implicated in the aetiology of AMD.252 
Blue light-induced generation of ROS by the lipofuscin chromophore is toxic to 
mitochondria and is known to initiate apoptosis in the RPE.253,254 Furthermore, it has 
been shown that blue light damage is proportional to the amount of light received and 
the amount of lipofuscin within RPE cells.255 Chromophores in photoreceptor outer 
segments (rhodopsin and cone opsins) are also susceptible to oxidative damage. While 
most UV light is absorbed by the cornea and lens, some fraction of blue light radiation 
reaches the retina and may activate potent retinal photosensitisers. Blue light 
absorption by MP can, therefore, indirectly be considered an antioxidant action 
because it prevents blue light from generating ROS which can potentially damage 
photoreceptor cells.256 
4.4.1.1 Blue light-filtering effects of MP in diabetes 
Several studies have investigated the protective effects of lutein and zeaxanthin 
administration against light-induced damage in experimental animal models. Evidence 
suggests that zeaxanthin can protect photoreceptors against light-induced apoptosis in 
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quail (the retinae of which, like those of primates, selectively accumulate lutein and 
zeaxanthin).257 Oral supplementation with zeaxanthin was found to decrease 
photoreceptor cell death and activation of microglia in this study, providing 
experimental evidence that xanthophyll carotenoids can protect photoreceptor cells in 
vivo.257 The effects of lutein in light-induced retinal degeneration has also been 
investigated in STZ induced diabetic murine models.186 Functional abnormalities 
secondary to diabetes-induced oxidative stress, (i.e. reduction in ERG a and b-wave 
amplitudes), were observed before histopathological changes in diabetic 
retinopathy.186 These changes were, however, successfully restored following 
administration of lutein, suggesting that carotenoids have the potential to normalise 
diabetes-induced early functional modifications in the retina.186 The beneficial effects 
of MP on diabetes in experimental animal and human studies will be explored in more 
detail in chapter six. 
4.4.2 Macular pigment as a potent antioxidant  
Carotenoids lutein, zeaxanthin and meso-zeaxanthin are part of the antioxidant 
defence system. By nature of their biological structure and function, these 
phytonutrients help neutralise ROS. Carotenoids interact synergistically with other 
antioxidants, minerals and vitamins, thereby, protecting the eye against the cumulative 
effects of damage due to light and oxygen.45,258,250 There is increasing evidence that 
higher intakes of fruits and vegetables (i.e. carotenoids lutein and zeaxanthin),22, 259 
can slow the progression of age-related cataracts and AMD.5, 260 The beneficial effects 
of higher intakes of fruit and vegetables in diabetes and diabetic retinopathy is 





Oxidative damage is one of the underlying causes of diabetic retinopathy. While free-
radicals can occur as normal by-products of cellular metabolism,262 the generation of 
ROS increases dramatically in the retina during times of local stress (i.e. 
hyperglycaemia). De novo synthesis of MP is not possible in humans, therefore, an 
important source of theses phytonutrients is a diet which is rich in fruit and 
vegetables,22 a diet which may be compromised in diabetes (Type 2 diabetes in 
particular).214 Additionally, there is a decline in the production of antioxidants and 
antioxidant enzymes with age, (reviewed by Liguori et al,263). Oxidative stress appears 
to be caused by both increased production of ROS and/or reductions in antioxidant 
defences, thereby, resulting in an altered redox state,264, 265 (reviewed in more detail in 
chapter six).   
 
In brief, carotenoids lutein, zeaxanthin and meso-zeaxanthin are powerful quenchers 
of singlet molecular oxygen and free radical scavengers.266-268 The quenching of 
singlet oxygen is primarily by a physical mechanism rather than a chemical one. The 
carotenoid molecule accepts the excitation energy from singlet oxygen. The added 
energy causes excitation of the carotenoid molecule, resulting in a triplet state and this 
triplet state dissipates energy harmlessly as heat through rotational and vibrational 
interactions and finally relaxes into a ground state. The structure of the carotenoid 
remains unchanged in this process.229, 267 Xanthophylls lutein, zeaxanthin and meso-
zeaxanthin can also scavenge ROS (free radicals such as hydroxyl and peroxyl 
radicals). The free radical can either obtain its missing electron from the electron-rich 
molecule of the carotenoid or the free radical adds itself to the carotenoid molecule to 
pair its single electron, thus forming a covalent bond.229, 267 Either way, the electron-
rich structure of the carotenoid molecule attracts free radicals and spares cell damage 
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to lipids, proteins or DNA.269 Figure 4.5 shows the photochemical mechanisms of 
protection by lutein and zeaxanthin.250  
 
Figure 4.5: Photochemical mechanisms of protection (Adapted from Roberts & 
Dennison 250). 
 
Carotenoids have a ready supply of available electrons that enable them to scavenge 
ROS and attenuate oxidative injury. Zeaxanthin, (with 11 conjugated double bonds), 
has a higher ability to quench singlet oxygen than lutein (with 10 conjugated double 
bonds).229,270 Meso-zeaxanthin, in conjunction with its binding protein, however, is 
even more effective.271 Meso-zeaxanthin differs from zeaxanthin in the spatial 
orientation of the hydroxyl group on the C3 chiral position, but the conjugated systems 
are the same. The order of efficiency of the macular carotenoids in quenching singlet 
oxygen is as follows: lutein < zeaxanthin < meso-zeaxanthin < all three combined.272 
A mixture of lutein: zeaxanthin: meso-zeaxanthin in a ratio of 1:1:1 however, has 
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shown to be the most effective in quenching singlet oxygen.272  
4.4.2.1 Antioxidant function of MP in diabetes 
Evidence is emerging which suggests that oxidative damage occurs in retinal vascular 
cells (endothelial and pericyte cells) as well as non-vascular cells (Muller cells, 
photoreceptor, bipolar and ganglion cells) in the early stages of diabetic retinopathy.184 
Hydroxyl-carotenoids, lutein, zeaxanthin, and meso-zeaxanthin readily supply 
available electrons that enable these carotenoids to scavenge ROS. Although the 
evidence exploring MP and diabetes is relatively sparse, it has been shown that plasma 
concentrations of lutein and zeaxanthin are lower in diabetes patients with non-
proliferative diabetic retinopathy compared with normal controls and that 
supplementation with these carotenoids can improve VA, contrast sensitivity and 
macular oedema in patients with diabetic retinopathy.15 The putative protective effects 
of MP in diabetic retinopathy in human and animal studies will be explored in more 
detail in chapter six. 
4.4.3 Neuroprotective and anti-inflammatory properties of MP 
The presence of lutein and zeaxanthin in substantial concentrations in the primary 
visual cortex 273 and the finding of better dark-adapted cone sensitivities in association 
with higher MP 274 combine to suggest a key role for MP in ocular and 
neurophysiologic health. The retina is part of the central nervous system and once 
damaged regenerates poorly, if at all. The majority of studies investigating the effects 
of MP augmentation in ocular disease, including AMD and diabetes, have reported 
beneficial effects on vision 21, 218 findings which suggest a neuroprotective effect of 
these carotenoids. While the exact mechanisms are not clear, there are a number of 
plausible explanations to explain why these phytonutrients improve neural function, 
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including, enhancement of membrane stability, modulation of synaptic activity and 
intracellular communication.256, 275, 276  
 
The orientation of xanthophyll molecules within the phospholipid bilayers not only 
protect against oxidative damage but also modulate the physical properties of these 
membranes.275 Macular xanthophylls are distributed between the lipid and protein 
components of membranes.226 The presence of polar hydroxyl groups at each end of 
the xanthophyll molecule ensures a roughly perpendicular orientation within the lipid 
bilayer.256, 275 The almost vertical orientation of the dipoles provides good conditions 
for macular xanthophylls to act as a blue light filter.275 Concomitantly, such an 
organisation has a direct effect on reducing the penetration of molecular oxygen into 
the hydrophobic membrane core, thus protecting vulnerable regions against oxidative 
damage.256 The high membrane stability and preferential transmembrane orientation 
in lipid bilayers of photoreceptor outer segments, in addition to their antioxidant 
properties, maximises their protective action in retinal membranes.275 
 
Lutein and zeaxanthin may also play a role in maintaining cell integrity and plasticity, 
by binding to tubulin.277 Tubulin has been identified as the major carotenoid binding 
protein found in abundance in the receptor axon layer of the fovea.277 Tubulin is also 
the main structural protein of microtubules.277, 278 Microtubules form important 
cytoskeletal structures that play a role in maintaining neuronal morphology, 
transporting cargo, and scaffolding signalling molecules.279 Reduced microtubule 
stability has been observed in neurodegenerative diseases such as Alzheimer’s disease 
and Parkinson’s disease 279 and research suggests the macular carotenoids modulate 
the stability of photoreceptor-axon microtubules, thereby, promoting cell integrity.278  
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Particular attention has also been given to the stimulatory effects exerted by 
carotenoids on gap junctional communication. While chemical synaptic transmission 
(via transmitters, neurotransmitters) is the dominant mode of signal transmission, 
inter-neuronal signal transmission is also mediated by gap junctions. Gap junctions 
provide low resistance avenues for electrical and/or metabolic communication of 
coupled cells.280 Direct coupling through gap junctions has been suggested to mediate 
communication between neurons and glial cells.280,281 The regulation of gap junctional 
communication is complex and the mechanisms related to carotenoid activity are not, 
however, fully understood. It has been suggested that lutein and zeaxanthin increase 
processing speed through their facilitative effect on gap junctional communication.282 
In theory, a high density of pigment may improve signal transduction in the visual 
system.282 The connection between photoreceptors and the visual cortex may also be 
strengthened, which could explain improvements in contrast sensitivity function after 
three months of supplementation with lutein and zeaxanthin in patients with non-
proliferative diabetic retinopathy.15 
 
There is also growing evidence to suggest that lutein and zeaxanthin may prevent the 
development of diabetic retinopathy by suppressing ROS induced by inflammation.14, 
283 Reactive oxygen species are considered a strong stimulus for the activation of a 
number of pro-inflammatory pathways and several intracellular signalling pathways 
of inflammation are associated with oxidative damage. In the endotoxin-induced 
uveitis (EIU) mouse model, the innate immune system causes intraocular 
inflammation which involves the neural retina.185, 284 One effect of retinal 
inflammation that impairs visual function is the decreased expression of rhodopsin, an 
essential protein that is vital for photo-transduction and photoreceptor function. In the 
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EIU mouse model, ERG showed a decrease in a-wave amplitude and photoreceptor 
dysfunction.185, 284-286 It is thought that a reduction of rhodopsin is caused by the 
upregulation of signal transducer and activator of transcription 3 (STAT3) and 
activation of inflammatory signals downstream, (i.e. IL-6). Once STAT3 activation 
exceeds a certain threshold, the IL-6-STAT3 pathway enters a vicious cycle, which 
exacerbates pathological conditions. It was found that the loss of rhodopsin resulted 
in shorter outer segments and a decrease in photoreceptor cell function.287 To 
investigate if lutein can protect visual function by suppressing inflammation the EIU 
model mice were pre-treated with lutein. Treatment with lutein prevented a reduction 
in the rhodopsin protein and preserved ERG a-wave, thereby, protecting photoreceptor 
cell function in the inflamed retina.230, 285 Lutein’s effect on rhodopsin preservation 
was accompanied by a suppression of STAT3 activation,230 which also suppressed the 
IL-6-STAT3 cycle, effectively preventing tissue damage.230 While the interaction 
between oxidative stress and inflammation is complex, these findings suggest that 
lutein also has an anti-inflammatory effect.230 
 
The benefits of MP are many and may relate to its blue light filtering effects, 
antioxidant, anti-inflammatory and neuroprotective properties. The link between 
hyperglycaemia and neurodegeneration is, however, not fully understood but various 
cues point to altered inflammation and the activation of retinal microglia as early 
features of diabetic retinopathy.288,289, 290 The protective effects of lutein and 
zeaxanthin in animal and human studies will be reviewed in more detail in chapter six. 
4.4.3.1 Polyunsaturated fatty acids 
The photoreceptor membranes of both rods and cones contain high quantities of long-
chain omega 3 PUFAs. Polyunsaturated fatty acids account for about 50% of the lipid 
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bilayer of rod outer segment membranes and proteins make up the remaining 50%. 
Polyunsaturated fatty acids are particularly susceptible to free radical damage because 
their conjugated double bonds are convenient sources of hydrogen atoms, which 
contain one electron. The lipid radical combines with oxygen to form lipid peroxyl 
radicals and lipid peroxides, which can only achieve a steady-state by stealing 
electrons from other PUFAs, thus, creating a cytotoxic cascade of reactions that 
consume valuable PUFAs and produce damaged molecules.291, 292 Docosahexaenoic 
acid (DHA) is the main omega-3 PUFA in photoreceptors and the most oxidisable 
fatty acid in the body.293 Docosahexaenoic acid contains six double bonds so the retina 
is inherently susceptible to lipid peroxidation. Lipid peroxidation of membrane 
PUFAs results in loss of membrane function and structural integrity.294  
 
Omega-3 fatty acids DHA and eicosapentaenoic acid (EPA) have, however, also been 
shown to inhibit a wide range of inflammatory mediators involved in the 
pathophysiology of diabetic retinopathy, as well as, decrease the formation of free 
radicals and induce the expression of endogenous antioxidant enzymes, (reviewed by 
Behl & Kotwani 295). The anti-inflammatory and anti-angiogenic responses of DHA 
appears to be more potent than EPA 296 and DHA is known to regulate immune 
function through microglia activation.292,297 Recent studies suggest that PUFAs and 
their metabolites could play a significant role in diabetic retinopathy,298 as both EPA 
and DHA inhibit the production of both IL-6 and TNF-α,299, 300 and PUFAs also 
suppress VEGF production.301, 302 Lutein, zeaxanthin and meso-zeaxanthin are ideally 
located in the rod outer segment membranes, suggesting a protective role as potent 
antioxidants for these important lipids.303,60, 291,304 Interestingly, the effect of 
supplementation with a multi-component nutritional supplement which included 
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omega 3 (EPA and DHA) and lutein/zeaxanthin, among other nutrients have been 
shown to exert positive and beneficial ocular effects in those with diabetic eye disease, 
(Type 1 and Type 2).21 This concept will be explored in more detail in chapter six. 
4.4.3.2 Vitamin D 
Vitamin D is also known to have anti-inflammatory and anti-angiogenic properties.305 
Evidence is accumulating that higher levels of vitamin D may protect against the 
development of diabetic retinopathy,306, 307 and that low plasma vitamin D levels are 
associated with increased severity of diabetic retinopathy.308 Abnormalities in many 
systemic inflammation markers (i.e. TNF- α, IL-6) have been found in Type 2 diabetes 
and it has been reported that vitamin D down-regulates the production of these pro-
inflammatory cytokines (reviewed by Palomer et al,309). Furthermore, the angiogenic 
effects of vitamin D deficiency have been shown to contribute to vascular damage in 
a group of young adolescents with Type 1 diabetes.310 Due to the cross-sectional nature 
of many of these studies, however, it is not known if vitamin D deficiency is a cause 
or a consequence of retinopathy. The relationship between vitamin D, MP and Type 2 
diabetes will be explored in more detail in chapter seven. 
4.5 Absorption, delivery and uptake of carotenoids in the eye 
While a diet rich in fruit and vegetables is important for achieving adequate intake of 
lutein and zeaxanthin (as well as other nutrients), concentrations of carotenoids in the 
retina to form MP are highly variable and reflect not only dietary consumption but 
also other factors such as individual efficacy of absorption,70 cholesterol and 
lipoprotein status,18, 71 body composition/bodyfat,17, 54 and metabolic status,6 among 
others. Individual differences in MP may also be influenced by non-dietary factors 
such as genetics,72 demographic and lifestyle characteristics. The bioavailability, 
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process of intestinal absorption, transport, and delivery of these phytonutrients to the 
retina will now be explored.  
4.5.1 Recommended daily intake values for carotenoids 
At present there is no official recommended dietary intake level or established 
physiologically significant cut off points for lutein/zeaxanthin in plasma above which 
‘protection’ or ‘prevention’ against chronic diseases (i.e. AMD, diabetic retinopathy) 
are ensured. Based on previous research,259 an intake of 6 mg of lutein and zeaxanthin 
per day for men and women has been suggested as a dietary target to reduce the risk 
of AMD.311 Mean daily intake of lutein and zeaxanthin combined, ranges from 0.8 mg 
to 4 mg per day, depending on the population studied and the method of dietary 
assessment used.22, 312 An Irish study, involving 826 subjects estimated mean 
lutein/zeaxanthin intakes of 0.6 - 2.4mg/day.49 The majority of lutein supplements 
contain in the range of 6 - 25mg/day. Many supplements, however, are often well in 
excess of the recommended levels of certain minerals and vitamins, with some dosages 
carrying potential adverse effects. It is worth noting that while lutein is considered a 
very safe compound, an exceedingly high daily ingestion of lutein (e.g. daily 20 mg 
supplement of lutein; 4 g of fish oil; and dietary consumption of lutein, which included 
a broccoli, kale, spinach, and avocado smoothie every morning) was associated with 
a case of crystalline maculopathy.313 In this regard, a comprehensive dietary approach 
to optimise carotenoid intake is preferable and would be a positive first step in 
maintaining eye health. 
4.5.2 Bioavailability, absorption and uptake of macular carotenoids 
Many factors can affect the bioavailability and absorption of carotenoids including; 1) 
food processing (raw, dehydrated, frozen, cooked); 2) meal composition; 3) activity 
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of digestive enzymes; and 4) the effective uptake of carotenoids by enterocytes.314 
Carotenoid metabolism begins in the stomach. The initial phase of 
digestion/absorption involves the extraction of carotenoids from the food matrix, 
followed by their incorporation into lipid droplets, and transfer to mixed 
micelles.315,316 The extent to which this happens depends on the quantity and nature of 
lipids present in the food bolus.314 Lipids increase the bioavailability of both free and 
esterified lutein,317 as they facilitate the extraction of carotenoids from the food matrix 
by providing a hydrophobic phase in which carotenoids can solubilise. Dietary 
triglycerides stimulate biliary secretion and consequently micelle production, 
therefore, can increase carotenoid availability for absorption (reviewed by 
Desmarchelier & Borel 314). Dietary fibre, on the other hand, can inhibit lutein and 
zeaxanthin absorption.318 It is also known that some micronutrients compete with 
carotenoids regarding their absorption. The presence of β-carotene can lead to 
competition for incorporation into mixed micelles and subsequent uptake by 
enterocytes.319  
 
Uptake and absorption of dietary carotenoids in the duodenum is by a facilitated 
process which utilises scavenger receptor class B member 1 (SR-B1),320 a cell surface 
glycoprotein and a member of CD-36 (cluster of differentiation 36) superfamily.321 
Once absorbed carotenoids follow the same route as other newly absorbed lipid 
molecules (e.g. fatty acids, cholesterol) and are incorporated with them in 
chylomicrons in the Golgi apparatus before secretion in the lymph (apolipoprotein B 
dependent route).314 As some carotenoids are also found in HDL and since the small 
intestine synthesises HDL, it is hypothesised that a fraction of carotenoids are also 
secreted into the lymph in HDL (apolipoprotein A dependent route).322  
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4.5.3 Plasma transport and effective uptake of carotenoids 
Carotenoids that reach the liver via chylomicrons are either stored there, eliminated in 
bile, or re-secreted into VLDL to be distributed to peripheral tissues.314 While 
carotenoids are detectable in all lipoprotein classes to varying degrees, most 
hydrophobic carotenoids such as lycopene and β-carotene are transported on LDL, 
whereas, the more hydrophilic xanthophyll carotenoids, such as lutein and zeaxanthin, 
are primarily carried by HDL.19,323,324 The Wisconsin hypo-alpha mutant (WHAM) 
chicken has very low levels of HDL due to a mutation in the ABCA1 transporter 
gene.18 When these chickens are fed a high-lutein diet, lutein levels increase in plasma, 
heart, and liver, but not in the retina, suggesting that HDL is critical for the delivery 
of carotenoids to retinal tissue.18  
 
Lipoprotein-bound xanthophylls, lutein, zeaxanthin and meso-zeaxanthin, accumulate 
in the macula. To reach the neural retina (Muller cells, receptor axons and retinal 
ganglion cells) carotenoids cross at the RPE. The RPE is similar to the blood-brain 
barrier for the retina in that it serves as a cellular and metabolic interface between the 
retina and the blood supply from the choroid.325 It has been suggested that lutein and 
zeaxanthin are preferentially take up by human RPE cells via an SR-B1 dependent 
mechanism.326 Differentiated ARPE-19 cells express lipoprotein receptors necessary 
for lipoprotein delivery (i.e. SR-B1, LDL receptor and CD-36).326 While xanthophylls 
are mostly associated with HDL in plasma, recent research suggests that zeaxanthin 
and meso-zeaxanthin are more efficiently delivered to ARPE-19 cells via HDL in an 
SR-B1-dependent process, whereas, lutein is more efficiently delivered via LDL and 
cell uptake is thought to involve the LDL receptor.327 It is possible that these 
mechanisms account for the selective accumulation of zeaxanthin and meso-
104 
 
zeaxanthin over lutein in the central macula.328  
 
Specificity and uptake of xanthophylls in specific regions of the retina may ultimately 
be driven by selective binding proteins such as glutathione S-transferase (GSTP1) for 
zeaxanthin and steroidogenic acute regulatory protein (a StARD family protein) for 
lutein.329 It is thought that tubulin may serve as a secondary high capacity deposition 
site for carotenoids within the Henle fibre layer.226, 329 Furthermore, a number of 
enzymes that metabolise ocular carotenoids have also been identified, including beta-
carotene 15,15′ oxygenase-1 (BCO1) which cleaves carotenes, an essential step for 
generation of vitamin A, and β-carotene 9′,10′ oxygenase-2 (BCO2) which cleaves 
carotenes and xanthophylls.330 The process by which carotenoids and their oxidation 
and degradation products are removed from the retina, however, is less clear. It is 
known that macular carotenoid levels are remarkably stable even in the face of large 
fluctuations in plasma levels that might occur with diet and/or supplementation. 
Moreover, non-human primates placed on carotenoid-deficient diets typically take 
several years to achieve non-detectable MP.331 Figure 4.6 provides a brief schematic 
to describe the current understanding of the whole process of uptake, transport, and 





Figure 4.6: Possible pathway for MP carotenoid uptake, transport, and accumulation 
in the human retina, (Adapted from Li et al, 329). 
Abbreviations: Choroicapillaris (CH); Bruch's membrane (BM); retinal pigment 
epithelium (RPE); inner segments (IS); outer plexiform layer (OPL); inner plexiform 
layer (IPL).  
4.6 Quantification of macular pigment in clinical practice 
The protective effect of MP, if any, can be investigated through the observation of MP 
levels. From the findings of epidemiological studies and AREDS2, there has been 
great interest in quantifying carotenoid status in the eye.5, 332 Macular pigment levels 
can be augmented with dietary modification,47 and/or nutritional supplementation,333 
therefore, in measuring MPOD on a wide-scale it may be possible to analyse the 
effects of MP augmentation on disease process and progression (i.e. the effects of MP 
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augmentation on diabetic retinopathy). It is extremely challenging, however, to 
measure MP in vivo and although several measurement modalities have been 
proposed, most techniques are only available in a research setting. In humans, 
measurement of MP in vivo is typically categorised into one of two groups: 
psychophysical (requiring a response from the subject) or objective (requiring minimal 
input from the subject), and will be discussed herein.  
4.6.1 Psychophysical techniques 
Psychophysical techniques include colour matching,9 heterochromatic flicker 
photometry (HFP),334 and customised-HFP (c-HFP).335 One of the more common 
methods of measuring MP is the HFP technique which is often used as a standard 
against which other techniques are validated.336, 337 The HFP method exploits the 
spectral absorption properties and retinal location of MP. The MPOD is determined 
by presenting a light stimulus of two alternating wavelengths, a green light (not 
absorbed by MP) and a blue light (maximally absorbed by MP) and the subject is 
required to make isoluminance matches.334 If the colours are alternated at an 
appropriate frequency and the luminance of the two colours are not perceived to be 
equal then the stimulus will appear as a flickering light.338 The radiance of the blue 
light is adjusted by the subject until the observed flicker is minimised.334 The 
procedure is performed centrally, typically at 0.50 retinal eccentricity (where MP 
peaks) and repeated at a parafoveal locus, typically 70 (where MP is optically 
undetectable).339 The log ratio of the amount of blue light absorbed centrally to that 
absorbed at a peripheral retinal locus (the reference point) gives a measure of the 
subject's MPOD. Customised-HFP enhances the HFP technique by optimising the 
flicker frequency for each individual.334, 335 The Macular Densitometer™ (a device 
which uses c-HFP) has been validated by comparing MP measurements to known 
107 
 
biochemical markers (i.e. plasma concentrations of MP's constituent carotenoids) and 
by comparing the data it generates with the in vitro spectral absorption curve of the 
macular carotenoids 339 (Figure 4.7). Importantly, HFP and c-HFP have demonstrated 
an ability to detect changes in MPOD following supplementation with MP's 
constituent carotenoids.333, 340 
 
 
Figure 4.7: Absorption spectra of lutein (red) and zeaxanthin (blue) in olive oil. A 
mixture of lutein plus zeaxanthin (dashed black line) closely approximates the 
absorption spectrum of the MP in the living human eye (Adapted from Bernstein et 
al,339). 
 
The HFP measurement relies on several assumptions; 1) the amount of yellowing in 
the media (e.g. the crystalline lens) would influence the measured MPOD value, 
however, the reference measure outside of the fovea cancels this effect.341 
108 
 
Consequently, varying degrees of crystalline lens absorption does not affect MP 
measurement and; 2) the peripheral reference locus (typically taken at 70 retinal 
eccentricity) has a negligible level of MP.339 An advantage of the HFP method is that 
pupil dilation is not necessary. A drawback of the technique, however, is that it 
requires significant patient training to produce meaningful results. Additionally, some 
protocols only take two measurements, centrally and peripherally, therefore, providing 
no information on the spatial distribution of MP. It is possible, however, to achieve a 
spatial profile of MPOD by altering the size and/or the eccentric position of the test 
stimulus. While the extra measurements increase the duration of the test, it produces 
a curve that can be used to describe the change in MPOD with increasing eccentricity 
from the central fovea 342 (Figure 4.8).  
 
Figure 4.8: Mean spatial profile of MPOD (Adapted from Nolan et al,342). 
109 
 
More recently researchers have tried to identify other image-based methods which are 
less technically demanding and can measure MPOD objectively. 
4.6.2 Image-based techniques 
Non-invasive methods for assessment of carotenoid status have evolved considerably 
over the past few decades. Fundus autofluorescence has gained a lot of interest as the 
technique is objective and provides high-resolution and quantitative spatial 
distributions of MP. It is rapid and, apart from good fixation on a target, requires 
minimal patient cooperation. Fundus autofluorescence exploits the fluorescent 
properties of lipofuscin present and the predictable attenuation of the fluorescence by 
MP.343 Lipofuscin is excited in vivo between 400 and 590 nm (peak excitation at 490-
510 nm) and emits autofluorescence at 520-800 nm (peak emission at 590-630 nm).344 
At the fovea, excitation light within the absorbance range of MP is partially absorbed 
by the carotenoids, resulting in an area of reduced fluorescence. The Heidelberg 
Spectralis use the two-wavelength autofluorescence technique to measure MP and 





Figure 4.9: Image of macular pigment measured by Heidelberg Spectralis (Left, 
excitation wavelength at 488 nm; Right, excitation wavelength at 514 nm) (Adapted 
from Bernstein et al,226). 
 
The Spectralis autofluorescence attenuation method is highly reproducible and 
provides a lot of spatial data.345 The instrument calculates the average MPOD, 
standard deviation (SD) and range of MPOD levels along a series of concentric one-
pixel width circles. The results are then plotted on a graph 00 to 150 with a red curve 
corresponding to the average MPOD at each eccentricity, a green curve corresponding 
to the SD of the average MPOD and a blue region corresponding to the high and low 
range of MPOD.343 A reference point is typically taken at 90 eccentricity where the 
MPOD is defined as zero. Two other analysis eccentricities routinely used are 0.50 and 






Figure 4.10: Macular pigment tracing from a healthy subject. (a) Macular pigment 
tracing at 0.50 (red), 20 (blue), and 90 (green) demarcated by the solid lines as 
indicated. (b) Macular pigment image showing the fovea and the degrees (0.50, red; 
20, blue; 90, green) from the centre of the macula lutea (Adapted from Conrady et al, 
343). 
A recent study, on subjects free of retinal disease, confirmed that measuring MP using 
autofluorescence imaging displays good concordance with c-HFP.337 Furthermore, 
MP volume under the curve 90 gave the strongest correlations with lutein, zeaxanthin, 
lutein and zeaxanthin, which demonstrates the importance of capturing all of the 
carotenoid content of the macula rather than focusing on the MPOD at just one or two 
eccentricities.343 Additional work, however, is needed to confirm its reliability across 
populations (e.g. patients with AMD and patients with diabetes). With the latest 
technology visually significant cataracts do not seem to suppress MP measurements 
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excessively especially when using MP under the curve 90.343 Some drawbacks to the 
method, however, is the need for specialised equipment which is expensive, its bright 
light levels and the need for pupil dilation. Current generation autofluorescence 
techniques based on ocular imaging systems, however, look promising and may be 
well-suited for busy clinical practice settings in the near future. 
4.6.2 Plasma analysis and dietary intake of carotenoids 
Systemic measures of carotenoids are also used as a surrogate for ocular 
concentrations of these phytonutrients. Methods include HPLC analysis of plasma and 
dietary assessment. Plasma HPLC analysis of carotenoids have correlated well with 
assessment of ocular carotenoid status,346-348 and are a good way of identifying patients 
who are adequately absorbing these phytonutrients. Plasma measurements, however, 
involve invasive blood draws and time-consuming analysis and are only available in 
a research setting. 
 
Dietary assessment tools have also been used to assess carotenoid intake. Methods 
include food frequency questionnaires [FFQs], food diaries and 24-hour recalls. 
Owing to their relatively lower administrative costs and their ability to assess usual 
and longer-term intake, FFQs have historically been the method of choice for 
epidemiological studies.349 Assessment of carotenoid intake in this way, however, has 
limitations. A common one is the overestimation of dietary intake as FFQs are greatly 
influenced by the accuracy of the portion size reported by the subject. Estimates 
obtained are also dependent on the use of accurate nutrient data sources. An issue with 
FFQs is that they may not always reflect food eaten by the population being examined. 
For example, FFQs developed for assessing lutein and zeaxanthin intake designed for 
an American population,350 may not be valid for estimating these carotenoids in, for 
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example, an Irish population. Additionally, as lutein and zeaxanthin concentration in 
food varies with time and geographical origin, carotenoid databases used to analyse 
dietary intake need to be up to date and developed using foods from the country of 
origin of the population being studied. An accurate assessment is also difficult given 
that current databases generally report lutein and zeaxanthin as a combined value. 
When carotenoids are considered together it makes it even more difficult to determine 
their respective roles in eye health.351 
 
A promising development in recent times is the ‘lutein/zeaxanthin screener’. This new 
tool estimates carotenoid intake and offers advantages over other dietary assessment 
tools in that it is easy to use, quick, and cost-effective. Intake of lutein and zeaxanthin 
can be calculated (although reported as a combined value) as crude estimates (i.e. 
lutein/zeaxanthin score) based on dietary intake and relative bioavailability of four 
common xanthophyll containing food groups (eggs, broccoli, maize, and dark leafy 
vegetables).352 The range of scores on the “lutein/zeaxanthin screener” is 0-75 and 
intake is categorised into low, medium and high. Dietary estimates of lutein and 
zeaxanthin combined have been shown to be positively and significantly correlated 
with plasma concentrations of these carotenoids (r=0.329,p<0.001), and this 
relationship remained after controlling for other variables such as age and body mass 
index (BMI).352  
4.7 The need for alternative biomarkers 
Despite some attempts, there is still no commercially available instrument that can 
successfully measure MPOD in vivo in clinical practice.336 While the 
‘’lutein/zeaxanthin screener’ looks promising dietary intake assessed using FFQs is 
self-reported and only crudely quantified and as a result is subject to both bias and 
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error. In addition to, plasma analysis of carotenoids involves complex analysis. 
Consequently, there is merit in examining the predictive capacity of a range of more 
commonly measured proxy biomarkers; i.e. [clinical (blood pressure), plasma 
(lipoproteins, inflammatory markers) and anthropometric (abdominal fat)], which 
might be used to identify patients at risk of low MP. The capacity of more commonly-
measured surrogate biomarkers to help identify people at risk of low MP (i.e. patients 














































5. MACULAR PIGMENT IS LOWER IN TYPE 2 DIABETES COMPARED 
WITH TYPE 1 DIABETES AND NORMAL CONTROLS. 
5.1 Abstract 
Purpose 
This cross-sectional study was designed to investigate the optical density of MP in 
Type 1 and Type 2 diabetes subjects relative to normal controls. 
Methods 
One hundred and fifty subjects were recruited to the study and divided into 
one of the three study groups based on their health status, as follows: Group 1: 
Healthy controls; Group 2: Type 1 diabetes; Group 3: Type 2 diabetes. Macular 
pigment optical density at 0.5° of retinal eccentricity was measured using c-HFP. 
Dietary intake of macular carotenoids was quantified using a lutein and zeaxanthin 
FFQ. Diabetes type, duration, medication, smoking habits, HbA1c, and plasma lipid 
levels were recorded, whereas VA, BMI, and diabetic retinopathy grade were 
measured for each participant. 
Results 
One-way analysis of variance revealed a statistically significant difference in 
BMI, age, HDL cholesterol and HbA1c between the three groups (p<0.01 for all). Chi-
square analysis revealed a statistically significant difference in diabetic retinopathy 
distribution (p<0.01). None of these variables exhibited a statistically significant 
correlation with MPOD for any study group (p>0.05 for all). There was no difference 
in dietary carotenoid intake between groups. Macular pigment optical density was 
lower among Type 2 diabetes subjects (0.33 ± 0.21) compared with Type 1 diabetes 
(0.49 ± 0.23) and normal controls (0.48 ± 0.35). General linear model analysis, 
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including age, BMI, diabetes duration, diabetic retinopathy status, HDL, and HbA1c 
as covariates, revealed a statistically significant effect of diabetes type on MPOD (F = 
2.62; p=0.04). 
Conclusion 
Macular pigment optical density was statistically significantly lower in Type 2 
diabetes compared with Type 1 diabetes and normal controls. Although BMI was 
higher in the Type 2 diabetes group, the lower MPOD levels observed among Type 2 
diabetes seem not to be attributable to differences in the dietary carotenoid intake or 


















Neurodegenerative diseases of the retina such as AMD and diabetic retinopathy are 
leading causes of worldwide blindness.353 Although the relationship between AMD 
and MPOD has been widely reported,221, 339 only a small number of studies have 
focused on MPOD and carotenoid intake in diabetes mellitus,6, 15 a condition similarly 
known to cause oxidative damage in the retina.354 
 
Diabetes, a lifelong progressive disease, is the result of the body’s inability to produce 
insulin or use insulin to its full potential and is characterised by high circulating 
glucose.355 Diabetic retinopathy represents the most common diabetic eye disease, and 
there is strong evidence that oxidative stress plays an important role in its 
development.354, 355 Chronic hyperglycaemia causes oxidative stress,355 which results 
in microvascular complications at the retina, where the neuronal elements responsible 
for vision are located. The relationship between hyperglycaemia, changes in redox 
homeostasis, and oxidative stress are key events in the pathogenesis of diabetic 
retinopathy.355 Oxidative stress is also involved in the initiation and progression of 
obesity and diabetes mellitus.356 The links between Type 2 diabetes and obesity are 
firmly established.357 Type 2 diabetes now also affects a much younger population 
because of sedentary lifestyles and increases in calorific intake and accounts for more 
than 90% of all cases of diabetes.358 The development of ocular complications in 
diabetes is related to disease control and longevity.11, 359, 360 After 20 years with 
diabetes, 75% of patients will have some form of diabetic retinopathy.360 Apart from 
good systemic control of blood sugar levels, hypertension, lipid profiles, and renal 
function, current treatment modalities for diabetic retinopathy are limited to laser 
photocoagulation 11 and/or intravitreal injections.12 These are effective modes of 
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treatment but they also have their limitations and side effects. New modalities should, 
therefore, be preventative in nature and ideally implemented long before overt clinical 
symptoms develop. Macular pigment is believed to possess antioxidant properties and 
to limit retinal oxidative damage by absorbing harmful short-wavelength blue light.3 
Macular pigment is highly concentrated at the central macula and is composed of the 
dietary hydroxyl-carotenoids lutein, zeaxanthin, and meso-zeaxanthin.46 These 
hydroxyl carotenoids are found in the retina to the exclusion of all other 700 
carotenoids found in nature.312 Concentrations of carotenoids in human plasma and 
deposition of the macular carotenoids in the retina to form MP are highly variable and 
reflect not only dietary intake but also factors such as carotenoid chemistry,361 
individual efficacy of absorption,70 fat intake,16 competition among carotenoids for 
absorption,17 cholesterol and lipoprotein status,18, 71 metabolic status,6 body 
composition, and BMI.17, 54 The relationship between MP and diabetes is only now 
attracting research interest, possibly as a result of the outcomes of clinical trials, which 
demonstrate a protective effect of lutein and zeaxanthin supplementation in another 
oxidative stress-related condition, AMD.221, 339 One experimental study on diabetic 
rats demonstrated a reduction in retinal oxidative damage after carotenoid 
supplementation.14 Lutein and zeaxanthin intake has also been shown to improve 
macular oedema in diabetic retinopathy patients.15 These results suggest that MP 
supplementation has the potential to inhibit or delay the development of macular 
disease in patients with diabetes.  
 
This study was designed to investigate the cross-sectional relationship, if any, between 
diabetes and central MPOD and to explore the influence of potential explanatory 
factors, including HbA1c, plasma lipid levels, BMI, and dietary carotenoid intake on 
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any relationship that might be observed. 
5.3 Materials and Methods 
Subjects 
Diabetic participants and normal control subjects were recruited for this cross-
sectional, case-control study at the Mater Misericordiae University Hospital in Dublin, 
Ireland. The study was approved by the Institutional Research Ethics Committee and 
adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained 
from all subjects before enrolment and examination. Generic inclusion criteria were 
as follows: subjects were to be older than 18 years, not having taken dietary 
supplements containing lutein, zeaxanthin or meso-zeaxanthin over the 6-month 
period before the study, and logMAR VA better than 0.2 (6/9) in the study eye. For 
normal (control) subjects, exclusion criteria included any sign of retinal or ocular 
abnormality and the presence of Type 1 or Type 2 diabetes. Patients with diabetes 
were excluded if they exhibited signs of ocular comorbidity (e.g. glaucoma, cataract, 
AMD), had previously undergone any form of treatment for diabetic retinopathy or 
maculopathy, or if they exhibited any signs of proliferative retinopathy or 
maculopathy. The study eye was selected using the eye with better VA, or, in cases of 
equal acuity, the right eye was selected as standard. Subjects were assigned into one 
of three study groups based on their ocular health status and diabetes type as follows: 
Group 1: Non-diabetic controls; Group 2: Type 1 diabetes; Group 3: Type 2 diabetes.  
Demographic and lifestyle information 
Demographic information, including age, gender, race, history of smoking (current 
smoker, ex-smoker, and never smoked) and duration of smoking in years was collected 
in relation to each subject.  
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Diabetes classification and diabetic retinopathy grading 
The following diabetes-related information was recorded for each diabetes participant: 
diabetes duration, diabetes type, and diabetic retinopathy grade. Subjects were 
classified based on their ocular health status and diabetes type as non-diabetic controls, 
Type 1 diabetes, and Type 2 diabetes. The duration of disease was recorded in years. 
Diabetic retinopathy was graded according to modified 2-field early treatment diabetic 
retinopathy study (EDTRS) protocol-grade range R0 M0 to R2 M0 by consultant 
ophthalmic surgeon, Mr Paul Connell, Mater Private Hospital. Medications for 
diabetes including insulin and oral hypoglycaemics were noted. Glycated 
haemoglobin (%) was also recorded. 
Anthropometric measurement 
Anthropometric measurements including weight and height were obtained using 
standardised techniques. Body weight was measured to the nearest 0.2 kg using a Seca 
Compact Digital Floor Scale 111, model 888 (Seca Limited), whereas, height was 
measured to the nearest 0.5 cm using a collapsible “Leicester Height Measure” 
stadiometer (CMS Weighing Equipment). Body mass index was given as weight (in 
kilograms)/height (in square metres, (kg/m2)).  
Plasma analysis 
Plasma blood levels including total cholesterol (TC) in millimoles per litre (mmol/L), 
LDL (mmol/L), HDL (mmol/L), TGs (mmol/L) and HbA1c (%) were recorded for 
each subject. 
Lutein and zeaxanthin intake. 
Dietary carotenoid intake was estimated using the lutein/zeaxanthin questionnaire 
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(Carotenoid & Health Laboratory, Jean Mayer USDA Human Nutrition Centre on 
Aging, Tufts University, USA).350 Lutein, zeaxanthin and total lutein and zeaxanthin 
in micrograms (mg) per day were quantified. 
Macular pigment optical density measurement  
Macular pigment absorbs blue light and is optically undetectable at 6° to 8° 
eccentricity.44 In this study, MPOD was determined using the Macular Metrics 
Clinical Densitometer (Macular Metrics, Rehoboth, MA), which is based on the 
principle of HFP.334 The basic measurement procedure involves presenting a small test 
stimulus that alternates between a measuring wavelength (458 nm), which is absorbed 
by MP and a reference wavelength (540 nm) not absorbed by the pigment. The subject 
adjusts the intensity of the measuring wavelength (458 nm) luminance until there is 
minimum flicker (matching luminance). The luminance of the reference wavelength 
(540 nm) remains constant. The ratio of the amount of measuring wavelength (458 
nm) light required to achieve the endpoint of matching luminance, or minimum flicker, 
for foveal and parafoveal readings is a measure of the amount of pigment present, and 
the logarithm of this ratio represents the optical density of MP. Before using the 
densitometer, all subjects were shown an explanatory video describing the method for 
recording null flicker matches. The measurement was conducted by a single examiner 
who was highly skilled and experienced with the technique. All subjects were naive 
to the HFP test. The MPOD measurement comprised the average of six readings 
(computed as the radiance value at which the subject reported null flicker) taken 
centrally at 0.5° retinal eccentricity and again at 7° retinal eccentricity. The target used 
for measuring MPOD at 0.5° eccentricity was a solid disc of 0.5° arc radius, and the 
parafoveal measurement was taken by asking the subject to fixate on a red light located 
precisely at 7° from central fixation. Measurements were deemed reliable and 
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acceptable only when the SD of null flicker responses was below 0.1. A c-HFP 
procedure was adopted, whereby flicker frequency was optimised for each participant 
before the measurement of MPOD. The starting flicker was set at 10 Hz to 11 Hz. If 
the subject was unable to find no/minimum flicker, this frequency was increased until 
no/minimal flicker could be identified. If the null one was too wide, the flicker 
frequency was reduced. The flicker frequency was adjusted until the subject found a 
narrow null zone.  
Statistical analysis  
The statistical software package SPSS for Microsoft Windows (v.21.0; IBM Corp., 
Armonk, NY) was used for analysis. Data are presented as mean ± standard deviation 
throughout. The data were tested for normality using the Kolmogorov–Smirnov test. 
One-way analysis of variance (ANOVA) was used to test for differences in normally 
distributed study parameters between groups, whereas the Kruskal–Wallis test was 
used to test for differences in group medians in non-normally distributed data. The 
Chi-square test was used to compare categorical data across the three study groups. 
Pearson’s product-moment correlation tests were performed to assess the relationship 
between MPOD and other study variables where appropriate. A general linear model 
approach was used to explore the relationship between diabetes type, other potential 
explanatory variables, and the dependent variable, MPOD. The level of statistical 
significance was set at the standard p<0.05. 
5.4 Results 
One hundred and fifty subjects were recruited to the study and divided into 1 of the 3 
study groups on the basis of their ocular health status and diabetes type, as follows: 
Group 1: Non-diabetic controls (n = 48; male = 20, female = 28); Group 2: Type 1 
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diabetes (n = 34; male = 17, female = 17); Group 3: Type 2 diabetes (n = 68; male = 
43, female = 25). Kolmogorov–Smirnov analysis revealed that BMI, TC, lutein intake, 
zeaxanthin intake, and MPOD data were normally distributed (p>0.05 for each), 
whereas all remaining variables exhibited non-normal distributions. Accordingly, 
parametric tests were applied, where relevant, to normally distributed data, and 
nonparametric equivalent tests to non-normally distributed data. A comparison of the 
demographic and clinical characteristics of each group is presented in Table 5.1.
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          Table 5.1: Demographic and clinical findings according to classification group. 
Variable Non-diabetic controls Type 1 Diabetes 
 
Type 2 Diabetes p value 
Sex Male = 20; Female =28 Male = 17; Female = 17 Male = 43; Female = 25 <0.07* 
Age (years) 52.48 ± 16.03 43.67 ± 12.98 62.67 ± 11.31 <0.01† 
BMI (kg/m2) 27.7 ± 4.8 27.33 ± 4.77 31.44 ± 6.16 <0.01‡ 
Smoking duration (years) 2.13 ± 0.62 2.35 ± 0.60 2.25 ± 0.65 0.33† 
Diabetes mellitus duration 
(years) 
- 22.73 ± 10.85 9.54 ± 7.33 <0.01† 
HbA1c (%) - 7.9 ± 1.08 6.88 ± 1.09 <0.01† 
TG (mmol/L) - 1.37 ± 2.06 1.55 ± 0.85 0.55† 
HDL (mmol/L) - 1.52 ± 0.46 1.14 ± 0.28 <0.01† 
LDL (mmol/L) - 2.37 ± 0.70 2.20 ± 0.74 0.15† 
TC (mmol/L) - 4.31 ± 0.82 4.03 ± 0.89 0.14‡ 
MPOD (SD) 0.48 ± 0.35 0.49 ± 0.23 0.33 ± 0.21 <0.01‡ 
Lutein Intake (mg/day) 0.95 ± 0.21 1.06 ± 1.29 0.95 ± 1.73 0.93‡ 
Zeaxanthin Intake (mg/day) 0.11 ± 0.12 0.16 ± 0.26 0.12 ± 0.25 0.54‡ 
Total Lutein & Zeaxanthin 
Intake, (mg/day) 
1.07 ± 1.25 1.23 ± 1.34 1.07 ± 1.83 0.88‡ 
Non-Proliferative  
Diabetic Retinopathy 
- Yes = 23 (68%) 
No = 11 (32%) 
Yes = 24 (35%) 




* Chi-square test † Kruskal-Wallis test ‡ One-way Analysis of Variance. 
Abbreviations: ANOVA, one way analysis of variance; BMI, body mass index; kg/m2, kilogrammes per metre squared; HbA1c, glycated haemoglobin level; HDL, 
high density lipoprotein; LDL, low density lipoprotein; mg/day; microgrammes per day;  mmol/L, millimoles per litre; TC, total cholesterol; TG, triglycerides.  
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Post hoc analysis (Tukey test) revealed that MPOD was statistically significantly 
lower in Type 2 diabetes compared with both normal controls (p=0.02) and Type 1 
diabetes (p=0.03), whereas the difference in MPOD between Type 1 diabetes and 
normal controls was not statistically significant (p=0.99). The distribution of MPOD 
for each of the study groups is presented in Figure 5.1  
 
 
Figure 5.1: MPOD distribution (mean ± 95% confidence intervals) according to 
diabetes status, illustrating the substantially lower MPOD levels among Type 2 
diabetes subjects. 
 
A general linear model analysis confirmed a significant effect of diabetes type on the 
dependent variable, MPOD (p=0.04), but no effect of potentially confounding 
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variables including age, BMI, diabetic retinopathy status, HDL cholesterol, or HbA1c 
on MPOD (p=0.16 – 0.74). While there was a significant difference in age between 
the three groups; Type 1 (mean age = 43.67±12.98); Type 2 (mean age = 62.67±11.31) 
and non-diabetic controls (mean age = 52.48±16.03) (p<0.01); age was controlled for 
in the general linear model and had no effect on MPOD (p=0.128). In addition, age, 
including controlling for confounding, was not significantly correlated with MPOD 
(r=-0.175; p=0.138). The distribution of MPOD according to diabetic retinopathy 
status, which demonstrated no influence on MPOD in the general linear model analysis 
(p=0.45), is presented in Figure 5.2.  
 
Figure 5.2: The distribution of MPOD (mean ± 95% confidence intervals) according 
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to diabetic retinopathy status, illustrating the significant overlap between groups. 
 
Body mass index was statistically significantly higher in Type 2 diabetes compared 
with normal controls (p<0.01) and Type 1 diabetes (p<0.01), whereas the difference 
in BMI between Type 1 diabetes and normal controls was not statistically significant 
(p=0.75). Body mass index, however, including controlling for confounding was not 
statistically significantly correlated with MPOD (r=0.08, p=0.51). The distribution of 
BMI for each of the study groups is presented in Figure 5.3. 
 
 
Figure 5.3: Body mass index distribution (mean ± 95% confidence intervals) 
according to diabetes status, illustrating substantially higher BMI levels among Type 




This study demonstrates that MPOD levels are significantly lower in Type 2 diabetes 
when compared with Type 1 diabetes, which represents an entirely novel finding. This 
observation is significant given that similar dietary carotenoid intake was observed 
among the study groups and in the context of shorter diabetes duration among the Type 
2 diabetes subjects. Similarly, the presence of non-proliferative diabetic retinopathy 
seems not to influence MPOD levels, which are, surprisingly, slightly higher on 
average in those with retinopathy compared with those without retinopathy, although 
lower in both diabetic groups compared with normal controls. The study further 
demonstrates that the MPOD levels in Type 2 diabetes are significantly lower than in 
normal controls, a finding, which is in general agreement with those of previous 
investigations that have explored the relationship between MPOD and diabetes. It has 
been shown, for example, that Type 2 diabetes subjects had lower MPOD when 
compared with non-diabetic controls, while Type 2 diabetes with mild non-
proliferative retinopathy exhibited similar MPOD levels to Type 2 diabetes without 
retinopathy.6 In addition, plasma lutein and zeaxanthin concentrations, which have 
been shown to be positively and significantly related to MPOD in normal subjects,49 
have been shown to be significantly lower in diabetes compared with normal 
subjects.15 In more advanced cases of diabetic eye disease, subjects with Grade 2 
maculopathy were found to have significantly lower MPOD than those without 
maculopathy.9 The apparent relationship between low MP levels and increasing 
severity of maculopathy prompted those study investigators to implicate oxidative 




Macular pigment optical density has a slow biological turnover, as it reflects the local 
balance between pro-oxidant stresses and antioxidant defences in the retina.49 The 
retina is particularly susceptible to oxidative stress because of its high oxygen 
consumption, the high proportion of PUFAs, and exposure to visible and short-
wavelength blue light.291 There is also considerable evidence that hyperglycaemia 
results in the generation of ROS, ultimately leading to increased oxidative stress in the 
retina,354, 355 which may play an important role in the aetiology of diabetic 
complications. Poor metabolic control and longer duration of diabetes are directly 
linked to the prevalence of diabetic retinopathy,359 whereas oxidative stress can be 
significantly reduced with aggressive control of hyperglycaemia.362 We found no 
association, however, between MPOD and either HbA1c or diabetes duration in this 
study. Paradoxically, despite their lower MPOD, metabolic control appeared better, 
diabetes duration was shorter, and diabetic retinopathy prevalence was lower for Type 
2 compared with Type 1 diabetes subjects. Although HbA1c has previously been 
shown to be inversely and significantly related to MPOD among a smaller sample of 
Type 2 diabetes subjects,6 our findings imply that lower MPOD in Type 2 diabetes is 
not attributable to the diabetic condition, duration, or level of control, and suggests a 
need to explore alternative explanatory causes. Furthermore, while there was a 
significant difference in age between the three groups (p<0.01), and some studies have 
demonstrated a decline in MPOD with age, 49, 55, 56 although not all 57, 58 age was not a 
predictor of MPOD on general linear model analysis. Also, we found no correlation 
between MPOD and age, while controlling for all other variables. 
 
Although BMI measures do not provide a precise indicator of adiposity, it is likely 
that the statistically significantly higher BMI levels observed in the Type 2 diabetes 
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group here, which averaged above World Health Organisation (WHO) defined BMI 
levels indicative of obesity (BMI>30),363 are reflective of excess adiposity in this 
group compared with the normal control and Type 1 diabetes groups. To date, there 
has been very little consensus on the relationship between types of obesity and MPOD. 
One study reported a lack of an association between MPOD and various obesity 
indices, including WC, WHpR, and BMI, in a South-Indian population.364 Conversely, 
other studies have shown significant inverse relationships between body fat and 
MPOD in humans,16, 17, 54 however, these relationships differed between men 16 and 
women.17 Lutein and zeaxanthin are known to accumulate in adipose tissue,257 and 
lower MPOD values have also been reported among individuals exhibiting body fat 
measuring greater than 27% when compared with those with lower body fat.54 Higher 
body fat percentage even within relatively healthy limits is associated with lower 
tissue lutein and zeaxanthin status 53 and renders the macular carotenoids less available 
to retinal tissue.68 Distribution of body fat in the body is also important, and it has been 
shown that lutein/zeaxanthin concentrations in adipose tissue differ according to body 
site, with levels demonstrably higher in abdominal fat than in the gluteofemoral fat 
depot.67 Interestingly, abdominal obesity is now considered an important risk factor 
and predictive indicator for the development of Type 2 diabetes and cardiovascular 
disease.365 Waist-to-height ratio has more recently been shown to have superior 
discriminatory power for detecting cardiovascular risk factors in both sexes 366 and 
should be considered as a screening tool for diabetes, hypertension, and cardiovascular 
disease in men and women.366 Future studies investigating the link between MPOD 
and obesity should, therefore, encompass more refined methods of body fat assessment 
including bioelectrical impedance analysis and WHtR,366 because BMI measurements 
alone may not be adequate to provide a true indication of adiposity, and this could 
133 
 
explain the lack of an association between MPOD and BMI in our study. Diets, which 
are high in fat and low in carotenoids, have been linked with increased oxidative 
stress.367 Obesity is also independently associated with increased oxidative stress 69, 
367, 368 and an increased BMI has also been shown to be associated with increased risk 
of DNA damage due to oxidative stress.369 Plasma 8-OHdG, for example, a known 
sensitive marker of oxidative DNA damage and total systemic oxidative stress in vivo, 
has been shown to be positively correlated with BMI in people with Type 2 diabetes 
mellitus.370 Adipose tissue produces bioactive substances called adipokines, which 
induce the production of ROS by a combination of mechanisms including 
mitochondrial and peroxisomal oxidation of fatty acids and overconsumption of 
oxygen,69, 368 thereby, initiate a process of oxidative stress.69, 368 Recent studies have 
highlighted the role of increased abdominal fat mass as a key driver of inflammation 
in Type 2 diabetes,371 a state closely associated with increased oxidative stress,69, 368 
and macrovascular disease.371 Chronic inflammation induces changes in metabolic 
pathways and is believed to play a significant role in the progression from obesity to 
Type 2 diabetes.372, 373 Despite the lack of any direct association between BMI and 
MPOD observed herein, it is plausible to suggest that; 1) more refined methods of 
body fat assessment such as bioelectrical impedance analysis 374 and WHtR 366 might 
reveal an association that could explain the lower MPOD values observed in Type 2 
diabetes subjects here and; 2) that the combined effect of increased competition for 
lutein/zeaxanthin deposition and increased inflammation and oxidative stress levels in 
association with higher BMI/body fat might explain, at least in part, the lower MPOD 
levels observed in the Type 2 diabetes group. There is no significant difference in 
MPOD between patients with or without retinopathy indicating that retinopathy status 
seems not to be the main driver in influencing MP levels. 
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High-density lipoprotein differences observed between Type 1 and Type 2 diabetes 
could also contribute to the lower MP levels observed in the Type 2 diabetes group. 
Macular pigment carotenoids are primarily transported by HDL in plasma.18, 71 It has 
been suggested that mechanisms governing the retinal capture and/or stabilisation of 
these carotenoids in the retina may be subject to HDL influence, by affecting receptor-
mediated uptake of these carotenoids from plasma.71 High-density lipoprotein 
deficiencies are associated with lutein and zeaxanthin tissue deficiencies, most notably 
in the retina.18 Furthermore, it has been suggested that individuals exhibiting elevated 
plasma TG concentrations and concurrently reduced plasma HDL concentrations may 
have a related and reduced capacity to transport lutein in plasma.71 Such features are 
very characteristic of Type 2 but not Type 1 diabetes.375 Lipoprotein profile is 
adversely affected by insulin resistance and might mechanistically explain (by 
eliciting a reduced capacity to transport macular carotenoids), why Type 2 diabetes is 
associated with lower MP levels compared with Type 1 diabetes where insulin 
resistance is much less prominent. A more comprehensive investigation into the 
association between lipoprotein profile, MPOD, and dietary carotenoid intake among 
diabetes subjects is therefore warranted. Average macular carotenoid intake was 
similar for the three study groups (p=0.88) and at levels that are consistent with the 
lower limits of average daily carotenoid intake, (ranges from 1.1 to 1.6 mg/day).49 
Although dietary intake is the primary driver of tissue carotenoid levels,3 the 
relationship between diet and deposition of these pigments in the retina is moderated 
by a number of factors. Retinal capture and/or stabilisation of these carotenoids in the 
macula, may, for example, be subject to influence by obesity-induced inflammation 
and oxidative stress,372, 373 competition between adipose and retinal tissue for the 
dietary carotenoids,17, 53, 54 impaired transport of circulating lutein/zeaxanthin,18, 71 
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and/or genetic influence,224 which may help to explain the significant effect of Type 2 
diabetes on MPOD. 
5.6 Limitations 
Limitations to this cross-sectional case-control study include the use of a dietary 
questionnaire designed for an American population among European participants, lack 
of plasma carotenoid analysis, lack of detailed body fat analysis, and the absence of 
other clinical parameters such as inflammatory markers. Further research is needed in 
the diabetic population to uncover the relationship between disease progression, BMI 
including WHtR, body fat composition, plasma cholesterol, inflammatory status, and 
dietary carotenoid intake, as well as the mechanism of retinal damage in the presence 
of low MPOD.  
5.7 Conclusion 
The effects of the adiposity, insulin resistance, inflammation, and HDL suppression, 
characteristics that differentiate Type 2 from Type 1 diabetes, on MPOD should be 
particularly emphasised. A longitudinal study, comparing MPOD in Type 1 and Type 
2 diabetes with parameters such as lipoprotein profile (including LDL, HDL, and 
TGs),18, 71 obesity indices (including WHtR, bioelectrical impedance analysis, BMI, 
WC, and waist-to-hip ratio (WHpR) measurements),366 and dietary intake of lutein and 
zeaxanthin, 350 would certainly provide a more holistic understanding of the 
relationship between MPOD and BMI in Type 2 diabetes patients over time. Certain 
features such as obesity,356 low HDL, and raised TGs are characteristic of Type 2 but 
not Type 1 diabetes,375 and these characteristics may indeed affect the transport, 
uptake, and stabilisation of these carotenoids in the retina and would, therefore, 
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6. A REVIEW OF THE PUTATIVE CAUSAL MECHANISMS 
ASSOCIATED WITH LOWER MACULAR PIGMENT IN 
DIABETES MELLITUS.  
6.1 Abstract 
Purpose 
Macular Pigment confers potent antioxidant and anti-inflammatory effects at the 
macula, and may therefore, protect retinal tissue from the oxidative stress and 
inflammation associated with ocular disease and aging. There is a body of evidence 
implicating oxidative damage and inflammation as underlying pathological processes 
in diabetic retinopathy, a major cause of vision impairment and blindness. Macular 
pigment has therefore become a focus of research in diabetes. This review explores 
the currently available evidence pertaining to MP levels in diabetes, and illuminates 
the potential metabolic perturbations implicated in MP depletion in diabetic eye 
disease. 
Methods 
This review was carried out in two stages. Firstly we identified all relevant published 
articles from human and animal studies which reported on the relationship between 
MP (lutein and/or zeaxanthin and/or meso-zeaxanthin) and diabetes (Type 1 & Type 
2), up until the year 2019. The second part of the search involved identifying 
publications which investigated the relationship between the metabolic perturbations 
typically associated with diabetes, and Type 2 diabetes in particular (e.g. 
adiposity/dyslipidaemia) and MP. PubMed, Google Scholar, Mendeley, Scopus, 
138 
 
Cochrane Library and the ISRCTN registry were used to search for literature of 
relevance to MP and diabetes. Relevant citations in the literature located through our 
search were also appraised. 
Results 
Metabolic co-morbidities commonly associated with Type 2 diabetes such as 
overweight/obesity, dyslipidaemia, hyperglycaemia and insulin resistance, may have 
added and independent relationships with MP. Increased adiposity and dyslipidaemia 
may adversely affect MP by compromising the availability, transport, and assimilation 
of these dietary carotenoids in the retina. Furthermore, carotenoid intake may be 
compromised by the dietary deficiencies characteristic of Type 2 diabetes, thereby, 
further compromising redox homeostasis. 
Conclusion 
Candidate causal mechanisms to explain the lower MP levels reported in diabetes 
include increased oxidative stress, inflammation, hyperglycaemia, insulin resistance, 
overweight/obesity and dyslipidaemia; factors, which may negatively affect redox 
status, and the availability, transport and stabilisation of carotenoids in the retina. 









The macula is an oval shaped area at the centre of the retina which consists of a dense 
collection of light-sensitive cone cells responsible for central, high-resolution vision 
and colour perception.376 At the centre of the macula lies the fovea, where MP is 
located. Macular pigment is comprised of three carotenoids; lutein, zeaxanthin and the 
retinal metabolite of lutein, meso-zeaxanthin.46,226 Lutein and zeaxanthin are not 
synthesised de novo in humans but are exclusively of dietary origin, typically derived 
from a diet rich in coloured fruit and vegetables,22 while meso-zeaxanthin can be 
generated by conversion from retinal lutein, 219 or may be obtained from dietary 
sources such as trout and salmon.220 The highest concentration of MP is found in the 
receptor axon layer of the foveola, while in the parafovea, MP is located in the inner 
plexiform layers,44,43 an area of the retina which is primed for the generation of ROS 
and consequently, oxidative damage.291 These hydroxyl-carotenoids are selectively 
located in the macula to the exclusion of all other dietary carotenoids. Figure 6.1 
highlights the location of MP and the macula within the eye. 
 
 
Figure 6.1: Diagram highlighting the location of MP and the macula within the eye. 
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Macular pigment has a number of important functions in the eye. Evidence suggests 
that MP contributes to visual performance and/or experience, as it acts as an optical 
filter for blue light (peak absorption ≈ 460 nanometres).226, 2 The importance of MP’s 
antioxidant and anti-inflammatory properties is supported by its capacity to protect 
against the cumulative damaging effects of oxidative stress,291 and inflammation,283 
which affect the macula in conditions such as AMD.5, 218, 259, 377 In light of this 
evidence, the relatively recent emphasis on MP as a possible ocular-protectant in 
diabetes,6 a pathological condition similarly associated with inflammation, oxidative 
stress and progressive retinal damage; is logical and represents a natural extension of 
previous work in AMD.5, 218, 259, 377 
 
The underlying molecular mechanisms associated with the onset of diabetes and the 
potential protective effects of lutein and/or zeaxanthin against retinal oxidative 
damage, inflammation and visual function have been explored in diabetic murine 
models.14, 20, 186, 215, 378-380 The onset of diabetes in alloxan and STZ diabetic mice and 
rats was accompanied by an increase in markers of oxidative stress and inflammation 
including: malondialdehyde (MDA), 8-hydroxyguanosine (8-OHdG), NF-𝜅B and 
VEGF, with a concomitant decrease in local antioxidants including GSH, and GPx.14, 
186, 215 Importantly, treatment with antioxidants (lutein and/or zeaxanthin) have been 
shown to lower oxidative stress and inflammation and increase endogenous 
antioxidants; findings which in some186, 215 but not all 20 studies occurred 
independently of any effects on hyperglycaemia. The beneficial effects of these 
carotenoids on retinal function have also been observed in diabetic murine models, 
and these include the preservation of ERG b-wave amplitude and prevention of 
neurodegenerative effects on the inner retinal layers.14, 186, 215  Findings from these 
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studies provide important insights into the potential role that MP may have in 
protecting against diabetic retinal disease, however, the observed findings need to be 
interpreted with caution, as higher MP dosages have been used in animal studies 
compared with those used clinically in humans, and many of these studies have never 
conclusively demonstrated retinal uptake of the administered carotenoids beyond the 
RPE and choroid.381, 382 A summary of the experimental animal studies examining 
MPOD in diabetes is outlined in Table 6.1. 
 
A number of cross-sectional studies,6, 7, 9, 383, 384 including findings from our own study 
group,7 and RCTs,15, 21 have explored the relationship between Type 1 and Type 2 
diabetes and MPOD in humans. The MPOD is generally found to be lower in diabetes 
6, 7, 9 with some studies suggesting that oxidative stress is implicated in its depletion.6, 
9 Lower levels of MPOD have also been associated with raised HbA1c levels and the 
presence of retinopathy in patients with Type 2 diabetes.6 In another study, patients 
with diabetes (Type 1 & 2) with grade 2 diabetic maculopathy, had significantly lower 
MPOD compared to those with no maculopathy (p=0.016).9 
 
Although oxidative stress is implicated as a causative factor, the exact reasons why 
MP is lower in diabetes, and Type 2 diabetes in particular 6, 7 are not fully understood. 
One study found lower levels of MP in Type 2 versus Type 1 diabetes,7 suggesting 
that other coincident metabolic and pathological abnormalities which are 
characteristic of Type 2 diabetes (e.g. overweight/obesity, dyslipidaemia), may 
explain the lower MPOD levels observed. Furthermore, lutein and zeaxanthin 
supplementation has been shown to exert positive and beneficial ocular effects in those 
with diabetic eye disease, including structural improvements in measures of macular 
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oedema and functional improvements in VA and other visual function measures.15, 21 
Table 6.2 outlines a summary of the cross-sectional studies and RCTs examining the 
relationship between MPOD and diabetes (Type 1 & 2).  
 
Although the evidence exploring MP and diabetes is relatively sparse, the findings 
which have been reported are sufficient to suggest that MPOD may be adversely 
affected by the condition, and that there is a plausible rationale to explore the possible 
benefits of lutein and/or zeaxanthin supplementation for ocular health and visual 
function in diabetes, particularly Type 2. The recent generation of such evidence has 
prompted this literature review, which is designed to explore and elucidate the 
metabolic perturbations and candidate causal mechanisms which may underpin the 






Table 6.1: Summary of experimental animal studies examining the relationship between lutein and/or zeaxanthin and diabetes. 
Author & Year Design: Animal Model Lutein and/or Zeaxanthin Outcome, Evidence & Conclusion 
Muriach et al 
(2006).215 
Albino mice (alloxan 
induced diabetes mellitus). 
Lutein (70% purity, 0.2 mg/kg 
body weight). 
Decrease in oxidative stress (decrease MDA and NF-κB, 
increase GSH and GPx); ERG b-wave restored. 
Kowluru et al 
(2008).14 
Rats (STZ induced 
diabetes mellitus). 
Zeaxanthin (0.02% or 0.1% 
equivalent to 8.4 mg/kg). Placebo 
controlled. 
Decrease in oxidative stress (decrease 8-OHdG, nitrotyrosine, 
iNOS, VEGF & ICAM-1 levels). 
Arnal et al 
(2009).380 
Rats (STZ induced 
diabetes mellitus). 
Lutein (in combination with DHA). 
Placebo controlled. 
Decrease in oxidative stress (MDA and nitrotyrosine, increase 
GSH & GPx). Restored ERG b-wave amplitude & latency time. 
Sasaki et al 
(2010).186 
Mice (STZ induced 
diabetes mellitus). 
Lutein (0.1 mg wt/wt). Placebo 
controlled. 
Decrease in ROS & ERK activation and apoptosis. Protection 
of inner retina from visual impairment. 
Tang et al 
(2011).378 
Mice (db/db) spontaneous 
diabetes. 
 
1% (kcal) Wolfberry (lutein & 
zeaxanthin). Placebo controlled. 
Lower expression of endoplasmic reticulum stress biomarkers, 
(BiP, PERK, ATF6, caspase-12) and restored AMPK, 
thioredoxin, Mn-SOD, and FOXO3α activities. 
Yu et al 
(2013).379 
Mice (db/db) spontaneous 
diabetes. 
Wolfberry diet (lutein and 
zeaxanthin). Placebo controlled. 
Activation of AMPK in mitochondria which caused 
retinoprotection in the retina of db/db mice. 
Kowluru et al 
(2014).20 
 
Rats (STZ induced 
diabetes mellitus). 
Multi-nutritional supplement, 
lutein=20 mg; zeaxanthin=40 
mg/kg of powder diet, in addition 
Carotenoids ameliorated capillary cell apoptosis. Improved 
ERG, a- and b- wave amplitudes. Decrease oxidative damage & 
increased antioxidant activity. Inflammatory markers (decrease 
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 to numerous antioxidants. Placebo 
controlled. 
in VEGF, IL-1β & NF-kB). 
Zhou et al 
(2017).385 
Rats (High fat diet and low 
dose STZ induced diabetes 
mellitus). 
Zeaxanthin (50 mg/kg; 200 mg 
dissolved in 10 ml corn oil). 
Placebo controlled. 
Supplementation with zeaxanthin reduced blood glucose, 
improved cognitive deficits, neural cell survival and increased 
p-AKT levels. Inhibited cleaved caspase-3 levels and NF-κB 
nuclear transcription in the hippocampus. 
 
Abbreviations: mg, milligram; MDA, malondialdehyde; NF-κB, nuclear factor κ B; GSH, glutathione; GPx, glutathione peroxidase; ERG, electroretinogram; STZ- streptozotocin; 
8-OHdG, 8-hydroxy-21 – deoxyguanosin; iNOS, inducible nitric oxide synthase; VEGF, vascular endothelial growth factor; ICAM -1, intercellular adhesion molecule; DHA, 
docosahexaenoic acid; ROS, reactive oxygen species; ERK, extra cellular receptor kinase; kcal, kilocalorie; BiP, binding immunoglobulin protein; PERK, protein kinase RNA-
like ER kinase; ATF6, activating transcription factor 6; AMPK, AMP-activated protein kinase; Mn SOD manganese superoxide dismutase; FOXO3α, forkhead O transcription 
factor 3 α; IL-1 β, interleukin 1 beta; p-AKT; phosphorylated serine/threonine kinase.
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Table 6.2: Summary of cross-sectional studies and RCTs examining the relationship between MPOD and diabetes. 
Author & Year Design Outcome, Evidence & Conclusion 
Davies & 
Morland (2002).9 
Cross-sectional study to assess MPOD in diabetes (N = 26) 
vs healthy, non-diabetic controls (N = 30). 
Those with maculopathy had lower levels of MP than those without 
maculopathy (p = 0.016). 
Zagers et al 
(2005).383 
Cross-sectional study to assess MPOD in diabetes (N=15) 
vs healthy non-diabetic subjects (N=14).    
The density of MP in diabetic participants was not different from that in 
controls (p = 0.3). 
Mares et al 
(2006).384 
Cross-sectional study on sub-sample of women who 
participated in CAREDS (n = 1698). MPOD measured by 
HFP.   
Lower MPOD was associated with diabetes. Relationship of dietary 
intake of lutein and zeaxanthin to MP differed between diabetic and 
non-diabetic women. 
Lima  et al,  
(2010).6 
Cross-sectional study including: non-diabetic controls 
(N=14), diabetic patients with (N=12) and without 
retinopathy (N=17). 
Type 2 diabetic patients, with or without retinopathy, had reduced 
MPOD vs. non-diabetic subjects. MPOD was inversely correlated with 
HbA1c levels. 
Scanlon  et al,   
(2015).7 
Cross-sectional study assessing MP in Type 1 (N=34) & 2 
(N=68) diabetic participants and healthy controls (N=48). 
MPOD levels were lower in diabetic participants vs controls (p =0.04). 
MPOD was lower in Type 2 vs Type 1 (p = 0.02) and Type 2 vs 
controls (p = 0.03).  
She et al, 
(2016).386 
Cross-sectional study assessing MP in diabetic patients 
without retinopathy (N=134), with early stage non-
proliferative diabetic retinopathy (N=48) and non-diabetic 
controls (N=219). 
MPOD levels were not significantly different between the three groups 
(i.e. diabetic participants with or without retinopathy and controls (p = 




Moschos et al, 
(2017).387 
Retrospective study on Type 2 diabetic patients (N=60; 120 
eyes) without diabetic retinopathy. Patients received 
carotenoid supplements containing lutein (10 mg), 
zeaxanthin (2 mg) and meso-zeaxanthin (10 mg) once a 
day for two years. 
MPOD was not measured in this study. OCT showed an increase in the 
central foveal thickness (p<0.001) and mf-ERG revealed increased 
retinal response density within the central 13° surrounding the fovea 
(rings 1 to 3) (p<0.001) at 2 years after the onset of carotenoids 
supplement intake.  
Gonzalez-Herrero 
et al, (2018).388 
Prospective controlled study assessing macular integrity 
and macular sensitivity by microperimetry in patients with 
non-proliferative diabetic retinopathy. Patients were 
assigned (1:1) to the DHA + xanthophyll supplementation 
group (N=12; 24 eyes) or the control group (N=12; 24 
eyes). 
Significant improvements in macular sensitivity at 90 days (p=0.030) in 
the supplemented group. Total antioxidant capacity levels increased and 
plasma IL-6 levels decreased significantly in the DHA + xanthophyll 
supplemented group but not in the control group. MPOD was not 
measured in this study. 
Cennamo et al, 
(2019).389 
Prospective controlled study assessing MPOD and 
microvascular density on OCTA in a cohort of Type 1 
diabetes patients with retinopathy (N=59, total of 82 eyes). 
The control group (N= 40; total of 80 eyes examined). 
MPOD was significantly lower in patients with retinopathy compared 
with controls (p<0.001). OCTA vessel density were significantly lower 
in diabetes patients than in controls (p<0.001). 
Hu et al, 
 (2011).15 
RCT: Controlled trial including non-proliferative diabetic 
retinopathy patients (N=61) & non-diabetic controls 
(N=60). 
Plasma lutein/zeaxanthin concentrations in diabetic retinopathy patients 
were lower than those in normal controls. Lutein/zeaxanthin intake can 




Chous et al, 
(2015).21 
DiVFuSS 
RCT:  Type 1 (N=27) and Type 2 (N=40) diabetes with no 
diabetic retinopathy or mild to moderate non-proliferative 
diabetic retinopathy versus placebo.  
Intervention group received 2 daily doses of a xanthophyll, 
antioxidant and plant extract supplement. 
Significant improvement in MPOD (p values: 0.008 to <0.0001); visual 
function on all measures (p values: 0.008 to <0.0001); plasma lipids (p 
values ranging from 0.01 to 0.0004), hs-CRP (p=0.01) and diabetic 
peripheral neuropathy (Fisher’s exact test, p=0.0024). These effects 
were observed without an effect on glycaemic control. 
 
Abbreviations: MPOD, macular pigment optical density; MP, macular pigment; CAREDS, carotenoids in age related eye disease study; HFP heterochromatic flicker photometry; 
HbA1c, glycated haemoglobin; DR, diabetic retinopathy; OCT, optical coherence tomography; mfERG; multifocal electroretinography; DHA, docosahexaenoic acid; IL-6, 
interleukin 6; OCTA, optical coherence tomography angiography; RCT, randomised control trial; VA, visual acuity; DiVFuSS, the diabetes visual function supplement study; hs-
CRP, high sensitivity – C reactive protein. 
148 
 
6.3 Literature search methods 
For the purpose of this review, partly because of the relative dearth of higher level 
RCT evidence, we have appraised all forms of published research, even lower level 
evidence sources, to ensure that the scientific and clinical implications of the available 
evidence might be synthesised into useful treatise, which accurately reflects what is 
known about this area, and what remains to be elucidated. All relevant published 
articles from human and animal studies which reported on the relationship between 
MP and diabetes (Type 1 & Type 2), were identified for the first stage of the review, 
up until the year 2019. Secondly, the review focused on identifying publications which 
investigated the relationship between the metabolic perturbations typically associated 
with diabetes, and Type 2 diabetes in particular (e.g. adiposity/dyslipidaemia) and MP. 
Pre-selected keywords including: ‘lutein’, ‘zeaxanthin’, ‘macular pigment’, 
‘diabetes’, ‘diabetes AND MP’, ‘diabetes AND lutein/zeaxanthin’, ‘BMI’, ‘body fat 
AND diabetes’, ‘adipose’, ‘high density lipoprotein AND diabetes, ‘triglycerides 
AND diabetes’, ‘oxidative stress’, ‘inflammation’, ‘hypertension AND MP’, ‘insulin 
resistance’, ‘hyperinsulinemia’, were entered into academic databases and search 
engines including PubMed, Google Scholar, Mendeley, Scopus, Cochrane Library and 
the ISRCTN registry to define our search of the literature relating to MP and diabetes 
up until 2019. Although many supporting publications were retrieved, in total, only 
eight animal studies (Table 6.1) and eleven human studies (Table 6.2) were included 
to help clarify our current understanding of the links between diabetes and MP. A total 
of thirteen papers on adiposity and MP (Table 6.3) and seven papers on MP and 
dyslipidaemia (Table 6.4) were included to help analyse the relationship between 
MPOD and the metabolic correlates of Type 2 diabetes (adiposity and dyslipidaemia). 
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The overall findings suggest that MP is lower in diabetes, Type 2 diabetes in particular; 
and that supplementation with macular carotenoids and/or other antioxidants may 
confer protection against diabetic eye disease. To elucidate the causal mechanisms and 
metabolic perturbations which might possibly explain the lower MP levels observed 
in diabetes, we will first explore the condition diabetes mellitus itself, including its 
association with oxidative stress and inflammation; and subsequently present the 
evidence linking adiposity and dyslipidaemia with Type 2 (or poorly controlled Type 
1) diabetes and MPOD. 
6.4 Diabetes mellitus 
Diabetes mellitus is a group of metabolic disorders caused by the complex interaction 
of genetics, environmental factors and lifestyle choices.390 Diabetes is characterised 
by a deficiency of insulin and/or systemic insulin resistance. Over the past number of 
decades, the number of people with diabetes, particularly Type 2 diabetes, has 
increased dramatically, making it a critical and universal public health challenge.391 
Type 1 diabetes usually develops in normal-weight children, teenagers and younger 
adults, and is an autoimmune condition involving the selective destruction of 
pancreatic β cells, ultimately resulting in complete deficiency of insulin.392 
Conversely, Type 2 diabetes is linked to a sedentary lifestyle and being overweight, 
and is characterised by systemic insulin resistance and subsequent pancreatic 
endocrine dysfunction, which results in attenuated insulin synthesis as well as 
inhibition of its cellular effects.390 Whilst diabetes is characterised by having higher 
than normal blood glucose levels, the pathogenesis and development of Type 1 and 
Type 2 diabetes differ; therefore, the relationship between MPOD and the different 
forms of diabetes should not be generalised. At presentation, Type 2 diabetes is most 
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often accompanied by other co-morbidities including overweight/obesity, insulin 
resistance, hypertension and dyslipidaemia, features which are less common in Type 
1 diabetes at diagnosis, but which may occur as complications of Type 1 diabetes later 
in the course of the disease. Oxidative stress and inflammation are implicated in both 
Type 1 and Type 2 diabetes; however, research has shown that these metabolic 
disturbances are very pronounced in Type 2 diabetes.393-397 The oxidative stress, 
inflammation, adiposity and dyslipidaemia which characterise diabetes, may have 
independent relationships with MPOD, and therefore constitute plausible causal 
mechanisms in diabetic eye disease. These pathological mechanisms merit further 
exploration and will be discussed in more detail herein. 
6.4.1 Oxidative stress and diabetes 
Chronic hyperglycaemia induces oxidative stress in patients with diabetes.398 
Oxidative stress, defined as the excessive production of ROS, results in oxidative 
injury when the redox balance is upset; i.e. where the level of oxidative species 
exceeds the capacity of the anti-oxidant defence system to neutralise them.355, 399 
Reactive oxygen species can include free radicals, which are partially reduced oxygen 
species containing one or more unpaired electrons (for example, superoxide anion or 
hydroxyl radical); and species with their full complement of electrons in an unstable 
or reactive state (for example, singlet oxygen or hydrogen peroxide).400 The body’s 
natural defence against oxidative damage is neutralisation by endogenous 
antioxidants,401 which include enzymatic antioxidants such as SOD, CAT and GPx, 
and non-enzymatic antioxidants such as GSH. Our endogenous antioxidant defence 
system, however, is incomplete without exogenous antioxidant nutrients including 
vitamin C, vitamin E, carotenoids (beta carotene, lutein, zeaxanthin & meso-
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zeaxanthin) and polyphenols.177 Exogenous antioxidants, such as those available in 
dietary fruit and vegetables, are therefore necessary to balance redox status. Through 
normal physiological processes, antioxidants inhibit or quench free radical reactions 
and can delay or inhibit cellular damage.399 When these processes are overwhelmed, 
however, as in Type 2 diabetes, ROS will readily react with lipids, proteins and nucleic 
acids, resulting in impaired cell function or cell death.402-404  
 
The retina is already at an increased risk of oxidative stress and damage, given its high 
oxygen demand and consumption, its exposure to visible light irradiation and its high 
concentration of PUFAs in the photoreceptor outer segments.405 These risks increase 
when the generation of free radicals and ROS is stimulated by environmental 
factors,406, 407 short-wavelength light exposure,408 and other internal stresses including 
inflammation,409 and hyperglycaemia.403, 404, 410 While PUFAs in the photoreceptor 
outer segment are thought to protect against oxidative and inflammatory damage, they 
can potentially act as a substrate for the propagation of free radicals as they provide a 
readily available source of electrons.291, 406 With increasing age, systemic antioxidant 
levels decline and ROS levels increase in most tissues, and this is associated with a 
number of neurodegenerative diseases, including AMD and diabetes.291, 411,9 
 
Hyperglycaemia, oxidative stress and changes in redox homeostasis are fundamental 
events in the pathogenesis of diabetic retinopathy. Various mechanisms have been 
suggested to contribute to the formation of reactive oxygen-free radicals. 
Hyperglycaemia causes tissue damage through five major pathways, namely increased 
flux of glucose and other sugars through the polyol pathway; increased intracellular 
formation of AGEs; increased expression of the receptor for AGEs (RAGEs) and its 
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activating ligands; activation of PKC isoforms; and activity of the hexosamine 
pathway.412 Over activation of these pathways can lead to damage of cellular 
organelles and enzymes, increased lipid peroxidation, and development of insulin 
resistance.413, 414 Several lines of evidence indicate that all five mechanisms are 
activated by a single upstream event: mitochondrial overproduction of ROS.415 
Locally, the occurrence of these metabolic changes, results in defective angiogenesis 
and the activation of a number of pro-inflammatory pathways which stimulate an 
influx of leukocytes which can alter vascular permeability in the retina.378 The role of 
hyperglycaemia in diabetic microvascular complications in the eye has been 
established by large-scale prospective studies in Type 2 diabetes (UKPDS).416 Beyond 
elevations in blood glucose, however, ROS formation is also increased by elevations 
in FFAs (a common feature of Type 2 diabetes), through their direct effect on 
mitochondria.417   
 
While, oxidative stress is increased in diabetes, the activities of antioxidant defence 
enzymes responsible for scavenging free radicals and maintaining redox homeostasis 
(SOD, CAT, GPx) are concomitantly diminished in the retina of both Type 1 and Type 
2 diabetes.355, 401, 418 The activity of non-enzymatic antioxidants is also depressed 
during hyperglycaemia-induced oxidative stress.418 Redox balance is important, as its 
disruption can cause antioxidants to become pro-oxidative, potentially precipitating 
damage to the retina. It cannot be assumed, however, that a single reductive or 
antioxidant treatment would be sufficient to reverse the underlying pathophysiological 
mechanisms of diabetic retinopathy. Antioxidant protection in the retina is provided 
mainly from vitamins C and E, carotenoids, GPx, SOD and CAT enzymes, and GSH 
compound,419 and many of these antioxidants are aided by micronutrients (e.g. copper, 
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zinc, selenium) which act as cofactors.420 The carotenoids lutein and zeaxanthin are 
very effective quenchers of singlet molecular oxygen and lipid peroxy radicals, 
however, in the process, these carotenoids are themselves oxidised to their 
corresponding radical cations.250 These cations must be reduced to regenerate the 
original carotenoid, thereby allowing their reuse as an antioxidant. Vitamin E (𝛼- 
tocopherol) reduces oxidised carotenoids, which leaves tocopherol oxidised.420 
However, oxidised tocopherol can be reduced and regenerated by vitamin C (ascorbic 
acid) and GSH, which are themselves further reduced by copper and zinc.5, 421 Dietary 
lutein, zeaxanthin and vitamins E and C, as well as endogenous antioxidant enzymes, 
therefore, act in concert with one another to lower the levels of ROS (via ROS 
detoxification) and to recycle oxidised lipid antioxidants (via re-reduction).  
 
The presence of oxidation products of the macular carotenoids in human and primate 
retinal tissue indicates that lutein, zeaxanthin and meso-zeaxanthin play an important 
antioxidant role there.45 Zeaxanthin appears to be a more potent anti-oxidant than 
lutein,270 with meso-zeaxanthin being even more efficacious, but only in conjunction 
with its binding protein.271 Li et al. 272, demonstrated that a 1:1:1 ratio mixture of 
lutein, zeaxanthin and meso-zeaxanthin quenches more singlet oxygen than any of 
these carotenoids individually at the same total concentration,272, 422 suggesting that 
they are most effective when acting synergistically with one another. Diet is a major 
lifestyle factor which can greatly influence the incidence and progression of Type 2 
diabetes. Some dietary and lifestyle modifications associated with enhanced 
antioxidant supply could therefore be an effective prophylactic means to prevent or 
limit oxidative stress in diabetic eye disease. Type 2 diabetes is associated with a 
sedentary lifestyle and being overweight, therefore, patients with Type 2 diabetes may 
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not only be exposed to diets which are high in fat and low in antioxidants,423 and to 
the increased oxidative stress imposed by their diabetes;6, 7, 9 but may also be subject 
to greater chronic oxidative stress as a result of their obesity itself.424 The co-
occurrence of these phenomena consequently demands an even greater supply of 
exogenous antioxidants (vitamin C, E, carotenoids lutein, zeaxanthin & meso-
zeaxanthin) to balance redox status and to combat this state of chronic oxidative stress 
to which the diabetic retina is exposed. While the control of blood glucose is critical 
in patients with diabetes, neuroprotective strategies and novel antioxidant treatments 
should also be considered to target the specific aetiologies and underlying 
pathophysiological mechanisms of the condition, and to ultimately protect against the 
vascular pathologies of diabetes. It is logical that natural antioxidants (lutein, 
zeaxanthin and meso-zeaxanthin) may have beneficial implications for diabetic 
retinopathy in this context. However, larger trials involving intensive assessment of 
oxidative stress, antioxidant defence activities and their effects on one another in the 
diabetic state are necessary before empirical supplementation of these carotenoids can 
be recommended clinically.   
6.4.2 Inflammation and diabetes 
Diabetic retinopathy has traditionally been considered a disease of the retinal 
microvasculature, associated with oxidative stress induced by hyperglycaemia. More 
recently, however, inflammation has been cited as a deleterious factor in the 
development of diabetic complications,10 and is now also implicated in the 
pathogenesis of many ocular diseases including AMD, 425 and diabetic retinopathy.426 
Numerous interplays exist between inflammation and oxidative stress and vice 
versa.427 Hyperglycaemia increases the levels of pro-inflammatory proteins,10 and it is 
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now believed that inflammatory processes underlie many of the functional changes in 
retinal vasculature observed histologically in early diabetic retinopathy, such as 
pericyte loss, microaneurysms, and occluded and degenerated capillaries.194 
 
While inflammation is normally a protective response to tissue stress, hyperglycaemia 
leads to a dysregulation of inflammation, which ultimately becomes chronic. 
Oxidative stress triggers inflammatory responses, and inflammation also enhances the 
production of ROS, which creates a self-perpetuating cascade towards oxidative tissue 
damage.428 The increased expression of many inflammatory proteins in diabetic 
retinopathy is regulated through the activation of pro-inflammatory transcription 
factors including NF-κB.429 Activation of NF-κB leads to the synthesis of pro-
inflammatory molecules such as IL-1, IL-6, TNF-alpha, c-Jun N-terminal kinase-1 
(JNK-1), inhibitor of nuclear factor kappa-B kinase subunit beta (IKK-β) and growth 
factors such as VEGF.378, 429 
 
In the retina, the microvascular endothelium forms an effective barrier to control the 
movement of blood, fluid and proteins across the vessel wall. This barrier is formed 
by tight junctions, which consist of over 40 different proteins and various 
inflammatory mediators including VEGF, TNF𝛼, PKC, IL-1𝛽, and IL-6.194, 430 
Dysfunction of these proteins is highly correlated with the pathogenesis of blood-
retinal barrier breakdown and increased vascular permeability, which leads to diabetic 
macular oedema, a major cause of vision loss in diabetic retinopathy.431 Inflammatory 
processes can induce oxidative stress, and similarly, oxidative stress can induce 
inflammation through the activation of multiple pathways. The coincident over-
activation of inflammation and oxidative stress can therefore deplete cellular 
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antioxidant capacity and reduce MP levels in the eye.4, 291 
 
The expression of various pro-inflammatory cytokines, such as TNF-α, IL-1 and IL-
6, are also increased from visceral adipose tissue (more common in Type 2 diabetes), 
and this has been linked to systemic inflammation and accompanying insulin 
resistance.432 The inhibition of signalling downstream of the insulin receptor is a 
primary mechanism through which inflammatory signalling leads to insulin 
resistance.10 Several cross-sectional studies have shown that insulin resistance and 
Type 2 diabetes are associated with higher levels of C-reactive protein (CRP), IL-6 
and TNF-alpha, all markers of subclinical inflammation.433-435 Various longitudinal 
studies have also shown that elevated levels of CRP and IL-6 are linked to the later 
development of Type 2 diabetes.436, 437  
 
Inhibition of different inflammatory mediators, including NF-kβ, IL-1β, VEGF and 
cyclooxygenase-2 (Cox-2), has been shown to limit the degeneration of retinal 
capillaries characteristic of early stage diabetic retinopathy.438 There is evidence to 
suggest that lutein and zeaxanthin may prevent the development of diabetic 
retinopathy by suppressing ROS induced by inflammation.377 Li et al. 283 investigated 
the anti-inflammatory effects of lutein on Muller cells in a murine model. Treatment 
with lutein led to lower production of the pro-inflammatory factors NF-kB, IL-1β and 
Cox-2, suggesting an anti-inflammatory role for lutein in protection against retinal 
ischemic/hypoxic injury.283 In another study, the protective effects of lutein and 
zeaxanthin against photo-oxidative damage to RPE cells were investigated. 
Supplementation with carotenoids modulated the inflammatory responses in these 
cultured RPE cells in response to photo-oxidation.439  
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The effects of zeaxanthin on diabetes induced retinal oxidative damage and 
inflammation have also been investigated in diabetic rats.14 It was found that 
zeaxanthin significantly inhibits diabetes-induced retinal oxidative damage and 
elevations in VEGF and its adhesion molecule, abnormalities which are commonly 
associated with the pathogenesis of diabetic retinopathy.14 Clinical findings have 
highlighted the inverse association between lutein and IL-6 in coronary artery disease 
patients.440 A recent novel RCT, the diabetes visual function supplement study 
(DiVFuSS),21 explored the effects of a nutritional supplement (which included lutein 
and zeaxanthin) on patients with Type 1 and Type 2 diabetes, and suggested that the 
preparation used mitigated the damaging effects of systemic inflammation on ocular 
function, and that these effects may have been mediated by enhancements in MPOD. 
Chronic low grade inflammation and oxidative stress co-exist in diabetes, particularly 
Type 2 diabetes but also poorly controlled Type 1 diabetes. Therefore, findings from 
DiVFuSS, which achieved significant increases in MPOD (27% mean increase in 
DiVFuSS group vs. 2% mean decrease in placebo group), as well as reductions in 
plasma high-sensitivity (hs)-CRP (60% mean decrease in DiVFuSS group vs. 11% 
mean decrease in placebo group), may be due in part to the inclusion of compounds 
which in combination, specifically target both inflammation and oxidative stress, and 
therefore, which block some of the oxidative and/or inflammatory pathways 
responsible for the progression of diabetic retinopathy.21 The inclusion of many 
compounds in this test formula and the fact that both types of diabetes patients (Type 
1 & 2) were examined renders interpretation of the outcome more difficult, however, 
these findings are promising as they clearly show that MPOD can be augmented in 




While it is clear that oxidative stress and inflammation are implicated in the initiation 
and development of diabetic retinopathy, it remains unclear whether the pathological 
effects of oxidative stress/inflammation are mediated through MPOD depletion in 
Type 2 diabetes. The current body of evidence which directly links lower MP levels 
with other metabolic correlates of diabetes, namely adiposity and dyslipidaemia; will 
now be explored to elucidate the possible mechanisms by which these metabolic 
factors mediate their effects on MPOD. It is important to note that both increased 
adiposity and dyslipidaemia (primarily reduced HDL) may adversely affect MP by 
compromising the availability,16, 17, 54, 441 and transport,18, 19 of dietary carotenoids to 
the retina. It follows that a condition such as Type 2 diabetes, which unfavourably 
affects these parameters, may have deleterious effects on MPOD, with clinically 
relevant outcome effects. An analysis of the literature is presented describing these 
putative mechanisms: (a) evidence in relation to MPOD and body fat/adiposity (n =13, 
Table 6.3); and (b) evidence concerning MPOD and dyslipidaemia (n =7, Table 6.4). 
6.4.3 Type 2 diabetes, MPOD & adiposity – the evidence. 
Diabetes mellitus is a chronic disorder which can alter carbohydrate, protein, and fat 
metabolism. Weight gain, following excessive calorie intake, results in the body 
becoming markedly resistant to the action of insulin. Despite initial impairment in 
insulin action, glucose tolerance can remain normal for some time because there is a 
compensatory increase in insulin secretion by pancreatic β-cells, which results in a 
well-compensated metabolic state, a condition known as hyperinsulinemia. There is 
now mounting evidence to indicate that persistently elevated plasma insulin levels can 
contribute to the development of hypertension, plasma lipid abnormalities and 
atherosclerosis.442 The escalating rates of insulin secretion as a result of advancing 
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obesity, however, cannot be maintained and Type 2 diabetes ensues.  
 
Intra-abdominal fat appears to be an important determinant of insulin sensitivity 
compared with subcutaneous fat.443 Visceral and subcutaneous fat differ in their 
phenotypic, physiological and functional aspects, as there are a greater number of 
macrophages, T lymphocytes and pro-inflammatory molecules in visceral versus 
subcutaneous fat in obese individuals. Abdominal adipose tissue produces a variety of 
adipocytokines including IL-1, IL-6, IL-8, TNF-alpha, leptin and resistin, therefore, 
the abdominal adipose mass acts as an important mediator of inflammation in 
diabetes.444 Obesity also leads to an increased size of adipocytes. The death of 
adipocytes, which is rare in healthy people, is very common in obese individuals and 
has been linked to adipocyte hypoxia. The accumulation of macrophages in the 
adipose tissue of obese individuals, not only eliminates the dead cells but also further 
increases their synthesis of inflammatory mediators IL-8, IL-6, IL-1, TNF-alpha.444 
The resultant inflammation becomes chronic, therefore, obesity is considered a low-
grade inflammatory condition which in turn leads to an increase in oxidative stress. 
Plasma 8-hydroxy-21–deoxyguanosin (8-OHdG), a known sensitive marker of 
oxidative DNA damage and of total systemic oxidative stress in vivo, has been shown 
to be positively correlated with BMI in people with Type 2 diabetes mellitus.370 Over-
expression of oxidative stress and the concomitant reduction in antioxidant defence, 
damages cellular structures,367 often resulting in further inflammatory responses. 
Antioxidant defences may be lower in overweight/Type 2 diabetes patients, due to 
their lower intake of antioxidant rich foods (e.g. fruits and vegetables), their increased 
utilisation of these molecules (e.g. increased inflammation/ROS in insulin dependent 
tissue such as the retina) and their impaired generation of other supportive anti-
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oxidants,367 factors which may collectively lead to MPOD depletion. 
 
The diminished response to insulin in Type 2 diabetes also leads to increased lipolysis 
in adipocytes. Enlarged adipocytes release FFAs and adipocytokines,418, 442 therefore, 
greater amounts of FFAs reach the liver via the portal vein, resulting in fatty liver 
infiltration. Mobilised FFAs are oxidised by vascular endothelium to generate ROS. 
Elevations of FFAs in plasma also inhibit insulin suppression of hepatic glucose 
production, leading to an increase in glucose production by the liver.445 This in turn, 
results in both insulin resistance and inflammation in the major insulin target tissues 
(skeletal muscle, liver and endothelial cells). Abnormal levels of lipids, fatty acids, 
and various adipocytokines from adipose tissue therefore initiate a vicious cycle of fat 
damage, inflammation, worsening insulin resistance, impaired β-cell insulin secretion 
and ultimately Type 2 diabetes.442, 446 The chronic low grade inflammation, associated 
with obesity and Type 2 diabetes leads to increased oxidative stress and further 
inflammation, putting a greater demand on antioxidant defences.  
 
Apart from its pro-inflammatory and pro-oxidant effects, adipose tissue is also a major 
body store for carotenoids such as lutein and zeaxanthin. Higher levels of body fat 
have been shown to be related to lower levels of circulating carotenoids,347 making 
these pigments less available to retinal tissue.68 Furthermore, a randomised controlled 
weight loss trial found that a significant weight loss in the intervention group was 
related to increases in plasma lutein.447 Higher BMI 448 and higher body fat percentage 
16 have both been linked with an increased risk of AMD. Studies have reported an 
inverse relationship between adiposity and BMI and MPOD,52, 54 with the observed 
relationships largely attributable to participants with a BMI > 29 kg/m2.54 One study 
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found that higher body fat percentage, even within relatively healthy limits, was 
associated with lower retinal tissue lutein and zeaxanthin status,53 suggesting that 
adiposity may affect the nutrient status of the retina. Gender differences in MPOD 
have also been reported,16, 17 which may imply differences in metabolism of MP, or 
reflect differences in adipose tissue storage of these dietary carotenoids between men 
and women. Competitive absorption by a larger overall fat mass (percentage fat mass 
is generally higher in women),449 or specifically by greater abdominal fat mass (which 
is more common in men),450 may reduce lutein and zeaxanthin uptake by the retina. 
Concentrations of carotenoids differ according to body site, with levels demonstrably 
higher in abdominal fat,67 which may explain the differences in MPOD currently 
observed between men and women.16, 17 Since adipose tissue may trap lutein and 
zeaxanthin 53 individuals who are overweight or obese (Type 2 diabetes) may 
consequently have lower concentrations of carotenoids lutein and zeaxanthin available 
at the macula. 
 
Overall the research appears to suggest that obesity has a negative impact on MPOD, 
however, there is also some evidence to the contrary. One study found that mean 
MPOD values did not differ significantly between subjects with various types of 
obesity and ideal weight subjects.364 Our previous study 7 is the only one to date which 
has examined the relationship between BMI and MPOD in a group with diabetes. This 
study found that MPOD was significantly lower and BMI was significantly higher in 
patients with Type 2 diabetes, compared to Type 1 and non-diabetic controls, 
highlighting the possibility that different relationships exist between MPOD status and 
Type 1 and 2 diabetes. The higher BMI levels observed in Type 2 diabetes are 
reflective of excess adiposity which acts as a store for lutein and zeaxanthin. However, 
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as described previously, obesity is also independently associated with increased 
oxidative stress,69, 367, 368 and with inflammation 372 which exacerbates oxidative stress, 
and may therefore have multiple depletive effects on MP. Unfortunately the cross-
sectional nature of this study 7 means that it cannot elucidate the extent or nature of 
any causal relationships between BMI and MPOD in these Type 2 subjects.  
 
The different presenting features of Type 1 and 2 diabetes and the interplay of their 
disease components with MPOD status (e.g. adiposity), may mean that the mechanistic 
relationship between these conditions and MPOD status, is not uniform across both. 
The fact that much of the research to date includes both diabetic groups may obfuscate 
any relationships present. Although, the evidence to date is somewhat conflicting, 
there appears to be a theoretical basis for a relationship between the characteristic body 
fatness of Type 2 diabetes and lower levels of MPOD. A summary of the studies 
investigating the association between MPOD and adiposity are outlined in Table 6.3.
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Table 6.3: Summary of studies linking MPOD and body fat. 
Author & 
Year 
Design Sample Results 
Johnson et al 
(2000).17  
Study 1: 15 week modified diet to increase 
lutein & zeaxanthin intake with plasma, buccal 
mucosal cell and adipose samples taken at 0, 4, 
8 & 15 weeks and 2 months post-intervention. 
Study 2: A cross-sectional analysis of 
relationships.   
1. N = 7 (4 women & 3 
men). 
2. N = 21 (13 women & 8 
men). 
1. Only plasma zeaxanthin increased from baseline and 
only at week 4. Adipose tissue lutein peaked at week 8. 
2. Significant negative correlations found between 
adipose tissue, lutein concentrations and MP for women. 
A positive effect was seen in men. 
Broekmans et 
al (2002).63 
Cross-sectional design looking at plasma and 
adipose tissue concentrations in relation to MP.    
376 healthy adults.  
Plasma (N=376) 
Adipose (N=187) 
Regression models showed a positive significant 
association between MP density and plasma lutein, 
plasma zeaxanthin, and adipose lutein concentrations in 
men after adjustment for age, but no relation in women. 




Cross-sectional study investigating MPOD, 
BMI, body fat percentage, dietary intake and 
plasma carotenoid concentrations. 
680 healthy adults. 
Body fat (N=400) 
Dietary (N = 280)  
Plasma (N = 280) 
Inverse association between MPOD and BMI (p < 
0.0008) and body fat (p < 0.01). 





body fat percentage, dietary carotenoid intake 
and plasma levels. 
Males (N= 45) 
Females (N=55) 
fat percentage in males (p<0.05) but not in females 
(p=0.14). 
Mares et al 
(2006).384 
Cross-sectional study investigating MPOD, 
dietary intake of lutein & zeaxanthin and other 
predictors of MP levels. 
Subsample of women who 
participated in CAREDS. 
N=1698 women aged 53-
86 years. 
MPOD is directly related to dietary intake and plasma 
levels of lutein & zeaxanthin. Higher abdominal fat is 
related to lower MPOD. 
Moeller et al 
(2009).451 
 
Intervention in a sub-sample of the Women’s 
Health Initiative to increase lutein and 
zeaxanthin through dietary modification. 
394 healthy adults. 
Intervention (N = 1581) 
Control/usual diet (N = 
236). 
Lower MPOD was associated with above median WC. 
This explained 2.7% of the variation. 
Kirby et al 
(2011). 447 
 
Randomised controlled weight loss trial. 104 subjects with BMI 
>28 kg/m2; Intervention 
group (N= 54); Control 
group (N= 50). 
Significant weight loss in the intervention group 
(p<0·0001), was related to plasma increases in lutein. 
Gupta et al 
(2012).364 
Clinical study; MPOD was compared to 
various anthropometric measurements 
including WHtR, WC, WHpR and BMI. 
161 healthy adults. 
Males (N= 82) 
Females (N= 79). 
Mean MPOD values did not differ significantly in various 
types of obesity when compared with normal subjects. 
Nolan et al 
(2012).52 
Prospective cohort study. Subset of TILDA 
participants with MPOD & 
Obese individuals had significantly lower MPOD (mean 
= 0.190) than either overweight individuals (mean = 
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BMI measures N = 4281 
adults aged over 50. 
0.208; p < 0.01) or those with normal weight (mean = 
0.213; p < 0.01). 
Bovier et al 
(2013).53  
Cross-sectional study investigating MPOD, 
assessment of body composition and plasma 
lutein/zeaxanthin status. 
100 healthy adults. 
Males (N=39) 
Females (N=61). 
Significant inverse relationship between body fat 
percentage (total and regional) and MPOD (p<0.01). 
Scanlon et al 
(2015).7 
Cross-sectional study to assess MPOD in Type 
1 and Type 2 diabetic participants and BMI, 
dietary intake and plasma carotenoid 
concentrations. 
102 diabetic participants, 
of which Type 1 (N=34) & 
Type 2 (N=68), and 48 
healthy controls. 
BMI was significantly higher and MPOD lower in Type 2 
vs Type 1 diabetics and healthy controls. BMI was not 
directly correlated with MPOD. 
Khan et al 
(2018).452 
Cross-sectional study investigating MPOD, 
whole body adiposity (% Fat) and intellectual 
ability. 
114 adults with 
overweight and obesity 
(≥25 kg/m2). 
MPOD was inversely related to body fat % (p=0.04) and 
positively associated with IQ (p=0.01) and fluid 
intelligence (p=0.01).  
Edwards et al 
(2019).453 
Cross-sectional study investigating MPOD, 
body fat % (DXA) and event related brain 
potentials. 
 
101 adults with 
overweight and obesity 
(≥25 kg/m2). 
MPOD was not significantly associated with body fat % 
in this study (p>0.07). MPOD was associated with mean 
and peak amplitude (N2) (p<0.04) and latency (P3) 
(p<0.01) of neuroelectric indices. 
 
Abbreviations: MPOD, macular pigment optical density; MP, macular pigment; BMI, body mass index; CAREDS, carotenoids in age-related eye disease study; kg/m2 , kilogram 
per metre squared; WC, waist circumference; WHtR, waist-to-height ratio; WHpR, waist-to-hip ratio; TILDA, the Irish longitudinal study of aging; IQ, intelligence quotient; DXA, 
dual-energy X-ray absorptiometry. 
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6.4.4 Type 2 diabetes, MPOD and dyslipidaemia – the evidence 
Insulin resistance and obesity, metabolic abnormalities commonly associated with 
Type 2 diabetes, may themselves lead to disturbances in the production and clearance 
of plasma lipoproteins.158 Dyslipidaemia is often characterised by low levels of HDL 
and hypertriglyceridemia. In addition, LDL particles are converted to smaller, more 
atherogenic lipoproteins.160 A number of factors are likely to be responsible for 
diabetic dyslipidaemia and these include insulin’s effects on liver apoprotein 
production, dysregulation of LPL, impaired action of CETP and the peripheral action 
of insulin on adipose and muscle.158 Hormone sensitive lipase and LPL are two 
enzymes which regulate mobilisation and deposition of fatty acids in adipose tissue in 
a reciprocal manner.454 Reduced insulin action leads to increased lipolysis in 
adipocytes with increased FFA release, which can mediate many adverse metabolic 
effects, most notably further insulin resistance 446 and dyslipidaemia.158 In diabetes 
greater amounts of fatty acids returning to the liver are reassembled into TGs and 
secreted in VLDL.455 In the presence of increased concentrations of VLDL in 
circulation, CETP will exchange VLDL TGs for cholesteryl ester in the core of HDL, 
which results in smaller HDL particles, which are more rapidly cleared from 
plasma.456 This explains the hypertriglyceridemia and reduced HDL commonly 
observed in Type 2 diabetes.158 Cholesteryl ester transfer protein also exchanges 
VLDL triglyceride for cholesteryl ester in the core of LDL and the net effect is a 
decrease in the size and an increase in the density of LDL particles.158 In vitro, small 
dense LDL can be oxidised more easily, and it binds to LDL receptors less avidly, 
than normal LDL. As a result diabetic patients are at an increased risk of 
cardiovascular disease. Many clinicians measure LDL density and/or size to predict 
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risk of cardiovascular disease. An increase in waist circumference (WC) and waist-
height ratio (WHpR) has been found to be associated with small dense LDL 
particles.158, 457 Therefore, intra-abdominal fat is a critical determinant of an 
atherogenic lipoprotein profile, including disruptions in the distribution of cholesterol 
in the different lipoprotein fractions.443  
 
The characteristic lipid profile in an individual with Type 2 diabetes (increased plasma 
VLDL, increased TGs, decreased plasma HDL and less commonly, an increase in 
LDL-cholesterol),158 may have important implications for MP levels in the eye, as 
studies have shown that the carotenoids lutein and zeaxanthin are primarily 
transported by HDL in plasma.18, 19 High density lipoprotein is a known ligand for SR-
B1, and this suggests a “piggy back” mechanism of lutein and zeaxanthin uptake into 
the retina via RPE cells which is mediated by SR-B1.326 This hypothesis is supported 
by evidence from lutein deficiencies observed in the retina of chickens with a genetic 
HDL defect but not in other organs, implying a major role for HDL in the receptor-
mediated transport of lutein to the eye.18 It has been argued that the subspecies of HDL 
containing apolipoprotein E supplies lipids and lipid soluble lutein and zeaxanthin to 
the retina, and that by increasing HDL, retinal lutein levels may be simultaneously 
augmented.441  
 
Omega-3 long chain-PUFA supplementation may also lead to increases in plasma 
HDL.458 Recent epidemiological studies indicate that increased dietary long chain-
PUFA intakes enhance MPOD,459 and that DHA facilitates the accumulation of lutein 
in the blood and macula. The mechanism by which DHA increases MPOD may relate 
to its effect on the transport and uptake of lutein into the macula by mediating changes 
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in lipoprotein levels.460 Putatively, this effect could also be mediated by the anti-
inflammatory effects of DHA, but this is conjectural and no direct evidence supports 
this effect within the retina.  
 
One observational study found that the correlation between MPOD, plasma lutein, 
zeaxanthin and lipids differed depending on the age profile of participants.461 In 
younger adults, MPOD was found to be influenced by plasma lutein, whereas in older 
adults, circulating lipids were an added determining factor.461 Mares et al.,384 queried 
whether any association with plasma lipids is truly strong enough to play a meaningful 
role in the pathogenesis of MPOD depletion. One study which used a diabetic cohort, 
involving a small group of 43 participants (14 controls, 17 with diabetes but without 
retinopathy and 12 with diabetes and with mild non-proliferative retinopathy), found 
no significant correlation between MPOD and plasma lipid levels.6 Our own research 
group, however,7 reported lower levels of MPOD in Type 2 versus Type 1 diabetes 
and noted significantly lower HDL values within the Type 2 group, with raising the 
possibility that lower HDL levels may have contributed to this difference. More 
recently, the DiVFuSS study 21 has demonstrated significant improvements in plasma 
LDL cholesterol level (9% mean decrease in the intervention group vs 1% mean 
increase in placebo group); HDL cholesterol (7% mean increase in the intervention 
group vs 3% decrease in placebo group); and TGs (8.6% mean decrease in the 
intervention group vs 2% mean increase in placebo group), suggesting a positive effect 
of the study formulation on plasma lipids. Whilst this effect was likely attributable to 
other non-carotenoid components of the supplement, the synchronous increase in 
MPOD observed in the intervention group may have been partially mediated by these 
favourable changes in lipid profile and their consequential impact on carotenoid 
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transport to the retina.18, 19, 71 In the broader context, the evidence from this study is 
sufficiently robust to prompt further lines of investigation into the role of MP 
supplementation either in isolation or as a multi-component supplement in diabetes. 
The research to date, however, is not conclusive and it remains unclear from the 
limited amount of observational and RCT data, whether plasma lipids (primarily HDL) 
play a meaningful role in determining MPOD status. Given the theoretical basis for an 
association between lipid profile and MP status, and the fact that lipid profile is often 
altered deleteriously in diabetes, further investigation is warranted. The relationship 
between dyslipidaemia and lower levels of MP is outlined in Table 6.4. 
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Table 6.4: Summary of studies linking MPOD with plasma lipids. 
Author & Year Design Sample Results 
Mares et al (2006).384 Cross-sectional study on women. 
MPOD measured by HFP.   
Sub sample of women who 
participated in the CAREDS 
(N = 1698). 
Plasma lutein & zeaxanthin correlated with plasma 
cholesterol (r = 0.17) but adjustment for this did not affect 
the direct association between plasma levels and MPOD. 
Lima et al (2010).6   
 
Cross-sectional study with 3 test 
groups: non-diabetic controls, 
diabetic participants without 
retinopathy & diabetic 
participants with retinopathy.  
43 Type 2 diabetes participants 
with and without retinopathy 
matched to controls. 
No significant associations were observed with lipid 
levels and MP (p = 0.08). 
Loane et al (2010).71 Cross-sectional study on healthy 
men & women, without ocular 
disease, aged between 20 -70 
years. 
Total no of subjects: N=302. 
N= 181 with negative family 
history of AMD;  
N=121 with positive family 
history of AMD. 
A significant and positive association between plasma 
HDL and plasma concentrations of lutein. A significant 
inverse association between plasma TG concentration and 
both plasma lutein concentration and MPOD in those 
with a positive family history of AMD. 
Renzi et al (2012).462 Cross-sectional study on young 
healthy subjects. MPOD 
measured by HFP.   
Relations between plasma 
lutein & zeaxanthin, MPOD 
and lipoprotein levels (N=108). 
HDL were significantly (p < 0.05) related to MPOD (r = 
0.33), to plasma lutein (r = 0.36) and to plasma 
zeaxanthin (r = 0.26). MPOD was also significantly 





Cross-sectional study assessing 
plasma concentrations and intake 
of lutein and zeaxanthin and 
MPOD using HFP. 
Healthy men and women aged 
(20-35 and 45 -65 years) (N = 
108). 
MP only correlated with plasma lutein & zeaxanthin 
when expressed in terms of cholesterol + TGs (p = 0.012) 
or LDL (p = 0.017). In the older group relationships were 
also seen with LDL (p = 0.002) and HDL (p =0.004). 
Nagai et al (2015).463 Cross-sectional study assessing 
plasma concentrations of 
carotenoids and lipoproteins. 
MPOD was measured using HFP. 
55 healthy volunteers (110 
eyes) aged 23-53 years. 
MPOD was positively correlated with plasma 
concentrations of lutein (p=0.00001), zeaxanthin 
(p=0.0005) and dietary lutein intake (p=0.002). Plasma 
oxidised LDL was inversely correlated with MPOD (p = 
0.006), after adjusting for age, sex, and plasma lutein.  
Chous et al (2015).21 DiVFuSS RCT:  Type 1 and Type 
2 diabetes with no diabetic 
retinopathy or mild to moderate 
non-proliferative diabetic 
retinopathy versus placebo.  
Intervention group received 2 
daily doses of a xanthophyll, 
antioxidant and plant extract 
supplement.  
Total group (N=67); Type 1 
(N=27); Type 2 (N=40). 
Intervention DiVFuSS 
supplement (N=39); Type 1 
(N=16); Type 2 (N=23). 
Placebo (N=28); Type 1 
(N=11); Type 2 (N=17). 
Significant improvement in MPOD (p values: 0.008 to 
<0.0001) and visual function on all measures (p values: 
0.008 to <0.0001); Mean LDL, HDL and TG levels 
within the intervention group at 6 months were -9%, 
+7%, -8.6% respectively versus  +1%, -3%, -2% 
respectively in the placebo group. 
 
Abbreviations: MPOD, macular pigment optical density; HFP, heterochromatic flicker photometry; CAREDS, carotenoids in age related eye disease study; MP, macular pigment; 
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AMD, age-related macular degeneration; TG, triglyceride; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; DiVFuSS, the diabetic visual and 
function supplementation study; RCT, randomised control trial.
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6.5 Causal mechanisms and metabolic perturbations associated with lower 
macular pigment in diabetes 
The candidate causal mechanisms explored herein as contributors to lower MPOD 
levels in diabetes relate primarily to Type 2 diabetes (or poorly controlled Type 1). 
The complex inter-relationship between oxidative stress/inflammation and the 
metabolic correlates of diabetes (adiposity, dyslipidaemia, insulin resistance, 
hyperinsulinemia and hyperglycaemia); and their associations with MPOD, both 
individually and as a whole, represent a significant scientific challenge. In summary, 
our analysis indicates that MPOD might be depleted through at least four causal 















Figure 6.2: Metabolic perturbations and supply deficiencies contributing to MP 
depletion in diabetes.  
Abbreviations: MPOD, macular pigment optical density; ROS, reactive oxygen 
species. 
6.5.1 Dietary determinants of MPOD in diabetes 
First and foremost, patients with Type 2 diabetes may experience lower levels of MP 
as a result of poor dietary intake of antioxidant nutrients (lutein, zeaxanthin and meso-
zeaxanthin). Lutein and zeaxanthin are not synthesised de novo in humans, therefore, 
a diet rich in fruit and vegetables is necessary to enhance MP levels in the eye.22 While 
the exact cause of diabetes is still not fully understood, dietary factors have garnered 
particular attention over the last number of years. In fact, some research indicates that 
up to 74% of Type 2 diabetes cases are directly attributable to obesity.464  
 
Many studies have reported a positive association between a high intake of sugars and 
the development of Type 2 diabetes.465-467 Research has also found an association 
between high fat intakes and Type 2 diabetes and impaired glucose tolerance,468, 469 
with some literature suggesting that high-fat, low-carbohydrate diets are associated 
with the onset of Type 2 diabetes.468 A global change in dietary intake has occurred 
over recent decades resulting from an increased use of sweeteners such as fructose and 
sucrose by the food industry.470 Recent evidence suggests a causal link between the 
high intake of sugar-sweetened soft drinks and obesity and diabetes. This is thought 
to arise from the large amount of fructose in these soft drinks, which impairs insulin 
sensitivity and raises blood glucose levels and BMI to dangerous levels.466, 471 Fructose 
consumption increases postprandial TG concentrations within hours,472 which 
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suggests that postprandial hypertriglyceridaemia is one of the earliest metabolic 
perturbations associated with fructose consumption. The most likely mechanism for 
this hypertriglyceridaemia is increased hepatic de-novo lipogenesis, which in turn 
upregulates VLDL production and secretion,473 factors which have a knock on 
suppressive effect on HDL, a known transporter of carotenoids to the eye.18, 19  
 
Studies have also found an inverse correlation between the intake of green leafy 
vegetables and risk of developing Type 2 diabetes; 214, 474 and that the consumption of 
fruits and vegetables may protect against the development of Type 2 diabetes, as they 
are rich in micronutrients, fibre and antioxidants,474 dietary components also known 
to enhance MPOD. A recent meta-analysis revealed that a higher intake of fruit, 
especially berries and green leafy vegetables, yellow vegetables and cruciferous 
vegetables or their fibre, is associated with a lower risk of Type 2 diabetes.214 Health 
benefits have also been observed with the Mediterranean diet,475, 476 a diet which 
contains an abundance of fruit and vegetables. While, the beneficial effects of fruits 
and vegetables on diabetes risk are likely to be multiple, these foods are the primary 
dietary source of carotenoids including lutein and zeaxanthin, highlighting their 
consumption as a key determinant of MPOD. Lower levels of MPOD in diabetes, 
might also be associated with high intakes of fried foods and fat,477 alcohol,478 red and 
processed meat,479 sugar-sweetened beverages,465, 466 and high glycaemic index 
foods,480 all of which have been linked with  higher levels of visceral fat and increased 
WC. Numerous studies have shown that obesity (in particular, central obesity) can 
increase the risk of Type 2 diabetes.481 
 
While the body’s natural defence against oxidative damage and inflammation is 
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neutralisation by endogenous antioxidants (enzymatic & non enzymatic), in 
association with exogenous antioxidants (vitamin C, vitamin E, carotenoids, β-
carotene, lutein, zeaxanthin and meso-zeaxanthin),177, 419 these antioxidant defences 
may be compromised in diabetes. Hence, it is clear that both over utilisation and under 
supply of antioxidant nutrients may contribute to lower levels of MP in the diabetic 
retina.  
 
Based on the outlined associations between nutritional and dietary factors and the 
components of the metabolic syndrome which may contribute to MPOD depletion, we 
outline dietary factors which: 1) may exacerbate the metabolic correlates associated 
with Type 2 diabetes (Table 6.5 a) and 2) may help to prevent or resolve the metabolic 
perturbations associated with Type 2 diabetes (Table 6.5 b).  
 
Overall, western dietary habits are a significant factor in the development of the 
metabolic syndrome. The continuous over-provision of energy via dietary 
carbohydrate and lipid, when unmatched by physical activity-induced energy 
expenditure, leads to a state of excess adiposity, chronic low grade inflammation, and 
oxidative stress and dyslipidaemia; features associated with Type 2 diabetes and which 
may lead to MPOD depletion.  
 
The importance of diet cannot be overemphasised in diabetes management. Given the 
variety of mechanisms which may contribute to MPOD depletion and the broader 
ocular risks associated with such MPOD depletion in diabetes, a comprehensive 
dietary approach is therefore necessary to optimise ocular health and MPOD status. 
The generous provision of brightly coloured fruits and vegetables which are rich in a 
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broad range of antioxidants including the target carotenoids lutein, zeaxanthin and 
meso-zeaxanthin represents an obvious recommendation. This, however, should be 
complimented by the inclusion of wholegrain fortified breakfast cereals for their 
folate, vitamin D and anti-obesogenic fibre content; and with plenty of oily fish to 
provide further vitamin D and omega-3 essential fatty acids to attenuate inflammation 
and correct or prevent hypertriglyceridaemia. These foods should be used to displace 
those which are high in fat, saturated fat, refined sugar and fructose; for example oily 
fish should replace red or processed meats at several main meals each week, fruit or 
raw vegetables should be used to replace snack foods high in fat, saturated fat, trans- 
fat and refined sugar (e.g. baked goods and confectionery); and low fat fortified milk 
should replace sugar-sweetened soft drinks. Starchy carbohydrates should be evenly 
distributed over the day to achieve better glycaemic control, with sterol or stanol 
enriched products used to reduce plasma LDL and consequently enhance LDL: HDL 
ratio. Finally, from a broader lifestyle perspective, these individuals should be advised 
to moderate their alcohol consumption to no more than two standard drinks per day 
with several alcohol-free days each week, and to engage in moderate intensity exercise 
(e.g. walking) on most days of the week to enhance their insulin sensitivity and 
optimise their blood glucose and lipoprotein profiles. Table 6.5 a. outlines the dietary 
factors causally associated with the metabolic correlates of Type 2 diabetes, and Table 
6.5 b. outlines the dietary factors associated with protection against the metabolic 
perturbations of Type 2 diabetes.
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Table 6.5: Dietary factors associated with the metabolic correlates of Type 2 diabetes. 
Metabolic correlates 
of Type 2 diabetes. 
a. Causal dietary factors associated with the 
metabolic correlates of Type 2 diabetes. 
b. Preventative dietary factors associated with the 
metabolic correlates of Type 2 diabetes. 
Oxidative Stress High protein (red meat),479 high fat (saturated fat).482, 
483 
High carbohydrate (refined sugar, fructose).465, 466, 484 
Whole grains (fibre),485 nuts (fibre, omega-3 PUFA).486 
Fruit and vegetables (antioxidants vitamin C & E, β carotene, 
lycopene, quercetin, resveratrol, flavonoids, lutein, zeaxanthin & 
meso-zeaxanthin). 5, 15, 21, 22, 214, 250, 259, 474, 476, 487, 488 
Fish (omega-3 PUFA),489   legumes (protein, phytochemicals).490 
Inflammation High fat (saturated fat, trans fat).491-493  
High carbohydrate (refined sugar, fructose).484, 494, 495  
Alcohol.496 
Oily fish and omega-3 FAs,489 folate,497 vitamin D.498  
Fruit & Vegetables (antioxidants vitamin C & E, β carotene, 
lycopene, quercetin, resveratrol, flavonoids, lutein, zeaxanthin & 
meso-zeaxanthin).377, 487 
Obesity Excessive energy consumption.499 
High fat (saturated).500-503 
High carbohydrate (refined sugar, fructose).465, 466 
Diet & exercise,504 high dietary fibre.505 
High fruit and vegetable (antioxidants vitamin C & E, β carotene, 
lycopene, quercetin, resveratrol, flavonoids, lutein, zeaxanthin & 
meso-zeaxanthin),487 high milk intake.506 
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Dyslipidaemia High fat (saturated fat, trans fat),507-509 high 
carbohydrate (refined sugar, fructose),510, 511 
Sodium,510 alcohol (especially binges),512 low physical 
activity.513 
High dietary fibre,505 omega-3 FAs,514, 515 
plant stanols/sterols,516 physical activity.458, 513 
 




It is important to note the significant limitations which currently prevail in the 
reviewed literature. The heterogeneity of studies is a major drawback. Small sample 
sizes, the merging of Type 1 and Type 2 diabetes patients in statistical analyses, 
and the complex interplay of diabetes and its accessory factors (adiposity, 
dyslipidaemia, oxidative stress and inflammation) with MPOD status are also 
challenging. While there is some preliminary positive evidence, primarily from 
animal studies 14, 20 and the DiVFuSS trial,21 that higher MP levels may be 
protective against retinal damage, there is limited evidence that low MPOD levels 
are detrimental to ocular health in diabetes, and the actual benefits of higher MPOD 
in terms of retinal disease development and/or progression in diabetes remain to be 
elucidated. 
6.7 Conclusion 
This review outlines our present understanding of the relationship between diabetes 
and MPOD. Macular pigment appears to be generally lower in diabetic populations 
compared to healthy controls,6 and this is noted particularly amongst patients with 
Type 2 diabetes.7 Impaired defence against ROS at the retina may not only be 
attributable to lower intake of foods rich in carotenoids and other antioxidants (e.g. 
fruit, vegetables, legumes) however, but may also arise from the increased 
utilisation of these antioxidants in diabetes (via chronic inflammation and oxidative 
stress). Adiposity, particularly abdominal fatness, is closely linked to Type 2 
diabetes, and is a significant factor in the condition’s pathogenesis. Excess fat tissue 
may not only compete with the retina for uptake of dietary carotenoids, but may 
also contribute to increased oxidative stress and inflammation, factors which may 
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negatively impact MP levels in the eye. Similarly, the hyperglycaemia which is 
characteristic of diabetes, also contributes to inflammation and oxidative stress, and 
their depletive effects on MPOD. Dyslipidaemia, more common in poorly 
controlled diabetes, is a metabolic correlate which may adversely affect the 
transport and assimilation of carotenoids into retinal tissue, by limiting the 
availability of their principal carrier HDL. The chronic low-grade inflammation and 
increased oxidative stress observed in patients with Type 2 diabetes may also 
increase the use of these carotenoids at the molecular level, and in so doing, may 
elevate our dietary requirement for them.  
 
In view of the limited evidence available, supplementation with lutein, zeaxanthin, 
and/or meso-zeaxanthin, either with or without other antioxidants, represents a 
fertile area for future interventional research. It is important to recognise, however, 
that in order to minimise the risk of MPOD depletion and/or ocular damage in 
diabetes, it is not sufficient to simply supplement with macular carotenoids. Rather, 
our review suggests the need for a more holistic evaluation of diet and lifestyle in 
relation to MPOD in diabetes. In this context, inflammation and oxidative stress, 
the dual pathogenic driving forces of diabetes which occur independent of 
hyperglycaemia, may be amenable to dietary intervention and nutritional 
supplementation. The incorporation of a number of dietary modifications (e.g. 
enhanced antioxidant, vitamin D and omega-3 fatty acid intake; and reduced fat, 
saturated fat, trans- fat and refined sugar consumption); alongside lifestyle changes 
such as increased physical activity; may not only address the under-supply of 
macular carotenoids, but may also abrogate the competitive storage, transport, 
inflammatory and oxidative features of Type 2 diabetes, which may compromise 
183 
 
MPOD status. The safety and low cost of such interventions further commend their 
potential value as a therapeutic adjunct in diabetic eye disease, and may come to 

























7. IDENTIFICATION OF SURROGATE BIOMARKERS FOR THE 
PREDICTION OF PATIENTS AT RISK OF LOW MACULAR 
PIGMENT IN TYPE 2 DIABETES. 
7.1 Abstract 
Purpose  
This cross-sectional study compared MP levels among persons with Type 2 
diabetes relative to healthy controls. Additionally, a range of behavioural, 
anthropometric, clinical and plasma measures were explored as possible predictors 
of low MPOD in diabetes.  
Methods  
Two health status groups; Group 1: Type 2 diabetes (n=188), and Group 2: Healthy 
controls (n=2,594) completed a full MP assessment using c-HFP, as part of TILDA. 
Clinical [blood pressure; cataract status; MPOD] and anthropometric [waist (cm); 
weight (kg); hip (cm)] measurements were taken, and a blood sample drawn for 
analysis of plasma biomarkers [lipoproteins; inflammatory markers (CRP and 
vitamin-D)].  
Results 
One-way analysis of variance revealed lower MPOD in subjects with Type 2 
diabetes relative to controls (p=0.047). Amongst participants with diabetes, those 
with low plasma vitamin D (≤50 nmol/L) had significantly lower mean MPOD 
compared to those with sufficient plasma vitamin D levels (>50 nmol/L) 
(0.173(0.148) vs. 0.226(0.145); p=0.006). Concomitantly, MP was significantly 
lower in diabetes participants with raised plasma TG over HDL lipoprotein ratio 
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(TG/HDL); values >1.74 mmol/L (0.172 (0.140) vs 0.215 (0.152); p=0.039). 
Macular pigment was also significantly lower in diabetes participants with 
hypertension (>140/90 mmHg); (0.177(0.130) vs 0.228(0.166); p=0.043). Body 
mass index, WHtR, and WC were all significantly negatively correlated with 
MPOD (Pearson’s correlation, p<0.05 for all). Significant correlates of MPOD in 
the multivariate regression model included smoking, cataract, and vitamin D, which 
collectively contributed 18.5% of the overall variability in MPOD status amongst 
participants with Type 2 diabetes.  
Conclusions 
This study provides additional evidence that low MP may indeed be a feature of 
Type 2 diabetes and further identifies smoking, cataract, and vitamin D status as 
















The prevalence of diabetes has been increasing steadily over recent decades and is 
now reaching epidemic proportions.517 Type 1 and Type 2 diabetes are the two main 
forms of diabetes, however, Type 2 diabetes is much more common and is estimated 
to affect more than 500 million people worldwide.518 Diabetic retinopathy, a 
debilitating microvascular complication of diabetes, is the most common cause of 
vision loss in people with diabetes and is a leading global cause of vision 
impairment and blindness among working-age adults.26  
 
The pathogenesis of diabetic retinopathy is multifactorial and remains poorly 
understood. Chronic hyperglycaemia induces oxidative stress in the retina,355 and it 
is thought that hyperglycaemia causes tissue damage through a number of major 
pathways, including the polyol pathway, activation of PKC, upregulation of AGE 
product formation and activity of the hexosamine pathway.412 Interaction of these 
biochemical pathways may cause a cascade of events, such as apoptosis, oxidative 
stress, inflammation, and angiogenesis, which can lead to damage of the diabetic 
retina, as reviewed by Al-Kharashi.519 It is thought that hyperglycaemia leads to a 
dysregulation of inflammation, which in turn leads to an increase in the level of 
pro-inflammatory proteins.372  
 
Inflammatory processes underlie many of the functional retinal vasculature 
alterations observed histologically in early diabetic retinopathy.194 Animal and 
human studies have confirmed that all retinal cell types, including inner retinal 
neurons, Muller cells, and astrocytes, are damaged by diabetes.204 Recognising both 
the clinical and histological aspects of retinal change in diabetic macular oedema 
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and diabetic retinopathy is essential to understanding the mechanisms of vision loss 
in diabetes, and in developing early-stage clinical interventions that effectively 
target the specific aetiologies and underlying pathological mechanisms of the 
condition. In fact, insulin resistance, impaired glucose tolerance, and Type 2 
diabetes may exist for many years before clinical retinal signs become evident.520 
 
The body’s natural defence against oxidative damage and inflammation is the 
neutralisation of ROS with endogenous antioxidants, both enzymatic and non-
enzymatic.401 These endogenous antioxidants work with exogenous antioxidants 
(vitamin C, vitamin E, and carotenoids such as β-carotene, lutein, zeaxanthin, and 
meso-zeaxanthin),177 together balancing redox status. The carotenoids, lutein, 
zeaxanthin, and meso-zeaxanthin, collectively known in the eye as MP; confer 
potent antioxidant and anti-inflammatory effects at the macula.5,283 These 
carotenoids are uniquely concentrated in the inner and central layers of the primate 
macula, and while there have been numerous studies looking at the role of 
carotenoids and other nutrients in the prevention of AMD, reviewed elsewhere,226 
the association between diabetes and MPOD levels, however, has received 
somewhat less attention. 
 
The evidence that does exist, however, suggests that the relationship is worth 
exploring in more detail. Plasma concentrations of lutein and zeaxanthin have been 
observed to be significantly lower in patients with diabetic retinopathy.15 
Furthermore, MP has been found to be significantly lower in patients with diabetes,6 
with one study reporting lower levels of MP in Type 2 versus Type 1 patients.7 It is 
also possible that MP may confer therapeutic benefits in diabetic eye disease. A 
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number of studies have explored the effect of MP supplementation in diabetes. 
Although the evidence is far from definitive, improvements in structural and 
functional measures of ocular health in response to macular carotenoid 
supplementation have been found. The earliest of these studies reported 
improvements in vision and macular oedema following supplementation.15 The 
DiVFuSS study suggested that a nutritional supplement containing lutein and 
zeaxanthin mitigated the damaging effects of systemic inflammation on ocular 
function and that these beneficial effects may have been mediated by enhancements 
in MPOD.21 Improvements in visual function have also been observed in patients 
with diabetes following supplementation, including in contrast sensitivity 521 and in 
electrophysiological indices of retinal function.387  
 
The reasons why MPOD levels might be adversely affected in diabetes are yet to 
be elucidated, but a number of factors might be important. At presentation, Type 2 
diabetes is most often accompanied by other co-morbidities including 
overweight/obesity, insulin resistance, hypertension and dyslipidaemia,522 which 
may adversely affect MP by compromising the availability,54 transport,18 
assimilation,18 and maintenance/retention of dietary carotenoids in the retina. De 
novo synthesis of carotenoids is not possible in humans, therefore, the chronic low-
grade inflammation,372 and pro-oxidative environment,355 associated with Type 2 
diabetes may negatively impact MPOD levels in the eye.  
 
Macular pigment levels can be measured in vivo, but are not routinely measured in 
clinical practice. Given the possibility that higher levels of MP may be beneficial 
for vision and ocular health in diabetes, the investigation of surrogate indicators of 
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MP status that are more readily and routinely measured is merited. The capacity of 
such an alternate biomarker to expedite the identification and treatment of patients 
at risk of low MP could be particularly important given that retinal damage can 
occur long before visual signs of diabetic retinopathy are evident. This study was 
designed, therefore, to compare MPOD in participants with and without Type 2 
diabetes and, more importantly, to explore a range of behavioural, anthropometric, 
clinical and plasma biomarkers as possible predictors of risk for low MPOD among 
individuals with Type 2 diabetes. 
7.3 Methods 
Study population 
The Irish Longitudinal Study on Ageing is a large prospective cohort 
study examining the social, economic and health factors which influence healthy 
ageing in older adults resident in Ireland.523 Cross-sectional data from TILDA was 
analysed in this study. A stratified clustered sample of 8,175 individuals, 
representative of the population of Ireland, aged 50 years and over, participated in 
Wave 1 of this study, which took place between October 2009 and July 2011. The 
study design of TILDA has been described in detail elsewhere.523, 524 Health and 
lifestyle data were captured in participants’ own homes using computerised aided 
personal interview (CAPI).525, 526 The presence or absence of eye pathology was 
determined using the CAPI with the question ‘’has a doctor ever told you if you had 
any of the following conditions: diabetes, AMD, cataracts or glaucoma’’. 
Participants were also asked whether they had ever been told by a doctor if they had 
high cholesterol or high blood pressure. Participants were asked to record all 
medications that they took on a regular basis, including those related to diabetes, 
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such as oral hypoglycaemic agents and/or insulin, which were coded using the 
Anatomic Therapeutic Classification (ATC) system. Participants were asked if they 
currently smoked or had ever smoked cigarettes regularly (daily for at least a year), 
and were categorised as never smoked, past smokers or current smokers. The 
International Physical Activity Questionnaire was used to classify participants’ 
level of physical activity into low, moderate or high levels. All participants were 
invited to attend a health assessment in one of two locations, Dublin or Cork. 
Macular pigment measurement was only conducted on participants who attended a 
health centre, therefore, a number of participants were automatically excluded from 
the current analysis: i.e. if they were unable to travel to a health centre or opted for 
a home assessment instead (n=875) and/or refrained from having either a home or 
health assessment (n=2,025). A total of 5,275 individuals participated in a health 
assessment, carried out by trained research nurses (Figure 7.1). This research 
adhered to the tenets of the Declaration of Helsinki and was approved by the 
Technological University Dublin Research Ethics Committee. All participants 
provided written informed consent prior to participation in the study. 
Diabetes classification 
Diabetes type was classified into ‘no diabetes’, ‘pre-diabetes’, ‘diagnosed diabetes’ 
and ‘undiagnosed diabetes’. Diagnosed diabetes was identified from the CAPI with 
the question ‘has a doctor ever told you that you have diabetes or high blood sugar?’ 
and also from prescribed diabetes medications at the time of the interview, 
identified using the ATC codes ‘A10A’ for insulin and ‘A10B’ for oral 
hypoglycaemic medications. A blood sample was provided for plasma analysis. 
Glycated haemoglobin, a long-term indicator of glycaemic control, was measured 
and participants were further classified as having ‘pre-diabetes,’ and ‘undiagnosed 
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diabetes’ against American Diabetes Association cut-off values.24 The TILDA 
protocol for blood sample collection, processing and storage has been described 
previously.525 Eleven respondents who reported a doctor’s diagnosis of diabetes 
before the age of 40 and who were on insulin therapy at the time of interview were 
excluded from analysis due to the suspicion that they might have Type 1 diabetes, 
in line with previously published data 130 (Figure 7.1). Duration of disease was 
quantified by asking those with a previous diagnosis ‘how old they were when first 
diagnosed?’  
Macular pigment optical density assessment 
Corrected VA was measured in both eyes using the ETDRS LogMAR chart at a 
distance of 4 metres, using the participant’s existing prescription where necessary. 
The eye with the best VA was chosen for the MP assessment or if there was equal 
vision in both eyes, the right eye was chosen. The MPOD was measured by HFP 
centrally at 0.5° of retinal eccentricity using the Macular Metrics Densitometer 
(Macular Metrics, Rehoboth, MA). This device was modified specifically for the 
TILDA study from a device originally described by Wooten et al.334 The established 
method employed for measuring MP has been described in detail previously.56 In 
brief, the subject viewed a stimulus that alternated between a wavelength which is 
absorbed by MP and one that is not. To account for the fact that participants may 
have different temporal (i.e. flicker) rates, the HFP task was customised for each 
subject, according to their age.335 If a fixed flicker frequency was used instead then 
a subject with a low flicker sensitivity (i.e. low critical flicker fusion frequency) 
would experience a large null flicker zone. While this does not prevent the test from 
being completed, it could lead to an over or underestimation of MPOD. Conversely, 
a subject with a high critical flicker fusion frequency may not be able to eliminate 
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flicker and this would make the test more difficult to complete. A ‘bracketing’ 
protocol was adapted in the TILDA study to allow quick but accurate customised 
MPOD measurements to be obtained, both centrally at 50 and peripherally at 70.56  
The examiner pre-set the radiance dial, either at the lowest blue light intensity 
(ascending measurement) or the highest blue light intensity (descending 
measurement), and a total of 6 measurements were taken. In other words, the 
examiner pushed a button that alternated the blue/green ratio until the subject 
reported no flicker or that flicker had started. The radiance value obtained was 
recorded for the 6 measurements in the MPOD log form (central measurement 
where MP peaks). The examiner then selected the target and fixation point required 
to measure MPOD at 7° retinal eccentricity (parafoveal target at 7°), where MP is 
optically undetectable, and another 6 measurements were taken. All radiance values 
obtained (12 in total) were used to calculate MPOD by taking the log ratio of MP 
peripherally (7 0 ) from the log ratio of MP centrally (0.50 ) and in this way the 
MPOD value at 0.5° was generated for that subject. Of the 5,275 participants who 
attended a health assessment, 2,782 were deemed suitable for the current analysis 
and successfully completed an MPOD assessment (participants with diabetes, 
n=188; non-diabetic controls, n=2,594). A number of subjects were excluded from 
the overall MPOD analysis (n=2,493) and possible reasons for this included: poor 
fixation, technical issues, poor VA (VA 6/18 Snellen (≤ 0.5 LogMAR)) and retinal 
pathology (AMD, glaucoma). Because Type 1 and 2 diabetes are considered 
different clinical conditions, the presenting features of the condition (adiposity, 
dyslipidaemia, oxidative stress, and inflammation) may not be uniform across both 
and may have different relationships with MPOD, therefore, a number of 
participants with suspect Type 1 diabetes (n=11), were excluded from the current 
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study. Participants with pre-diabetes (HbA1c: 5.7 - 6.4%) were also excluded from 
the current analysis (n=111). Of the 8,500 participants that took part in Wave 1 of 
TILDA, 188 Type 2 diabetes participants and 2,594 controls were deemed suitable 
for the study (Figure 7.1). 
 
 
Figure 7.1: Flowchart illustrating the selection of study participants and reasons 
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for exclusion from the original participant group. 
Abbreviations: AMD, age-related macular degeneration; MPOD, macular pigment 
optical density, n, number of participants; TILDA, The Irish Longitudinal Study on 
Ageing; VA, Visual Acuity. 
Anthropometric assessment 
Height (cm) and weight (kg) were measured to one decimal place as described in 
detail elsewhere.525 Body mass index was calculated from measured height and 
weight as: weight (kg)/height (m2). Waist circumference and hip were measured to 
the nearest cm. Waist-to-height ratio and WHpR were calculated based on these 
measured data. Cut-offs were applied to classify participants as obese or non-obese 
for the following variables (BMI; WC; WHtR, and WHpR).527  
Blood pressure 
Two blood pressure (BP) measurements were taken using the OMRONTM digital 
automatic BP monitor (Model M10-IT) with arm cuff.525 Seated mean systolic 
(mmHg) and mean diastolic (mmHg) BP were used for analysis. The participant 
was defined as hypertensive if mean seated systolic BP exceeded 140 mmHg or 
mean seated diastolic BP exceeded 90 mmHg. 
Plasma analysis 
Respondents were not asked to fast before the health assessment. Blood was 
extracted using defined phlebotomy protocols,525 and analysed for a complete lipid 
profile, which included TC, HDL, LDL, and TGs, measured in mmol/L. 
Triglyceride over HDL ratio (TG/HDL), TC/HDL ratio and non-HDL cholesterol 
(TC minus HDL) were calculated for subsequent analyses. Cut-offs were applied 
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to indicate high or ideal plasma lipid levels as per 2016 European Society of 
Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines.528 Research 
suggests that inflammation plays a role in the development of Type 2 diabetes,10, 529 
therefore, anti-inflammatory marker plasma vitamin D [(25(OH)D); nanomoles per 
litre (nmol/L)] and inflammatory marker CRP, [micrograms per litre (μg/l)] were 
also measured. Respondents were considered vitamin D deficient if plasma levels 
were ≤50 nmol/L, and sufficient if plasma levels were >50 nmol/L as per the 
Institute of Medicine (IOM) vitamin D guidelines.530 A threshold of >3.00 μg/l for 
high and ≤ 3.00 μg/l as ideal was used for plasma CRP.531  
Statistical analysis 
The statistical software package SPSS for Microsoft Windows (version 23.0; IBM 
Corp., Armonk, NY) was used for all analyses. To account for the fact that the study 
response rate varied among different subgroups of the population, inverse 
probability weights were calculated for the main sample using the Quarterly 
National Household Survey (2010).532 Participation rates for the health centre 
assessment also varied according to geographic location, health, education, age, and 
smoking, therefore, a specific “health centre weighting” was applied. A more 
detailed description of the weighting procedure used in TILDA is described by 
Barrett et al.532 
 
Our data are presented as mean ± standard deviation throughout. These data were 
tested for normality using the Kolmogorov-Smirnov test. For group comparison 
between participants with diabetes and non-diabetic controls, ANOVA was used to 
test for differences in means for normally distributed parameters, while the Kruskal-
Wallis test was used to test differences between group medians for non-normally 
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distributed parameters. For categorical data, cross-tabulation with Chi-square 
analysis was used. The distribution of MPOD was skewed, therefore, a square root 
transformation of the MPOD data was performed (Figure 7.2 and 7.3). The derived 
data were normally distributed and used as the dependent variable for subsequent 
statistical analyses of MPOD on the diabetes group. For ease of interpretation, mean 
and SD of MPOD data is presented as the non-transformed original measure for 
Type 2 diabetes participants. Pearson’s product-moment correlation tests were 
performed to assess the relationship between normalised MPOD and other study 
variables where appropriate. Boxplots and scatterplots were used to graphically 
highlight statistical findings. Multiple linear regression was used to investigate the 
un-confounded associations between behavioural, anthropometric, clinical and 
plasma biomarker indicators and normalised MPOD. The level of statistical 





Figure 7.2: Distribution of MPOD as normal optical density value with data 




Figure 7.3: Distribution of MPOD using a square root transformation now 
normally distributed [Mean = 0.437; Std. Dev = 0.175; N=2,872]. 
7.4 Results 
Two thousand seven hundred and eighty-two subjects, analysed as part of Wave 1 
of TILDA, were divided into two study groups: Group 1: Non-diabetic controls 
(n=2,594) and Group 2: Type 2 diabetes (n=188). Respondents ‘diagnosed with 
diabetes’ and those with ‘undiagnosed diabetes’ were grouped together and 
classified as having Type 2 diabetes for subsequent analyses. Characteristics of the 
study population according to their diabetes status are presented in Table 7.1. Group 
average MPOD was 10.3% lower in participants with Type 2 diabetes [mean 
MPOD =0.20 (0.148)] compared with non-diabetic controls [mean MPOD = 0.223 
(0.161)], and this difference was statistically significant [t (2780) = -1.989, 
p=0.047)]. Participants with Type 2 diabetes also differed from the control group 
across all other demographic, behavioural, anthropometric, clinical and plasma 
parameters examined (p<0.0001 for all), with the exception of education (primary, 
secondary or third level), alcohol intake, and plasma TC/HDL ratio (p>0.05 for 
these variables; Table 7.1). 
 
Participants with diabetes were older, and more likely to be male with a current or 
past history of tobacco use. In general terms, the behavioural, clinical and 
anthropometric profile of these participants was poorer than that observed in the 
control group, with lower levels of physical activity, greater levels of obesity and 
higher prevalence of hypertension and cataract. Similarly, plasma analysis revealed 
that participants with diabetes were typically more hyperglycaemic, more 
dyslipidaemic and displayed lower anti-inflammatory marker elevation (plasma 
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Table 7.1: Characteristics of the study population according to diabetic status. 
          Variable Normal Controls 
(n=2594) 
Type 2 Diabetes 
(n=188) 
p 
Demographic Factors    
Age years (Mean (SD)) 
Age category years † (%) 
                          50-64 
                          65-74 















                               Male 










                               Primary 
                               Secondary 











Behavioural Factors    
Smoking (%) 
                                Current 











                                Never 47.22% 37.23% 
Alcohol (%) 
                                Yes 
                                 No 












                                 Low 
                                 Moderate 












Anthropometric & Clinical Biomarkers 



























MPOD** (Mean (SD)) 0.223 (0.161) 0.20 (0.148) 0.047†† 
Cataracts (%) 6.51% 13.83% 0.0001‡ 
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TC/HDL Cholesterol Ratio 
TG/HDL Cholesterol Ratio 






















Vitamin D (nmol/L) 59.91 (25.86) 51.90 (22.72) 0.0001* 
CRP (μg/l) 2.83 (6.95) 5.23 (11.94) 0.0001* 
HbA1c (%) 5.06 (0.27) 6.22 (0.934) 0.0001* 
 
‡ Chi-square test; *Kruskal–Wallis test; ††One-way analysis of variance (ANOVA);  
MPOD sqrt; P values reflect the probability associated with the given F statistic. Sig., significance.  
†Age: the age division corresponds to groupings used in previously published cohort studies.52 
**MPOD, P values are reported using MPOD square root transformation (sqrt).  
Abbreviations: BMI-body mass index; kg/m2- kilograms per metre squared; NA – non-applicable; WC-waist circumference; cm - centimetres; WHtR-waist-to-height 
ratio; WHpR-waist-to-hip ratio. HbA1c-glycated haemoglobin; TC-Total cholesterol; HDL-High-density lipoprotein; LDL-Low-density lipoprotein; TG-
Triglycerides; Non HDL- Total cholesterol minus HDL; CRP-C-reactive protein; mmHg- millimetres of mercury; mmol/L -millimoles per litre; nmol/L -nanomols 
per litre; μg/l-micrograms per litre. Normotensive (≤140 mmHg systolic; ≤90 mmHg diastolic); Hypertensive (>140 mmHg systolic; >90 mmHg diastolic).
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Biomarker associations with MPOD among participants with diabetes 
(1) Demographic and behavioural factors  
Smoking was the only demographic or behavioural factor significantly associated 
with lower MPOD (F (2,185) = 6.019, p = 0.003). Post hoc analysis revealed that 
participants who never smoked had significantly higher normalised MPOD 
(mean=0.235(0.148)) compared with current smokers (mean=0.124(0.113); t (96); 
= 3.58, p=0.001). There was also a significant difference in MPOD between past 
(mean=0.19[0.151] and current smokers (t (116); = 2.268, p=0.025). However, 
there was no significant difference in MPOD between non-smokers and past 
smokers (t (158) = 1.723, p=0.087); [Figure 7.4 (A)]. 
(2) Anthropometric and clinical biomarkers 
MPOD was negatively correlated with BMI, WC, and WHtR (Pearson’s correlation 
= -0.202, -0.161, -0.189 respectively, p<0.05 for all), but not with WHpR 
(Pearson’s r = -0.111, p>0.05). Cut-offs were applied to classify participants as 
obese and non-obese for all anthropometric measures, including BMI, WC, WHtR, 
and WHpR.527 Macular pigment optical density, however, was not significantly 
different in individuals with excess compared with normal adiposity indices for all 
anthropometric measures (p>0.05 for all; Table 7.2). Although MPOD tended to be 
lower in subjects with cataracts, and in those with elevated WHtR and WHpR (all 
trending towards significance), only hypertension emerged in the univariate linear 
regression analysis as associated with lower MPOD [Table 7.2; Figure 7.4 (B)].
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Table 7.2: MPOD according to anthropometric and clinical biomarkers in a diabetic population (normalised MPOD). 




25th 50th 75th sig 
p 






















Ideal (≤102 M, ≤88 F) 



















Ideal (≤1.00 M, ≤0.85 F)    



















Ideal (≤0.57 M, ≤0.53 F) 

















































































†† ANOVA was used to check for MPOD differences among anthropometric and physical biomarkers. P values are reported using MPOD square root transformation (sqrt) 
(normalised MPOD) and reflect the probability associated with the given F statistic. Sig., significance.  
The following cut-offs were applied to indicate ideal or excess obesity measures and normotensive/hypertension for the following variables: BMI-body mass index; [ideal ≤ 30; 
excess > 30 kg/m2 - kilograms per metre squared; WC-waist circumference; ideal ≤ 88 F; ≤ 102 M; excess > 88 F; >102 M cm - centimetres; WHtR-waist-to-height ratio; ideal 
≤ 0.53 F; ≤ 0.57 M; excess >0.57 F; >0.53 M; WHpR-waist-to-hip ratio; ideal ≤ 0.85 F; ≤1.00 M; excess > 0.85 F; >1.00 M; M=Male; F=Female; 527 Normotensive (≤140 
mmHg systolic; ≤90 mmHg diastolic); Hypertensive (>140 mmHg systolic; >90 mmHg diastolic). 
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(3) Plasma biomarkers 
Macular pigment optical density was significantly lower among participants with a 
raised TG/HDL ratio [Mean=0.172 (0.140)] compared to those with ideal levels 
(Mean =0.215(0.152); t (185); = 2.080, p=0.039; Table 7.3; Figure 7.4 (C)). One 
way analysis of variance revealed no significant difference in MPOD between those 
with high and low TC, HDL, LDL, TGs, non-HDL, and TC/HDL (p= 0.287-0.946) 
(see Table 7.3). Participants who were vitamin D deficient had significantly lower 
MPOD [mean = 0.173(0.148)] compared to participants who had sufficient levels 
[mean = 0.226 (0.145); t (185), = -2.796, p=0.006; Table 7.3; Figure 7.4 (D)]. 
Figure 7.5 shows a significant positive relationship between normalised MPOD and 
plasma vitamin D (r=0.218, p=0.003). There was no significant association between 










Table 7.3: MPOD according to plasma biomarkers in a diabetic population (normalised MPOD). 




25th 50th 75th sig 
p 
Plasma Biomarkers       
TC (mmol/L) 
Ideal (≤ 5.00) 



















Ideal (> 1.6) 


























































Non-HDL Cholesterol Ratio 









































Vitamin D (nmol/L) 
Deficient (≤ 50) 



















Ideal (≤ 3.0) 







































††ANOVA was used to check for MPOD differences among plasma biomarkers. P values are reported using MPOD square root transformation (sqrt) (normalised MPOD) and 
reflect the probability associated with the given F statistic. Sig., significance.  
The following cut-offs were applied to plasma levels: HDL, high-density lipoprotein; [high risk ≤1.6; low risk >1.6 millimoles per litre (mmol/L)];  LDL, low-density lipoprotein; 
[high risk > 2.6; low risk ≤ 2.6 mmol/L]; TC, total cholesterol; [high risk > 5.00; low risk ≤ 5.00 mmol/L]; TG, triglycerides; [high risk >1.7; low risk ≤1.7 mmol/L];TG/HDL, 
triglyceride to high density lipoprotein ratio; [high risk >1.74; low risk ≤1.74 mmol/L]; TC/HDL, total cholesterol to high-density lipoprotein ratio; [high risk >3.5; low risk 
≤3.5 mmol/L]; Non-HDL, total cholesterol minus high-density lipoprotein; [high risk >3.4; low risk ≤ 3.4 mmol/L] as per 2016 ESC/EAS guidelines;528 plasma vitamin D 
(25(OH) D) levels in nanomoles per litre (nmol/L) [deficient ≤50; sufficient >50 nmol/L] as per IOM vitamin D guidelines;530 plasma CRP levels in micrograms per litre (μg/l) 
209 
 








Figure 7.4: Box plots of MPOD differences by (A) Smoking status (B) Hypertension status (C) Triglyceride over High Density  





Figure 7.5:  Scatterplot showing a significant positive relationship between 
normalised MPOD and Vitamin D (25(OH) D) plasma levels. 
Multivariate model 
Demographic and behavioural factors 
Smoking remained a strong, negative predictor of MPOD after adjusting for 
covariates. Current smoking was significantly associated with lower MPOD (Beta 
coefficient = - 0.097; p=0.022; Table 7.4). 
Anthropometric and physical biomarkers 
The presence of cataract remained the only clinical parameter to be negatively 
associated with MPOD in a diabetic population after adjusting for covariates (Beta 
coefficient = - 0.078; p<0.049). None of the other anthropometric or clinical 
parameters (WHtR, hypertension, diabetic retinopathy or duration of disease) 




Vitamin D remained a significant and positive predictor of MPOD in the 
multivariate model, although this was a subtle effect (Beta coefficient = 0.001; 
p=0.029). None of the other plasma biomarkers (TG/HDL, HbA1c or CRP) 
remained significantly associated with MPOD (p>0.05 for these variables).  
 
The correlates of MPOD identified as significant in the multivariate regression 
model (smoking, cataracts, and low vitamin D status) contributed 18.5%  of the 
overall variability in MPOD status amongst patients with Type 2 diabetes, 










Table 7.4: Multivariate relationship between behavioural, anthropometric, clinical, plasma biomarkers and MPOD in a diabetic population 
(n=188); (F (13,146) = 2.545, p=0.003; R2 = 0.185). 








Constant 0.428 0.197 2.175 0.031 
Age 0.001 0.002 0.700 0.485 
Sex*  (Female) -0.007 0.025 -0.259 0.796 
Smoking† 
            Past 













WHtR -0.192 0.183 -1.046 0.297 
Cataracts‡ (Yes) -0.078 0.039 -1.988 0.049 
Vitamin D (nmol/L) 0.001 0.001 2.204 0.029 
CRP (μg/l) 0.001 0.001 1.382 0.169 
TG/HDL Cholesterol Ratio -0.015 0.013 -1.170 0.244 
HbA1c (%) -0.006 0.017 -0.373 0.710 
Duration (years) 0.003 0.003 1.093 0.276 
Retinopathy†† (Yes) -0.092 0.058 1.585 0.115 




R2 = 0.185; F = 2.545; p= 0.003. Dependent variable = MPOD sqrt (normalised MPOD); Std. Error, Standard Error. 
*Male = control group; † Never smoked = control group; ‡ No Cataracts = control group; ††No Diabetic Retinopathy = Control group; ‡‡ Hypertension= Control group. 
Abbreviations: CRP - C-reactive protein; HbA1c- glycated haemoglobin; μg/l – micrograms per litre; nmol/l – nanomoles per litre; WHtR- waist to height ratio; TG/HDL- 




Consistent with previous investigations 6, 7 this study provides further evidence that 
patients with Type 2 diabetes have significantly lower MPOD, compared with non-
diabetic controls. Additionally, MPOD was inversely associated with a range of 
behavioural, clinical and anthropometric biomarkers including smoking, 
hypertension, and bodyweight. Body mass index, WHtR, and WC were all negatively 
associated with MPOD on univariate analysis, in the Type 2 diabetes group, (Pearson’s 
r, p<0.05 for all). Some novel relationships were observed among the plasma 
biomarkers, with low plasma vitamin D and raised TG/HDL ratio associated with low 
MPOD levels; findings not previously reported. Current smoking, the presence of 
cataract and low plasma vitamin D persisted as predictors of low MPOD in the 
multivariate model, after adjusting for all other covariates, albeit collectively 
explaining just 18.5% of the variability in MPOD.  
 
Our finding that hypertensive participants with diabetes had significantly lower 
MPOD compared to normotensive participants with diabetes is important given that 
hypertension is an established risk factor for the development and progression of 
diabetic retinopathy.533 The association between MP and hypertension is not well 
documented; however, one study has reported a link between lower MPOD and self-
reported diagnosis of high blood pressure.52 Chronic hypertension causes vascular 
endothelial shear stress and circumferential wall stress.151 This, in turn, leads to 
endothelial damage, increased ROS production and activation of inflammatory 
cascades.534 One recent study found lower levels of GSH and increased levels of 8-
OHdG, a marker of oxidative stress, in diabetes patients with hypertension, supporting 
the hypothesis that oxidative stress increases considerably in hypertension, especially 
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as a diabetic co-morbidity.535 Endogenous antioxidants become depleted when both 
conditions coexist, which leads to an increased need for exogenous antioxidants (i.e. 
vitamins C and E, carotenoids lutein, zeaxanthin, and meso-zeaxanthin) to balance 
redox status, which may explain our observation that hypertension in the presence of 
Type 2 diabetes may have an added negative impact on MPOD status on univariate 
analysis. While we did not reach statistical significance in multivariate analyses, future 
studies with larger cohorts could further investigate this finding. 
 
The inverse relationship observed between adiposity and MPOD confirms previous 
findings among patients with Type 2 diabetes.7 Adipose tissue, visceral fat in 
particular; may act as a sink/reservoir for macular carotenoids,54 thereby influencing 
carotenoid concentrations in plasma,347 and subsequent retinal uptake.18 Distribution 
of body fat is also a significant factor, as it has been shown that concentrations of 
lutein and zeaxanthin are higher in abdominal fat,67 and abdominal adiposity is 
characteristic in Type 2 diabetes. Excess visceral fat also contributes to inflammation 
and oxidative stress due to the increased production of adipocytokines (IL-1, IL-6, IL-
8, and TNF-alpha).372 The chronic low-grade inflammation, associated with obesity 
and Type 2 diabetes leads to increased oxidative stress and further inflammation, 
putting a greater demand on antioxidant defences. Antioxidant defences may also be 
lower in overweight/Type 2 diabetes patients, due to their lower intake of antioxidant-
rich foods (e.g. fruits and vegetables), their increased utilisation of these molecules 
(e.g. increased inflammation/ROS in insulin-dependent tissue such as the retina) and 
their impaired generation of other supportive anti-oxidants, reviewed by Savini et 
al,367 which may collectively lead to MPOD depletion.68 Dietary intake of lutein and 
zeaxanthin was not, however, assessed as part of the TILDA study (this limitation is 
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discussed further below). 
 
Of interest, and to our knowledge a novel finding; is that MPOD was significantly 
lower for participants with a raised TG/HDL ratio. This observation is important given 
that Type 2 diabetes patients commonly display an altered lipoprotein profile, termed 
diabetic dyslipidaemia (i.e. raised TGs and low HDL), and that diabetes patients in the 
current study had indeed significantly higher TGs and significantly lower HDL plasma 
lipid levels than the non-diabetic control group. The characteristic lipid profile of 
individuals with Type 2 diabetes,158 may have important implications for MP levels in 
the eye, as dietary carotenoids are transported on circulating lipoproteins.18 The 
general consensus is that xanthophylls associate with HDL,327 and that HDL levels are 
therefore important for the efficient delivery and uptake of lutein and zeaxanthin to 
the eye.18 The relationship between MPOD and plasma lipid levels has previously been 
investigated in patients with diabetes, with a marginal negative association between 
MPOD and TGs and a marginal positive association between MPOD and HDL 
observed (p<0.08 for both).6 We previously reported significantly lower levels of 
MPOD in patients with Type 2 versus Type 1 diabetes, and noted significantly lower 
HDL values within the Type 2 diabetes group, postulating that lower HDL levels may 
have mediated this difference.7 More recently, the DiVFuSS study,21 has demonstrated 
significant improvements in plasma LDL, HDL, and TGs, in a group of patients with 
diabetes who participated in a 6-month RCT. The coincident increase in MPOD 
observed in the intervention group may have been partially mediated by these 
favourable changes in lipid profile.18 We acknowledge, however, that the lack of 
dietary information on carotenoid intake is a limitation of the current study, (discussed 
in further detail below), as MPOD is influenced by both lutein and zeaxanthin intake 
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as well as transport and assimilation (i.e. mediated by HDL) in the target tissue. This 
information would have added to the interpretation of our findings. While we found 
that lower MPOD was associated with raised plasma TG/HDL levels on univariate 
analysis (p=0.039), plasma TG/HDL did not remain as a predictor of MPOD in 
multivariate analyses. Future studies, however, based on a larger number of diabetic 
participants could further investigate this finding. 
 
Our findings in relation to smoking are not surprising given that smoking is associated 
with increased oxidative stress, not only through the increased systemic production of 
ROS but also through a weakening of the antioxidant defence systems.65 The reported 
associations between cigarette smoking and diabetic retinopathy, however, are more 
variable, with some studies reporting an association,536 while others have found no 
such relationship.537 Chronic hyperglycaemia causes oxidative stress, so the increased 
production of ROS in diabetes may be compounded further by smoking, another 
important source of free radicals. Exposure to cigarette smoking causes profound 
oxidative damage to human RPE cells.538 Interestingly, we found no difference in 
MPOD between previous smokers and non-smokers, perhaps indicating that MPOD 
repletion is possible in diabetes patients through smoking cessation.  
 
Cataract status remained a predictor of low MPOD in the multivariate model in line 
with previous observations.260, 539 The marginal statistical significance of this 
association in the univariate model (p=0.068) was more than likely limited by the 
small sample size in the current study (n=26 with cataracts). The evidence that 
carotenoids, lutein, and zeaxanthin, are protective against the development of cataract, 
however, is well documented 260, 539 suggesting the possibility of a causal role for 
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MPOD depletion in the pathogenesis of cataract development in diabetes. With 
ageing, there is a natural decrease in the production of antioxidants and antioxidant 
enzymes and a concomitant increase in phototoxic chromophores in the lens.250 
Phototoxic reactions, whether caused by endogenous or exogenous singlet oxygen 
photo-sensitisers, lead to a modification of lens proteins, which eventually causes 
opacification of the lens (i.e. cataractogenesis) (reviewed by Roberts & Dennison 250). 
The phototoxic reaction damage can be prevented by the appropriate antioxidant 
quenchers. Lutein and zeaxanthin both accumulate in the lens 540 and research has 
shown a lower prevalence of nuclear cataract amongst those with higher intakes of 
xanthophylls.539 Furthermore, findings from the AREDS2 revealed that participants in 
the lowest quintile of dietary lutein/zeaxanthin intake experienced slower cataract 
progression with carotenoid supplementation.260 Although the development of cataract 
is an age-related phenomenon, other factors appear to influence their progression 
including poor diet, smoking, UV light exposure, and metabolic factors. In the current 
study, a greater percentage of patients with diabetes had cataract (13.83%) compared 
with controls (6.51%), (p<0.0001). Cataract status does not appear to relate to MPOD 
levels among non-diabetic individuals,52 suggesting a relationship that is particular to 
cataract in the presence of Type 2 diabetes, which may impact MPOD levels in this 
patient group. To our knowledge, this is the first study to report an association between 
low MPOD and the presence of cataract in diabetes. 
 
That vitamin D emerged as a positive predictor of MPOD in Type 2 diabetes after 
controlling for other covariates represents a particularly novel and interesting finding. 
Although the best-known function of vitamin D is to help the body absorb and use 
calcium, other important roles include protection of the eye during inflammation, 
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oxidative stress, fibrosis, and angiogenesis.541 Vitamin D insufficiency is common 
amongst the general population, and particularly amongst those who are obese, 542 or 
who have diabetes.543 Our findings support this observation as both the control and 
Type 2 diabetes group had mean vitamin D levels which fell well below the optimal 
recommended level,544 and as the participants with Type 2 diabetes had significantly 
lower plasma vitamin D compared with the control group (p<0.0001). Vitamin D 
receptors are expressed in the eye, including the RPE,545 which suggests that vitamin 
D is biologically relevant to the eye.307 Research shows that human adult RPE cells 
(ARPE-19) also express the 1α-hydroxylase enzyme required to convert 25(OH) D to 
its biologically active 1,25 (OH)2 D form.
546  
 
The ability to inhibit neovascularisation has also led researchers to examine vitamin 
D’s involvement in diabetic retinopathy development.547 Plasma vitamin D 
concentrations have previously been found to be inversely related to the severity of 
retinopathy in patients with diabetes,307 with this study suggesting that the 
measurement of serum 1,25(OH) 2 D3 concentrations might be helpful in predicting 
retinopathy progression, and that a detailed ophthalmologic examination is indicated 
for diabetes patients whose plasma vitamin D levels are low.307 The DiVFuSS study 
recently examined the effects of supplementation with a novel multi-component 
nutritional supplement, which included vitamin D and the antioxidants lutein and 
zeaxanthin, on ocular health and visual function in a group of participants with 
diabetes.21 Individuals receiving the DiVFuSS formula improved on all measures of 
visual function, and although not statistically significant (p=0.07), four subjects were 
downgraded from moderate to mild non-proliferative diabetic retinopathy following 
the intervention, while one subject on placebo was upgraded from mild to moderate 
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non-proliferative diabetic retinopathy over the same period.21 Positive outcomes from 
DiVFuSS may in part be due to supplementation with a compound that specifically 
targets both inflammation and oxidative stress. It is plausible that these findings may 
have been mediated by enhancements in MPOD (27% mean increase in DiVFuSS 
group vs 2% mean decrease in placebo group), and by vitamin D’s attenuating effect 
on inflammation with reductions in plasma hs-CRP (60% mean decrease in DiVFuSS 
group vs 11% mean decrease in placebo group).21 Although CRP levels were 
significantly higher in participants with diabetes [mean =5.23(11.94)], compared with 
non-diabetic controls [mean=2.83(6.95)], (p=0.0001), in our study, MPOD was not 
significantly different in diabetic participants with an elevated CRP level compared 
with ideal levels (p=0.120; Table 7.3). These findings, however, warrant further 
investigation. 
7.6 Limitations 
There are a number of important limitations to the current study which should be 
recognised. Firstly, the use of self-reported data is not ideal. Diabetes diagnosis was 
based on respondent’s recall rather than health records. Concomitantly, respondents 
were not explicitly asked what type of diabetes they had. Instead, patient medications 
(self-reported) and age at diagnosis were used to account for possible Type 1 cases, 
which may have led to some misclassification. The presence or absence of cataract 
was also based on patient’s recall rather than direct examination. Secondly, small 
patient numbers in some of the sub-group analyses may have limited the statistical 
power to detect associations that may exist (Type II error possibility). It is worth noting 
that the prevalence of diagnosed and undiagnosed Type 2 diabetes in these older adults 
resident in Ireland was found to be relatively low compared to other populations (8.6% 
and 0.9% respectively), which would account for low participant numbers in the 
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current study.130, 520 Another limitation was that dietary intake of the macular 
carotenoids was also not assessed, therefore, it was not possible to control for potential 
confounding from variable intake of lutein and zeaxanthin. Macular pigment 
constituent carotenoids cannot be synthesised de novo in humans, therefore, lower 
levels of MPOD may be experienced in participants with poor dietary intake of 
antioxidants. Mares et al,384 found that MPOD was directly related to dietary intake of 
carotenoids, lutein, and zeaxanthin, but even more strongly with plasma levels, 
suggesting that unmeasured physical and medical factors may also influence the 
uptake, distribution and utilisation of lutein and zeaxanthin.384 The absence of plasma 
analysis of lutein and zeaxanthin was also a weakness in our study.  
 
Furthermore, it is worth noting that measures of MP are subject to genetic variation. 
Macular pigment optical density is a multi-factorial phenotype, associated with 
variation in genes related to carotenoid transport, uptake, and metabolism, and may be 
independent of known dietary and health influences in MPOD.72 The MP determinants 
reported herein (current smoking, presence of cataracts and vitamin D status) 
explained 18.5% of the overall variability in MPOD, in participants with diabetes. Diet 
is an important determinant of MPOD, therefore, cautionary interpretation of our 
findings is advised. Finally, while the current study used a large, nationally 
representative population, MPOD was only measured on participants who were able 
to attend a health centre. 
 
Despite these drawbacks, there were a number of strengths to the current analysis. The 
design of the TILDA study is a particular strength, in particular, the selection of 
participants from which our diabetes and controls were drawn, which was 
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representative of the Irish population aged 50 and over. Plasma lipoproteins (HDL, 
TG/HDL) and inflammatory markers (vitamin D, CRP) were analysed and blood 
pressure was measured, which represents an advance on previous research carried out, 
research which was based on self-reported doctors’ diagnosis of high cholesterol and 
hypertension.52 The additional use of HbA1c helped identify undiagnosed and pre-
diabetes cases. Finally, anthropometric measures such as WHtR and WHpR were used 
to analyse overweight/obesity in conjunction with BMI and WC. 
7.7 Conclusion 
Overall our findings suggest that individuals with Type 2 diabetes have lower MP 
relative to healthy controls, although the clinical importance of the observed level of 
difference is questionable. Future studies with larger cohorts could further investigate 
this finding, as the difference in MPOD, although significant (p=0.047), was marginal. 
Hyperglycaemia and other anthropometric, metabolic and clinical correlates 
associated with diabetes (e.g. excess adiposity, dyslipidaemia, hypertension, and 
cataract), may relate to a state of chronic oxidative stress and inflammation, processes 
which also underlie many of the functional alterations in the retinal vasculature in 
diabetic retinopathy. Both over utilisation (i.e. in response to elevated oxidative 
stress/inflammation) and undersupply of antioxidant nutrients (dietary deficiency, 
excess adiposity, and dyslipidaemia) may contribute to lower levels of MP in the 
diabetic retina. Clinical benefits may be realised through the early identification of 
MPOD depletion in Type 2 diabetes. Given the borderline statistical significance of 
many of our findings, more work needs to be done to verify and refine our 
understanding of the observed relationships. The MPOD difference of 0.053 OD in 
participants with sufficient vitamin D (>50nmol/L) versus deficient levels (≤50 
nmol/L), although significant (p<0.006), is not clinically meaningful as it stands. 
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Macular pigment optical density measurement is not routinely available, however, the 
capacity of commonly-measured surrogate plasma biomarkers (HDL, TG/HDL, 
vitamin D), and anthropometric measurements (WHtR, WC) to identify people with 
diabetes at risk of low MP merits further consideration. The novel and important 
findings reported herein should now be subject to further research, to better understand 


















8. INVESTIGATION OF SURROGATE BIOMARKERS ASSOCIATED 




Macular pigment confers potent antioxidant and anti-inflammatory effects at the 
macula but its optical density in the eye is not routinely measured in clinical practice. 
This study explored a range of anthropometric, clinical, and plasma measures which 
are commonly measured and which may be associated with lower MPOD, in a large, 
population-based sample of older adults.  
Method 
Two thousand five hundred and ninety four subjects completed a full MP assessment, 
as part of Wave 1 of TILDA. The MPOD was measured using c-HFP. Clinical [blood 
pressure], plasma [lipoproteins, inflammatory markers] and anthropometric [waist 
(cm), hip, (cm), height (cm) weight (kg)] biomarkers were measured for each 
participant.  
Results 
Mean (SD) MPOD for the study group was 0.223 (0.161) with a range of 0 to 1.08. 
One way analysis of variance revealed that MPOD was significantly lower among 
participants with: low plasma HDL (p =0.038), raised plasma TG/HDL ratio (p=0.003) 
and raised TC/HDL ratio (p=0.030). Subjects with an elevated WC had significantly 
lower MPOD [mean = 0.216(0.159)] compared to those with an ideal WC [mean = 
0.229(0.162); p=0.034]. Significant correlates of MPOD on mixed linear model 
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analysis included education, smoking status and WC. 
Conclusions 
Higher abdominal fat is associated with lower MPOD in this representative sample of 
older Irish adults. While altered lipoprotein profiles (low HDL, raised TG/HDL ratio, 
raised TC/HDL ratio), may affect the transport, uptake and stabilisation of carotenoids 
in the retina, these plasma biomarkers were not predictive of low MPOD after 
adjustment for abdominal circumference. Although WC emerged as a possible 
anthropometric predictor of lower MPOD, its effect size appears to be small and 


















The concept that MP may have a protective role in neurodegenerative eye conditions 
such as AMD, glaucoma and diabetes is well documented.4, 353, 548 The macula is 
particularly important for central high resolution vision and blindness results when 
this area is lost to disease. The carotenoids lutein, zeaxanthin, and meso-zeaxanthin, 
collectively known as MP, accumulate at the macula to the exclusion of all other 
dietary carotenoids. Macular pigment has a unique distribution within the retina, 
selectively located within the fibres of Henle in the fovea and in the inner nuclear layer 
of the parafovea,43, 549 implying that MP plays an important role in vision and macular 
health, and that it is biologically relevant to the eye.44, 45  
 
The selective absorption of short-wavelength light prior to photoreceptor light capture 
means that MP plays an important role in visual performance in healthy eyes.2 
Concomitantly, through its optical filtration and antioxidant properties, MP protects 
the retina from photo-oxidative damage, thereby, reducing the risk of various eye 
diseases, including AMD 5 and diabetes.15, 21 Decreased MPOD appears to be a risk 
factor for the development of these diseases,6, 7, 55 and numerous studies investigating 
the effects of MP augmentation have also reported beneficial effects in diseased eyes.5, 
15, 218 While the aetiopathogenesis of conditions such as AMD and diabetes remain a 
matter of debate, there is growing consensus that oxidative damage,291, 355 and 
associated inflammation 10, 242 play a significant role. The macular carotenoids exhibit 
neuroprotective functions at the macula,4, 230 and it has been shown that lutein and 
zeaxanthin can affect immune responses, reduce inflammation and have anti-
angiogenic properties in the eye.4, 550, 551 Therefore, the density of MP, offers potential 
as a clinical biomarker of retinal health.  
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Macular pigment levels can be measured in vivo, but the relevant instrumentation is 
not commonly available in clinical practice. Other indirect techniques for assessing 
MP status such as dietary and plasma analysis have limited practical application and 
are not used in clinical practice. Previous investigators have examined and identified 
possible predictors of MPOD, and found associations with dietary intake,384 plasma 
cholesterol and lipoprotein status,18, 71 metabolic status,6, 7 overweight/obesity status,52 
and smoking.52 Many of these studies, however, were based on opportunistic sampling 
and restricted to small sample sizes,6, 7, 71 or relied on self-reported data.52 While one 
study investigated determinants of MPOD on a larger older cohort (n=1698), this 
research was conducted on female subjects only.384  
 
Consequently, there is merit in exploring the association between MPOD and more 
commonly measured clinical and biometric parameters, which might be used to 
identify patients at risk of low MP, so that practitioners can implement strategies for 
preventative intervention. While self-reported data provide a reasonable measure of 
overall health status, concerns exist regarding the magnitude of bias from using these 
measures in analysis.552, 553 This study was designed, therefore, to address some of the 
limitations of previous investigations by examining the predictive capacity of a range 
of measured (rather than self-reported) clinical (blood pressure), plasma (lipoproteins, 
inflammatory markers) and anthropometric (abdominal fat) parameters in a large 
representative group of older men and women.523 
8.3 Methods 
Study design and population 
Cross-sectional data from Wave 1 of TILDA were analysed in this study, which was 
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conducted during the period between October 2009 and July 2011. A sample of 8,175 
individuals representative of the population of Ireland aged 50 years and older 
participated in the study, as described in detail elsewhere.523, 524 In brief, information 
on health behaviours and lifestyle patterns were captured by trained professional 
interviewers in participants’ own homes using CAPI.525 Participants were then invited 
to take part in a health assessment.526 Macular pigment measurement was only 
conducted on participants who attended a health centre (Figure 8.1). In total 5,275 
consented to and participated in the health centre based assessment. The current study 
was approved by the Technological University Dublin Research Ethics Committee 
and all experimental procedures adhered to the tenets of the Declaration of Helsinki. 
All participants provided written informed consent prior to participation in the study. 
Demographic, health and lifestyle factors 
Demographic, health, and lifestyle factors were captured for the study group. The 
presence or absence of eye pathology was determined using the CAPI with the 
question ‘’has a doctor ever told you if you had any of the following conditions: 
diabetes, AMD, cataracts or glaucoma?’’. Participants were asked if they currently 
smoked or had ever smoked cigarettes regularly (daily for at least a year), and were 
categorised as never smoked, past smokers or current smokers. Blood pressure was 
measured and participants were defined as hypertensive if mean seated systolic BP 
exceeded 140 mmHg or mean seated diastolic BP exceeded 90 mmHg.  
Macular pigment optical density assessment 
Macular pigment optical density was measured by c-HFP using the Macular Metrics 
Densitometer (Macular Metrics, Rehoboth, MA). This device was modified 
specifically for the TILDA study and the method of measurement has been described 
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in detail elsewhere.56 In brief, MPOD was measured centrally at 0.5° (i.e. 1° stimulus) 
and peripherally at 7o (parafoveal target at 7°). Macular pigment assessment was 
carried out on the eye with the best VA or if there was equal vision in both eyes the 
right eye was chosen.56 Corrected VA was measured using the ETDRS LogMAR chart 
at a distance of 4 metres using participants’ existing prescription where necessary. 
Participants with a VA worse than 0.5 LogMAR were excluded from the analysis 
(Figure 8.1).  
Anthropometric assessment 
Height (cm) and weight (kg) were measured to one decimal place using a Seca wall 
mounted measuring rod and Seca electronic floor scales, as described in detail 
elsewhere.525 Body mass index was calculated from measured height and weight as: 
weight (kg)/height (m2), with obesity classified as a BMI > 30 kg/m2.363 Waist and hip 
circumferences were measured to the nearest cm. Ideal WC was defined as a WC of ≤ 
88 cm in women and ≤ 102 cm in men, while central obesity was defined as a WC > 
88 cm in women and > 102 cm in men. Waist-to-height ratio and WHpR were 
calculated based on measured data. Cut-off thresholds for ideal and excess WHtR were 
taken as less than or greater than 0.53 in women and 0.57 in men respectively. For 
WHpR a cut off threshold of less than or greater than 0.85 in women and less than or 
greater than 1.00 in men defined ideal and elevated WHpR.527, 554  
Plasma analysis 
A blood sample was provided for plasma analysis using defined phlebotomy protocols, 
which are described in detail elsewhere.525, 526 Respondents were not asked to fast 
before the health assessment and plasma was analysed for a complete lipid profile, 
including TC, HDL, LDL and TGs, each measured in mmol/L. Triglyceride over HDL 
232 
 
ratio, TC/HDL ratio and non-HDL cholesterol were calculated from measured data. 
Cut-offs were applied to indicate high/low or ideal plasma lipid levels as per 2016 
ESC/EAS guidelines (Table 8.2).528 Plasma vitamin D levels [(25(OH)D); nmol/L] 
were also measured and participants were considered vitamin D deficient if plasma 
levels were ≤50 nmol/L and sufficient if plasma levels were >50 nmol/l as per IOM 
vitamin D guidelines.530 Inflammatory marker CRP [μg/l] and HbA1c (%) were also 
measured. A threshold of > 3.00μg/l for high and ≤ 3.00μg/l for ideal was used for 
plasma CRP 531 and a cut off of ≤ 5.00% and > 5.00% was used for HbA1c. 
Statistical analysis 
The statistical software package SPSS for Microsoft Windows (v.25.0; IBM Corp., 
Armonk, NY) was used for analysis. To account for the fact that the study response 
rate varied between different subgroups of the population, inverse probability weights 
were calculated for the main sample (CAPI participants) using the Quarterly National 
Household Survey 2010. The probability of participation in the health centre also 
varied according to health, education, age and smoking, therefore, a specific ‘health 
centre weight’ was created. A detailed description of the weighting procedures used 
in TILDA is given elsewhere.532  
 
Demographic data for eligible study participants were compared to those of the overall 
health centre population using Chi-square analyses, to explore if they differed from 
the representative sample. Data for the study group were tested for normality using the 
Kolmogorov-Smirnov test. One-way analysis of variance was used to test for 
differences in means for normally distributed parameters. For categorical data, cross-
tabulation with Chi-square analysis was used. Pearson’s product-moment correlation 
tests were performed to assess the relationship between normalised MPOD and other 
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study variables where appropriate. A mixed linear model analysis (fixed effect) was 
carried out to estimate the independent association between putative predictor 
variables (behavioural, clinical, anthropometric, and plasma biomarker parameters) 
and normalised MPOD. Data are presented as mean ± standard deviation throughout. 
The level of statistical significance was set at p< 0.05 for all analyses. 
8.4 Results 
In total, 8,175 individuals aged 50 years and older participated in the study. Of these, 
5,275 consented to and participated in the health centre based assessment as part of 
Wave 1 of TILDA. For various reasons, 2,681 were excluded from the current 
analysis, leaving an overall study population of 2,594 (Figure 8.1). The main reasons 
for exclusion related to unsuccessful MPOD measurement or the presence of retinal 
pathology. Participants were identified with AMD, cataracts and glaucoma from the 
CAPI. The presence or absence of diabetes was identified from prescribed diabetes 
medications at the time of the interview (identified using the ATC codes ‘A10A’ for 
insulin and ‘A10B’ for oral hypoglycaemic medications), from the CAPI and/or from 
measured HbA1c [HbA1c > 6.4% (diabetes); 5.7 - 6.4% (pre-diabetes)], as per 





Figure 8.1: Flowchart illustrating the selection of study participants and reasons for 
exclusion from the original participant group. 
Abbreviations: AMD, age related macular degeneration, MPOD, macular pigment 
optical density, VA, visual acuity, TILDA, the Irish Longitudinal Study on Ageing. 
 
A Chi-square test of independence was performed to examine the relationship between 
the centre population (n=5,275) and participants with a valid MPOD assessment 
(n=2,594). The age profile of study participants [mean age = 61.95 (8.47) years; range 
50 to 93 years] was similar to the overall health centre assessed population [mean age 
= 61.40 (7.62) years; range 51 to 86 years] and there was no significant difference in 
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sex or education status between the two groups (p=0.882 and p=0.768 respectively). 
Mean (SD) MPOD for the study group was 0.223 (0.161) with a range of 0 to 1.08. 
Differences in normalised MPOD by demographic (age group, sex, education status), 
health and lifestyle variables (smoking, hypertension, physical activity and cataracts) 
were examined. Participants were divided into three age groups: 50-64 years (mean 
MPOD =0.223[0.160]); 65 to 74 years (mean MPOD=0.223[0.164]); and 75 years and 
over (mean MPOD =0.216[0.151]). Age was not significantly associated with MPOD 
on one-way ANOVA (p=0.852). Additionally, age as a continuous variable was not 
significantly associated with MPOD (r=-0.003, p=0.883). Our findings concur with 
previously reported statistically significant associations between gender, educational 
status and smoking with MPOD in the TILDA dataset (p<0.05 for all), despite a 
slightly different study sample (participants with AMD, glaucoma, diabetes and pre-
diabetes were excluded from the current analysis of older individuals, but not in a 
previous study).52  
Clinical, anthropometric and biomarker associations with MPOD 
(1) Clinical factors 
We found no correlation between measured hypertension status (with or without 
treatment) and MPOD in the current study [n= 2,591; t=1.105; p=0.331]. 
(2) Anthropometric factors 
The MPOD was significantly and negatively correlated with all anthropometric 
measures (BMI; WC; WHtR and WHpR) on univariate analysis (Pearson’s r = -0.047; 
-0.073; -0.060; -0.081 respectively, p<0.05 for all). Waist circumference, however, 
emerged as the only anthropometric variable associated with lower MPOD on binary 
univariate analysis. Participants with an elevated WC had significantly lower MPOD 
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[Mean =0.216(0.159)] compared to participants with ideal WC [Mean = 0.229(0.162); 
n=2,589; t=2.119; p=0.034; Table 8.1; Figure 8.2], although the differences were not 
clinically meaningful, as illustrated in Figure 8.2. MPOD did not differ significantly 
according to any other anthropometric measures (p>0.05 for all; Table 8.1). 
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Table 8.1: The MPOD according to anthropometric biomarkers in the study population (n=2594); (normalised MPOD). 
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One way ANOVA was used to check for MPOD differences among anthropometric and physical biomarkers. P values are reported using MPOD  
square root transformation (sqrt) (normalised MPOD) and reflect the probability associated with the given F statistic. Sig., significance.  
The following cut-offs were applied to indicate ideal or excess obesity measures and normotensive/hypertension for the following variables:  
BMI-body mass index; [ideal ≤ 30; excess > 30 kg/m2 - kilograms per metre squared; WC-waist circumference; ideal ≤ 88 F; ≤ 102 M;  
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excess > 88 F; >102 M cm - centimetres; WHtR-waist-to-height ratio; ideal ≤ 0.53 F; ≤ 0.57 M; excess >0.57 F; >0.53 M;  
WHpR-waist-to-hip ratio; ideal ≤0.85 F; ≤1.00 M; excess > 0.85 F; >1.00 M; M=Male; F=Female. 
Abbreviations: BMI- body mass index; cms - centimetres; F-female; kg-kilogram; M-male; MPOD-macular pigment optical density;  




Figure 8.2: Violin plot of MPOD differences according to waist circumference status 
(ANOVA). 
(3) Plasma biomarkers 
Participants with ideal plasma levels of HDL had significantly higher MPOD than those with 
low HDL levels [n=2587; t=-2.077; p=0.038; Table 8.2; Figure 8.3 (A)]. The MPOD was also 
significantly lower among participants with a raised TG/HDL ratio [n=2587; t = 2.994, 
p=0.003; Table 8.2; Figure 8.3 (B)] and among participants with a raised TC/HDL ratio 
[n=2574; t=2.166; p =0.030; Table 8.2; Figure 8.3 (C)]. The magnitude of all statistically 
significant differences were not, however, clinically important, as illustrated in Figure 8.3. 
One-way analysis of variance revealed no significant difference in MPOD levels for any other 
plasma biomarkers (p>0.05 for all); Table 8.2). 
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Table 8.2: The MPOD according to plasma biomarkers in the study population (n=2594), (normalised MPOD). 
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High (>0.87) 1402 0.214[0.158] 0.095 0.182 0.304 
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One way ANOVA was used to check for MPOD differences among plasma biomarkers. P values are reported using MPOD square root  
transformation (sqrt) (normalised MPOD) and reflect the probability associated with the given F statistic. Sig., significance.  
The following cut-offs were applied to plasma levels: HDL, high density lipoprotein; [high risk ≤1.6; low risk >1.6 millimoles per  
litre (mmol/L)];  LDL, low density lipoprotein; [high risk > 2.6; low risk ≤ 2.6 mmol/L]; TC, total cholesterol; [high risk > 5.00;  
low risk ≤ 5.00 mmol/L]; TG, triglycerides; [high risk >1.7; low risk ≤ 1.7 mmol/L];TG/HDL, triglyceride to high density lipoprotein  
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ratio; [high risk >0.87; low risk ≤ 0.87 mmol/L]; TC/HDL, total cholesterol to high density lipoprotein ratio; [high risk >3.5;  
low risk ≤ 3.5 mmol/L]; Non-HDL, total cholesterol minus high density lipoprotein; [high risk >3.4; low risk ≤ 3.4 mmol/L]  
as per 2016 ESC/EAS guidelines;528 plasma vitamin D (25(OH) D) levels in nanomoles per litre (nmol/L) [deficient ≤ 50;  
sufficient >50 nmol/L] as per IOM vitamin D guidelines;530 plasma CRP levels in micrograms per litre (μg/l) [high risk > 3.00 mg/L;  
low risk ≤ 3.00 μg/l];531 and HbA1c (glycated haemoglobin) in millimoles per mol (mmol/mol) [high > 5.00 %;  
ideal ≤ 5.00 % (42.1 mmol/mol) as per American Diabetes Association guidelines.24 
Abbreviations: CRP - C-reactive protein; HbA1c- glycated haemoglobin; HDL-high density lipoprotein; LDL-low density 
lipoprotein; μg/l – micrograms per litre; MPOD-macular pigment optical density; non HDL –TC-HDL; nmol/L – nanomoles  
per litre; TC-total cholesterol; TC/HDL- total cholesterol over high density lipoprotein; TG-triglyceride; TG/HDL- triglyceride  





Figure 8.3: Violin plots of MPOD differences by (A) High Density Lipoprotein (HDL); 
(B) Triglyceride over High Density Lipoprotein (TG/HDL) Ratio and (C) Total 
Cholesterol over High Density Lipoprotein (TC/HDL) Ratio (ANOVA). 
Mixed linear model effects 
A mixed linear model analysis was carried out on normalised MPOD versus 
demographic, behavioural, anthropometric and plasma biomarker independent 
variables. Low education, current smoking and elevated WC were significant 
predictors of MPOD in this regression model (Table 8.3). None of the plasma 
biomarkers (HDL, TG/HDL, TC/HDL, Vitamin D, CRP or HbA1c) were significantly 
associated with MPOD in this model (P >0.05 for all variables; Table 8.3).  
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Table 8.3: Mixed linear model effects; relationship between demographic, behavioural, anthropometric and plasma biomarkers, and  
MPOD in a normal population. 
Parameter Estimate Std. error T (normalised MPOD) 
p 
Constant 0.448 0.085 5.297 0.000 
Sex* (Female) 0.011 0.008 1.284 0.199 
Education 
           Secondary 














            Past 













WC (cm) -0.001 0.000 -2.415 0.016 
HbA1c (%) 0.006 0.013 0.454 0.650 
Vitamin D (nmol/L) -0.000 0.000 -0.728 0.467 
CRP ‡ (>3μg/l) 0.000 0.000 0.745 0.456 
HDL (mmol/L) -0.009 0.012 -0.781 0.435 
TG/HDL Cholesterol Ratio -0.001 0.005 -0.161 0.872 
TC/HDL Cholesterol Ratio -0.001 0.005 -0.145 0.885 
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Hypertension ‡‡ (mmHg) (No) 
             Hypertensive 
             Hypertensive 















0.018 0.014 1.291 0.197 
 
Dependent variable = MPOD sqrt (normalised MPOD). 
*Male = reference group; † Never smoked = reference group; ‡ CRP (≤ 3mg/L= reference group); †† No Hypertension = reference group; ‡‡  
Yes cataracts = reference group. WC (cms); HbA1c (%); vitamin D (nmol/L), HDL (mmol/L); TG/HDL ratio; TC/HDL ratio – as continuous variables. 
Abbreviations: Std. Error - Standard Error; cms - centimetres; CRP - C-reactive protein; HbA1c- glycated haemoglobin; HDL-high density lipoprotein;  
μg/l – micrograms per litre; mmHg- millimetres of mercury; nmol/L – nanomoles per litre; WC-waist circumference; TC/HDL- total cholesterol over high  




The key finding to emerge from this study is the observation that participants with 
increased central adiposity, as indicated by an elevated WC, had significantly lower 
MPOD compared to those with ideal measures. Macular pigment was also lower 
amongst participants with an altered lipoprotein profile, i.e. in participants with raised 
plasma TG/HDL ratio, raised plasma TC/HDL ratio and low plasma HDL. 
Additionally, male gender, current smoking and low educational status was associated 
with lower MPOD, findings which concur with previously reported analyses on a 
similar cohort.52 Elevated WC, current smoking and low educational attainment 
persisted as predictors of low MPOD on mixed linear model analysis, after adjusting 
for all other covariates. 
 
Consistent with most previous reports,16, 52, 54, 384 MPOD was, in fact, significantly and 
negatively associated with all measures of overweight/obesity, including BMI, WC, 
WHtR, WHpR, (Pearson’s r; p<0.05 for all). With cut-off levels applied to classify 
participants into binary categories (obese or non-obese),527 elevated WC emerged as 
the main anthropometric variable associated with lower levels of MPOD. Carotenoids, 
such as lutein and zeaxanthin, are known to accumulate in adipose tissue, and in 
visceral fat in particular,54, 219 therefore, distribution of body fat is an important 
consideration.67 Higher WC has previously been reported to be the strongest non-
dietary predictor of low MPOD,384 and findings from the Third National Health & 
Nutrition Examination Survey revealed that participants with higher WC values were 
increasingly likely to have hypertension, diabetes, dyslipidaemia and the metabolic 
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syndrome,555 metabolic correlates independently associated with lower MPOD.6, 7, 18  
 
As an indicator of ‘abdominal’ obesity 384, 555 WC is receiving increased attention as a 
more clinically relevant measure of adiposity compared with BMI. Intra-abdominal 
fat may have different metabolic consequences compared with other patterns of fat 
distribution or overall adiposity, as it is more biologically active. Intra-abdominal fat 
is associated with inflammation due to the increased production of adipocytokines.372, 
442 The associated inflammation becomes chronic, therefore, obesity is now considered 
a low-grade inflammatory condition, which in turn leads to an increase in oxidative 
stress.69 Chronic inflammation and associated oxidative stress exert a greater demand 
on antioxidant defences within the body; defences which tend to be lower in the 
obese,367 and older adults.556 Sex differences exist in relation to how body fat is 
deposited,449 and there is evidence for gender-related differences in the accumulation 
of carotenoids.16, 17 Interestingly, we found that MPOD was 9% lower in males 
compared with females (p=0.004), possibly explained by the fact that men store more 
fat in the visceral (abdominal) fat depot,555 thereby, making these pigments less 
available to retinal tissue.68, 326 Thus, lower antioxidant activity may relate not only to 
lower intake of antioxidants and phytochemical rich foods in older adults (e.g. fruits, 
vegetables and legumes),557 reduced activity of endogenous anti-oxidative 
enzymes,556,367 but also due to an increased utilisation of these molecules. Collectively, 






Another interesting finding is the observation that MPOD was significantly lower in 
participants with raised plasma TG/HDL ratio (>0.87 mmols/L), and in those with 
raised plasma TC/HDL ratio (>3.5 mmols/L). Although these relationships did not 
persist on mixed linear model analysis, the lower MPOD levels observed among 
participants with low plasma HDL corroborates previous findings which identified an 
association between plasma HDL and MPOD.462 Dyslipidaemia is often characterised 
by low levels of HDL, raised TGs and smaller, more atherogenic LDL particles.160 As 
carotenoids are bound to circulating lipoproteins, the relation between plasma levels 
of the various lipoproteins and MPOD is of interest. Evidence suggests that HDL is 
the major carrier of lutein to the eye.18 Furthermore, HDL is a known ligand for SR-
B1, and the mechanism of xanthophyll uptake by the retina appears to be entirely SR-
B1 dependent.326  
 
Vitamin D deficiency has repeatedly been associated with ocular disease.306, 547 
Additionally, vitamin D deficiency is common world-wide, particularly so in older 
adults.498, 558 Of interest, we recently reported that individuals with Type 2 diabetes 
who were vitamin D deficient (≤50 nmol/L), had significantly lower MPOD, and that 
vitamin D was a significant positive predictor of MPOD on multivariate analysis in 
this study group.559 The current study, however, suggests that the association between 
vitamin D status and MPOD does not persist among older adults who are free of ocular 
pathology. Furthermore, no relationship was observed between MPOD and the 





This population-based representative study advances previously published work which 
also utilised TILDA data to explore MPOD,52 as the analyses herein relied much less 
on self-reported data. A large number of subjects were excluded from the overall MP 
analysis (n=2,014), and possible reasons for this included: technical issues, poor 
fixation and poor VA, among others. While c-HFP is one of the most common methods 
of measuring MP, it is challenging to perform, particularly so for older adults.56 
Research has shown that some participants have difficulty performing this technique, 
with dropout rates varying from 10 to 20%.56, 560 A Chi-square test of independence 
was performed, however, comparing the centre population (n=5,275) and the smaller 
sample of participants with a valid MPOD assessment (n=2,594), and this test 
confirmed that there was no significant difference in age, sex or education status 
between the two groups. More importantly, the attenuated number of participants in 
the current study did not appear to impact on the validity of our findings as we 
confirmed previously reported analyses on a similar cohort.52 Despite differences in 
inclusion criteria, the relationship between education and smoking status and MPOD 
observed therein and elsewhere was confirmed in our analysis.52, 384 Some 
discrepancies did emerge, however. Self-reported measures of high cholesterol, for 
example, were not associated with MPOD according to the previous analysis,52 
whereas the analysis of direct cholesterol measures taken herein suggest that 
dyslipidaemia (i.e. low plasma HDL, raised TG/HDL, raised TC/HDL) may have 
implications for the delivery and uptake of MP in the eye. Additionally, while an 
inverse association between self-reported high blood pressure and MP was also 
previously reported,52 we found no association between measured hypertension 
(treated or untreated) and MPOD on either univariate or mixed linear model analysis. 
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These direct measurements (systolic and diastolic, mmHg), would appear to outweigh 
self-reported data.52 Interestingly, we recently reported that individuals with diabetes 
and hypertension, had significantly lower MPOD compared to those without,559 which 
suggests that when conditions co-exist the redox balance may become increasingly 
upset, and that oxidative stress may increase considerably in hypertension, especially 
as a diabetic co-morbidity.535 Hypertension, however, does not appear to affect or 
deplete MP, in older adults, who are free of ocular pathology. 
 
A number of variables did not persist as predictors of MPOD on mixed linear analysis, 
(i.e. sex, and plasma lipoproteins), despite significant outcomes on univariate analysis. 
While gender (male) and lipoprotein (low HDL, raised TG/HDL, raised TC/HDL) 
status contribute to lower levels of MP, it appears that WC status is a more robust 
predictor of low MPOD. It is important to note, however, that the small difference in 
mean MPOD between participants with and without elevated WC suggests that any 
effect size is likely to be modest and not particularly useful in terms of predictive 
capacity from a clinical perspective.  
Macular pigment was measured using c-HFP, a technique that has been validated in 
older subjects 335, 560 and found to be reliable.560 Macular pigment measurements have, 
however, shown a degree of variability across studies.59, 335, 384, 561 For example, 
Stringham et al, 335 measured the density of MP in patients with intermediate AMD, 
using a similar device and retinal eccentricity (0.50), and the mean optical density was 
(0.37±0.24). Subjects in CAREDS had an average MP level of (0.36±0.22) right eye 
and (0.34±0.21) left eye, and these participants were of a similar age.384 We 
252 
 
acknowledge that the mean MPOD in the current study was notably lower than 
previously reported.335, 384 While, we found no correlation between age and MPOD in 
the current study, our findings suggest that older Irish adults have lower MP levels on 
average. It is worth noting that the prevalence of conditions which might affect MPOD 
levels is relatively high in Ireland, including AMD,562 glaucoma,563 and Type 2 
diabetes.130 The lower levels of MP observed in the current study, may, therefore, 
reflect the combined influence of inadequate dietary intake and increased utilisation of 
these phytonutrients.556 Given the variety of mechanisms which may contribute to 
macular pigment depletion, and the ocular risks associated with such depletion in this 
age group, the importance of diet cannot be over-emphasised. The provision of 
coloured fruit and vegetables which are rich in a broad range of antioxidants including 
the target carotenoids lutein and zeaxanthin and/or supplementation with these 
nutrients represents an obvious recommendation, given the putative protection that this 
pigment confers against age-related vision loss. These recommendations should now 
be subject to further research. 
8.6 Limitations 
Limitations of the current study include the failure to assess dietary intake or plasma 
levels of the carotenoids lutein and zeaxanthin as MPOD is influenced by both intake 
and individual efficacy of absorption.70 It is also worth noting that the high variability 
and lower levels of MPOD observed across different people may also be subject to 
genetic variation 72 a factor that is not accounted for in our analysis. Information on 
supplement usage was also not assessed, which would have added to the interpretation 
of our findings, particularly those in relation to vitamin D and MPOD.  
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Despite these limitations, there were a number of strengths to the current analysis. 
Plasma lipoproteins and inflammatory markers were analysed and blood pressure was 
measured, an advance on previously used self-reported data.52 Participants with 
comorbidities, AMD, glaucoma and diabetes, were eliminated from the current 
analysis and HbA1c was used to help identify undiagnosed and pre-diabetes cases. 
The use of measured rather than self-reported anthropometric data for WC, WHtR and 
WHpR is a further strength of the study. Finally, the representative study design of the 
TILDA study, the unique sampling method which includes both males and females, 
and the detailed exclusion criteria, we believe that our findings and the conclusions 
drawn from our findings concerning MPOD are representative of the older Irish 
population.  
8.7 Conclusion 
In conclusion, we report that elevated WC and dyslipidaemia may have important 
implications for the storage, delivery and uptake of lutein and zeaxanthin in the eye. 
Determinants of MPOD (i.e. education status, tobacco use, WC), remain statistically 
significant following mixed linear model analysis. Although no strong predictor of 
MPOD status emerged in this analysis, the capacity of more commonly-measured 
surrogate biomarkers to help identify people at risk of low MP merits further 
consideration. Given the marginal statistical significance of many of our findings, 
further research is necessary to refine our understanding of the observed relationships 





9. SUMMARY, CONCLUSIONS AND DIRECTION FOR FUTURE WORK 
9.1 Summary and conclusions 
This work was designed to explore the optical density of MP in patients with diabetes 
mellitus and to compare their levels with those of normal healthy controls. The 
findings reported and the conclusions drawn herein are based on the outcomes of two 
cross-sectional, case-controlled studies, one of which investigated MPOD in 
participants with Type 1 and Type 2 diabetes in a hospital setting; and the other, which 
explored MPOD amongst Type 2 diabetes participants in TILDA, a large, randomly-
selected population representative of older adults in Ireland. Although the optical 
density of MP can be measured in vivo it is not routinely measured in clinical practice. 
Therefore, as part of this research, surrogate biomarkers for the prediction of MPOD 
in patients at high risk of MPOD depletion (i.e. Type 2 diabetes and older adults) were 
investigated and identified in the TILDA cohort. A literature review of the evidence 
describing macular carotenoid depletion in diabetes (particularly Type 2 diabetes) was 
also performed, to identify the causal mechanisms by which diabetes mellitus and its 
metabolic perturbations contribute to lower MP levels. The conclusions and future 
research proposed as a result of the outcomes of this work are as follows. 
Macular pigment is lower in Type 2 diabetes 
Consistent with previous investigators who have explored the relationship between 
MPOD and diabetes, 6, 9 this research provides further evidence that low MP may 
indeed be a feature of diabetes. Furthermore, the current work demonstrates that 
MPOD is significantly lower in those with Type 2 diabetes participants compared to 
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those with Type 1; this represents an entirely novel finding. Overall, the behavioural 
(smoking), clinical (blood-pressure, presence of cataracts), anthropometric (body 
weight, BMI, WHtR) and plasma (lipoproteins, inflammatory markers) parameters of 
participants with Type 2 diabetes were poorer than those observed in non-diabetic 
controls. Hyperglycaemia and other anthropometric, metabolic and clinical correlates 
associated with diabetes may, therefore, constitute readily measurable proxies for the 
presence of chronic oxidative stress, inflammation and other pathological processes 
which underlie many of the functional alterations observed in diabetic retinopathy, 
and which also appear to be responsible for MPOD depletion in diabetes. 
Surrogate biomarkers for the prediction of patients at risk of low macular pigment in 
Type 2 diabetes. 
Tobacco use and the presence of cataract were significantly associated with lower 
MPOD levels amongst participants with diabetes. Metabolic comorbidities 
characteristic of Type 2 diabetes (i.e. overweight/obesity, dyslipidaemia and 
hypertension) were also significantly negatively associated with MPOD. The 
combined effect of increased lutein/zeaxanthin sequestration by excess adipose 
tissue, increased inflammation and elevated oxidative stress associated with 
overweight/obesity (i.e. BMI, WHtR, WC), appear to explain, at least in part, the 
lower MPOD levels observed in these Type 2 diabetes participants. Unfavourable 
lipoprotein status (i.e. raised TG/HDL) may also contribute to lower MPOD, as MP 
carotenoids are primarily transported by HDL in plasma,18, 71 and mechanisms 
governing their retinal capture and/or stabilisation in the retina are also subject to 
HDL influence.71 Furthermore, hypertension, especially as a co-morbidity of 
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diabetes, appears to further deplete MPOD levels due to its role in elevated oxidative 
stress.535 The borderline statistical significance of these findings, however, means 
that more work needs to be done on larger, purposively selected study populations to 
verify and refine our understanding of how these factors affect MPOD levels. 
 
Vitamin D emerged as a positive predictor of MPOD in participants with Type 2 
diabetes which is again, a novel finding. In addition, MP levels were significantly 
lower in participants with Type 2 diabetes who were deficient in vitamin D (i.e. ≤ 
50nmol/L). Vitamin D status does not appear to be associated with MPOD in older 
adults who are free of ocular pathology (i.e. AMD, glaucoma, diabetes/pre-diabetes). 
These findings suggest that the chronic low-grade inflammation and oxidative stress 
associated with Type 2 diabetes may indeed explain the lower MPOD levels 
observed in those with this condition and that the low vitamin D status associated 
with these pathological processes may itself be used as a predictor of low MPOD in 
patients with diabetes (Type 2). Findings from the DiVFuSS trial 21 are promising 
and appear to suggest that supplementation with a compound which specifically 
targets both inflammation and oxidative stress (i.e. vitamin D and carotenoids, 
lutein/zeaxanthin and meso-zeaxanthin) may be beneficial in protecting against the 
mechanisms underlying diabetic retinopathy.21 Furthermore, in line with previous 
research,307 a dilated eye examination might be recommended for diabetes patients 
whose low plasma vitamin D levels indicate an elevated risk of diabetic retinopathy. 
Further research is, however, needed to articulate the links between inflammatory 
status, disease progression and the ameliorative effects of supplementation with 
carotenoids and other vitamins (i.e. vitamin D) amongst those with diabetes. 
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Current findings suggest that the exogenous antioxidants lutein, zeaxanthin and 
meso-zeaxanthin, become depleted in diabetes. Although no strong predictor of 
MPOD depletion emerged, the capacity of more commonly used everyday measures 
to help identify patients at risk of low MPOD in diabetes, such as anthropometric 
status (WC, WHtR) and plasma biomarkers (TG/HDL, vitamin D)  merits further 
consideration. Further research should now be undertaken to refine our 
understanding of these observed relationships. 
Causal mechanisms putatively associated with lower macular pigment in diabetes 
mellitus. 
A review of the evidence pertaining to MP levels in diabetes mellitus suggests that 
MP is lower in diabetes (Type 2 diabetes in particular). Candidate causal mechanisms 
to explain the lower MP levels reported include oxidative stress, inflammation, 
overweight/obesity and dyslipidaemia. In summary, hyperglycaemia, oxidative stress 
and changes in redox homeostasis are fundamental events in the pathogenesis of 
diabetic retinopathy. The body’s natural defence against oxidative damage is 
neutralisation by endogenous antioxidants (enzymatic and non-enzymatic), supported 
by exogenous antioxidants (i.e. vitamin C, vitamin E, carotenoids lutein, zeaxanthin 
and meso-zeaxanthin). While oxidative stress is increased in diabetes, the activities of 
the antioxidant defence system are concomitantly diminished. In addition, 
inflammation is involved in the development of diabetic complications. Inflammatory 
processes underlie many of the functional changes in retinal vasculature observed 
histologically in early diabetic retinopathy. Oxidative stress triggers inflammatory 
responses and inflammation also enhances the production of ROS. Locally, the 
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occurrence of these metabolic changes can lead to MPOD depletion in the eye. 
Adipose tissue (more common in Type 2 diabetes) is another source of inflammation 
and also a major body store for carotenoids, lutein and zeaxanthin. Competitive 
storage by increased visceral fat may not only compete for retinal uptake but also 
independently increase oxidative stress and inflammation, thereby, reducing 
antioxidant capacity and MP levels in the eye. Finally, reduced insulin action in Type 
2 diabetes may also increase the risk of dyslipidaemia. The characteristic lipid profile 
of an individual with diabetes (i.e. increased TGs and low HDL) may have important 
implications for the delivery and uptake of MP in the eye. 
 
Impaired defence against ROS at the retina may not only be attributable to the 
increased utilisation of these antioxidants in diabetes (via chronic inflammation and 
oxidative stress) but may also arise as a result of increased adiposity (visceral fat in 
particular) and dyslipidaemia (i.e. low HDL, raised TGs), metabolic correlates which 
may adversely affect MP by compromising the availability, transport, and assimilation 
of these dietary carotenoids in the eye. Furthermore, lower intake of foods rich in 
carotenoids and other nutrients (i.e. fruit, vegetables, legumes), is common in Type 2 
diabetes. Overall, dietary advice focused on enhanced antioxidant supply and the 
optimal provision of anti-inflammatory nutrients (e.g. vitamin D, omega-3 essential 
fatty acids), along with lifestyle modifications such as increased physical activity to 
better manage bodyweight and plasma lipids, may be an effective prophylactic means 
to control oxidative stress/inflammation in diabetic eye disease and potentially slow 
the progression of diabetic retinopathy. 
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Surrogate biomarkers for the prediction of patients at risk of low macular pigment in 
older Irish adults. 
Finally, given the possibility that higher levels of MP may be beneficial for vision 
and ocular health, and that MPOD is not routinely measured in clinical practice, a 
range of behavioural, anthropometric, clinical and plasma measures were also 
explored as possible predictors of low MPOD amongst a cohort of non-diabetic older 
adults. Several findings emerged from this investigation. Of note, low educational 
status, current smoking and elevated WC were all significant predictors of lower 
MPOD in this non-diabetic cohort. That an elevated WC (>102cm in males, >88cm 
in females) was independently associated with lower MPOD levels is particularly 
interesting, given that participants with higher WC values are also more likely to 
have hypertension, diabetes, dyslipidaemia and the metabolic syndrome,555 
metabolic correlates independently associated with lower MPOD. 6, 7, 18 This lends 
credence to the theory that central adipose sequestration of carotenoids plays a role 
in MPOD depletion, and adds further support to the recommendation that WC be a 
routine measure in identifying patients at risk of low MPOD. However, further 
research is needed in this area as the difference in MPOD (0.013 OD), while 
statistically significant, was not at a level deemed clinically significant.  
 
Macular pigment was significantly lower amongst non-diabetic participants with low 
plasma HDL, raised plasma TG/HDL ratio, and raised TC/HDL ratio. Of interest, 
dyslipidaemia can often precede the overt appearance of Type 2 diabetes by several 
years.171 These findings suggest that the characteristic lipid profile of individuals 
who are overweight or obese, or who have emerging metabolic disease or established 
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Type 2 diabetes,158 (i.e. raised TGs and low HDL), may indeed have important 
implications for MP levels in the eye. While plasma lipoprotein biomarkers were not 
predictive of low MPOD on regression analysis, these preliminary findings warrant 
further investigation to fully elucidate any relationships which might exist.  
 
Eye-care practitioners are well-positioned to help motivate patients towards dietary 
modification (for example enhanced carotenoid and vitamin D intake) and lifestyle 
changes (such as increased physical activity). Notably, formal educational status was 
a positive predictor of MPOD amongst older subjects. It is well known that 
educational status is a marker for overall socioeconomic status (SES),564 and that 
lower SES is associated with a constellation of risk factors thought to mitigate the 
accumulation of carotenoids at the macula, (i.e. tobacco use,65 overweight/obesity,16, 
17, 54 dyslipidaemia,18 oxidative stress,552 and inflammation).553 Furthermore, research 
has shown that people who are less educated with lower incomes consume more 
energy-dense, micronutrient-dilute food, compared with their higher 
SES counterparts, who have higher fruit and vegetable intake.565 Current smoking 
emerged as a significant predictor of low MPOD in both Type 2 diabetes participants 
and amongst older, non-diabetic adults. Apart from its association with lower overall 
antioxidant intakes and increased oxidative stress and antioxidant utilisation, 
smoking is also a significant, yet preventable, direct cause of trauma to the eye which 
can lead to blindness. Given the emerging evidence that MP is important for vision 
and ocular health,4 and that smoking is an established modifiable risk factor for 
AMD,49, 62 more effort is needed to increase patient awareness of the harmful effects 
of smoking on the eye. Clinical practitioners can play an important role in educating 
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patients on the importance of carotenoid intake (i.e. fruit, vegetables, legumes) and 
of smoking cessation, lifestyle changes which may help to maintain healthy eyes in 
the long-term. 
 
Given the ready availability of such data, the use of commonly measured proxies to 
help identify people at risk of low MP is worth exploring. The marginal statistical 
significance of many of our findings in this area means that further research is 
necessary to refine our understanding of these observed relationships. In time, this 
may contribute to the establishment of a checklist to be used in the screening and 
identification of individuals at high risk of MPOD depletion and its consequent 
ocular pathologies. 
9.2 Strengths and limitations of the current research 
The different presenting features of Type 1 and Type 2 diabetes and the interplay of 
their disease components with MPOD were analysed and compared with non-diabetic 
controls in the initial study. There were several strengths to this analysis. The MPOD 
was measured using c-HFP method, dietary intake of carotenoids was quantified, 
plasma lipids (TC, HDL, TG, and LDL) and HbA1c were measured, to explore the 
influence of potential explanatory factors on central MPOD in diabetes (Type 1 and 
Type 2). There were, however, a number of limitations which should also be 
recognised. While c-HFP technique is considered the gold standard psychophysical 
method for measuring MPOD, the clinical densitometer can only take two 
measurements, centrally and peripherally, therefore, providing no information on the 
spatial distribution of MP. Although, dietary intake of lutein and zeaxanthin was 
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quantified, the FFQ used in this study was designed for an American population 
(among Irish participants), which was not ideal. The lack of plasma carotenoid 
analysis was also a drawback. Body mass index was used to assess overweight/obesity, 
however, this measure alone does not provide a precise indicator of adiposity, visceral 
fat in particularly (more commonly found in Type 2 diabetes). Therefore, future 
studies investigating the link between MPOD and obesity should encompass more 
refined methods of body fat assessment including WC, WHtR and WHpR. 
Inflammatory markers (i.e. vitamin D and CRP) were also not analysed as part of this 
study. Finally, small patient numbers in some of the sub-group analyses may have 
limited our ability to detect statistical effects. 
 
Findings from this study, however, helped inform the type of analysis performed in 
the TILDA study. There were a number of strengths to the TILDA study. The design 
of the study itself was a particular strength. Diabetes participants and non-diabetic 
controls were drawn from a large randomly selected sample, representative of the Irish 
population aged 50 and over. Plasma lipoproteins including the various lipoprotein 
fractions (TC/HDL, TG/HDL, non-HDL) and inflammatory markers (vitamin D, 
CRP) were analysed and blood pressure was measured. The additional use of HbA1c 
helped identify undiagnosed and pre-diabetes cases. Overall, the detailed exclusion 
criteria used was a key strength of the study. Anthropometric measures such as WHtR, 
WHpR and WC, were also used to analyse overweight/obesity, an advance on previous 
analysis which used BMI only. There were, however, also a number of weaknesses to 
the study, which are worth noting. Firstly, the use of self-reported data was not ideal, 
particularly concerning diagnosis of diabetes (Type 1 vs Type 2), duration of disease 
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and the presence of cataract (all self-reported). Customised-HFP was used to measure 
MPOD, which requires significant patient training to produce meaningful results, 
particularly for older participants. A large number of subjects had to be excluded from 
the current study (n=2,014) due to their inability to successfully complete MPOD 
measurements. In addition, small participant numbers in some of the diabetic sub-
group analyses may have limited statistical power to detect associations (i.e. Type II 
error). Furthermore, dietary intake of lutein and zeaxanthin and plasma analysis of 
carotenoids were not assessed, therefore, it was not possible to control for potential 
confounding from the variable intake of lutein and zeaxanthin. 
 
Finally, the review paper provided an in-depth analysis of the causal mechanisms and 
metabolic perturbations putatively associated with lower MP in diabetes (Type 2 
diabetes in particular).This article provided a holistic evaluation of diet (and/or 
supplementation) and lifestyle in relation to MPOD and diabetes and the latest 
available evidence was explored. Some limitations which prevailed, however, 
included small sample sizes in the reviewed literature and the merging of Type 1 and 
Type 2 diabetes patients in statistical analyses. Additionally, the complex interplay of 
diabetes and its metabolic correlates (adiposity, dyslipidaemia, oxidative stress and 
inflammation) with MPOD status represented a particular challenge.  
9.3 Directions for future work 
Macular pigment has a unique concentration within the retina and is biologically 
relevant to the protection of the eye.44, 45 While existing evidence suggests that MP is 
protective against the onset and progression of diabetic retinopathy based on animal 
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studies,14, 20, 186 and one RCT,21 the potential protective effects of MP against diabetic 
retinopathy in humans need be clarified, particularly in cases where MP levels are low. 
Therefore, the findings of this current work should now prompt and inform the 
development of a well-designed, placebo-controlled clinical trial to help us further 
understand the relationship which exists between MPOD and diabetes, and the 
implication of this relationship for ocular health.  
 
Future studies should measure carotenoid intake and MPOD levels in a range of 
patients with diabetes (Type 1 & Type 2), at various stages of the disease (i.e. no 
retinopathy, non-proliferative, proliferative, with or without diabetic macular 
oedema), and compare their clinical outcomes, carotenoid intake and MPOD levels 
with those of individuals not afflicted with the condition. Disease progression and 
macular health should be monitored prospectively (ideally over 2 years or more). As 
dietary estimation of carotenoids and antioxidants is complex and challenging, this 
work should also be extended to embrace placebo-controlled supplementation trials 
with both ocular carotenoids in isolation (lutein, zeaxanthin and meso-zeaxanthin 
alone) or as part of a multi-component antioxidant/anti-inflammatory preparation. 
Clinical outcome measures should include MPOD augmentation, structural 
parameters of the macula (as assessed with OCT) and disease progression.  
 
Insulin resistance, impaired glucose tolerance and Type 2 diabetes can exist for many 
years before retinal signs become evident in diabetes, therefore, it is important that 
both the clinical (HbA1c, lipids, BP and inflammatory markers) and histological 
(structural) aspects of the condition are recognised and monitored. There is merit in 
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exploring the association between MPOD and more commonly assessed parameters 
such as behavioural (tobacco use), anthropometric (WC, WHtR), plasma (HDL, 
TG/HDL, vitamin D and CRP) and clinical (blood pressure, presence of cataracts) 
measures. This could help to determine whether MPOD levels and specifically the risk 
of low MPOD status, can be predicted using these data. Also, whether clinical 
interventions designed to alter these parameters and the course of the disease itself can 
also elicit more favourable MPOD status and ocular health outcomes.  
 
Clinical health benefits may be realised through the early identification of MPOD 
deficits in diabetes patients and through the implementation of appropriate 
interventions (supplementation with carotenoids and other nutrients) which may help 
to prevent or slow the progression of diabetic retinopathy. Importantly, a combination 
of lifestyle behaviours such as the avoidance of smoking, physical activity, and the 
adoption of a healthy dietary pattern (i.e. increased fruit and vegetable intake) may not 
only lower the prevalence of Type 2 diabetes but may also protect against the 
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Appendix 1: Macular Pigment and Diabetes Consent Form 
 
Macular Pigment Optical Density Study and Diabetes 
We are currently recruiting for an observational study looking at the levels of macular 
pigment in a diabetes population at the Mater Hospital, in conjunction with the Dublin 
Institute of Technology. The main aim is to examine whether the levels of macular 
pigment are correlated with diabetes, and also the level of diabetic retinopathy that 
each individual may have, and assess whether changes in the levels of these pigments 
affect visual acuity. Participation in this study is entirely voluntary and non‐
participation does not affect your current treatment at the Mater Hospital. All results 
will be examined anonymously. 
Participation involves photographing the back of the eye with a special non‐invasive 
instrument which measures the levels of macular pigment. As these levels can be 
affected by dietary intake, we will also conduct a food intake questionnaire to control 
for this. We envisage performing these tests and questionnaires at the time of your 
screening/OPD clinic visit. Should you wish to participate in this important research 
study please sign on the dotted line below as consent. 
Paul Connell  
Consultant Vitreoretinal Surgeon Mater Hospital. Date: ………………………… 
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Appendix 2: Diabetes & Macular Pigment Study - Data Capture Form 
EXCLUSION CRITERIA: 
 Ocular diseases other than non-proliferative diabetic retinopathy 
 Previous ocular surgery or ocular trauma 
 Best corrected vision < 6/18  
 Taking MP supplements (e.g. Macushield, Ocuvite Lutein, Vitalux, 
Vision Ace, Lutein Omega 30, etc) 
 
Date (D/M/Y): ______________________     
Location: ____________________________________________ 
Name: ________________________________________________    
MRN: ________________________________ 
Sex: M / F     DOB (D/M/Y): __________________________    
Race: ______________________________ 
Current smoker: Y / N    Previous smoker: Y / N    
BMI (kg/m2): ________________________ 
Type of diabetes: 
None: ____  Type 1: ____  
Type 2: _____ 
Duration of diabetes (years): 
 
Study group: 
____ Non-diabetic (control) 
____ Diabetes, no DR 





____ Diabetes, non-proliferative DR 
Study Eye: 
Right eye: ____ 
Left eye: ____ 
Left visual acuity: 
 
 
Previous laser treatments 
for DR: 
Right eye: Y / N  Date: 
____________________ 
 
Left eye: Y / N   Date: 
_____________________ 
Medications for diabetes: 
____ Insulin 
____ Oral hypoglycaemics 
 







Most recent blood data recording:                                         Date (D/M/Y): 
HbA1C (%):  
Triglycerides (mmol/L):  
HDL cholesterol (mmol/L):  
LDL cholesterol (mmol/L):  
Total cholesterol (mmol/L):  
 
MPOD Right: ____________   SD: _____________  MPOD Left: ____________SD: 
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Appendix 4: TILDA Documentation 
TILDA. (2019). The Irish Longitudinal study on Ageing (TILDA) Wave 1, 
2009-2011. [dataset]. Version 1.9. Irish Social Science Data Archive. 
SN:0053-01. www.ucd.ie/issda/data/tilda/wave1 
Tilda Data Documentation: https://tilda.tcd.ie/data/documentation/ 
TILDA Release Guide v4.1 
https://www.ucd.ie/issda/t4media/0053-00_TILDA_Release_Guide_v4.1.pdf 




Fifty plus in Ireland 2011;First results from the Irish Longitudinal Study on 
Ageing (TILDA): https://tilda.tcd.ie/publications/reports/pdf/w1-key-findings 
report/Tilda_Master_First_Findings_Report.pdf 
 Computer Aided Personal Interview - TILDA 
https://www.ucd.ie/issda/t4media/005301_TILDA_Wave1_CAPI_Questionn
aire.pdf 
Wave 1 Self Completion Questionnaire 
https://tilda.tcd.ie/data/documentation/doc/wave1/Wave%201%20Self%20C
ompletion%20Questionnaire.pdf 
TILDA Wave 1 Derived Variables Codebook 
https://www.ucd.ie/issda/t4media/0053-
01_TILDA_Wave1_Derived_Variables_Codebook_v1.9.pdf 
